WorldWideScience

Sample records for antimitotic drugs

  1. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Ju-Hwa; Yoo, Hye-In; Kang, Han Sung; Ro, Jungsil [Research Institute, National Cancer Center, Ilsan-gu, Goyang-si, Gyeonggi-do (Korea, Republic of); Yoon, Sungpil, E-mail: yoons@ncc.re.kr [Research Institute, National Cancer Center, Ilsan-gu, Goyang-si, Gyeonggi-do (Korea, Republic of)

    2012-02-03

    Highlights: Black-Right-Pointing-Pointer Sal sensitizes antimitotic drugs-treated cancer cells. Black-Right-Pointing-Pointer Sal sensitizes them by prevention of G2 arrest and reduced cyclin D1 levels. Black-Right-Pointing-Pointer Sal also sensitizes them by increasing DNA damage and reducing p21 level. Black-Right-Pointing-Pointer A low concentration of Sal effectively sensitized the cancer cells to antimitotic drugs. -- Abstract: Here, we investigated whether Sal could sensitize cancer cells to antimitotic drugs. We demonstrated that Sal sensitized paclitaxcel (PAC)-, docetaxcel (DOC)-, vinblastin (VIN)-, or colchicine (COL)-treated cancer cell lines, suggesting that Sal has the ability to sensitize the cells to any form of microtubule-targeting drugs. Sensitization to the antimitotic drugs could be achieved with very low concentrations of Sal, suggesting that there is a possibility to minimize Sal toxicity associated with human cancer patient treatments. Sensitization by Sal increased apoptosis, which was observed by C-PARP production. Sal sensitized the cancer cells to antimitotic drugs by preventing G2 arrest, suggesting that Sal contributes to the induction of mitotic catastrophe. Sal generally reduced cyclin D1 levels in PAC-, DOC-, and VIN-treated cells. In addition, Sal treatment increased pH2AX levels and reduced p21 levels in antimitotic drugs-treated cells. These observations suggest that the mechanisms underlying Sal sensitization to DNA-damaging compounds, radiation, and microtubule-targeting drugs are similar. Our data demonstrated that Sal sensitizes cancer cells to antimitotic drugs by increasing apoptosis through the prevention of G2 arrest via conserved Sal-sensitization mechanisms. These results may contribute to the development of Sal-based chemotherapy for cancer patients treated with antimitotic drugs.

  2. Natural products as antimitotic agents.

    Science.gov (United States)

    Dall'Acqua, Stefano

    2014-01-01

    Natural products still play an important role in the medicinal chemistry, especially in some therapeutic areas. As example more than 60% of currently-used anticancer agents are derives from natural sources including plants, marine organisms or micro-organism. Thus natural products (NP) are an high-impact source of new "lead compounds" or new potential therapeutic agents despite the large development of biotechnology and combinatorial chemistry in the drug discovery and development. Many examples of anticancer drugs as paclitaxel, combretastatin, bryostatin and discodermolide have shown the importance of NP in the anticancer chemotherapy through many years. Many organisms have been studied as sources of drugs namely plants, micro-organisms and marine organisms and the obtained NP can be considered a group of "privileged chemical structures" evolved in nature to interact with other organisms. For this reason NP are a good starting points for pharmaceutical research and also for library design. Tubulin and microtubules are one of the most studied targets for the search of anticancer compounds. Microtubule targeting agents (MTA) also named antimitotic agents are compounds that are able to perturb mitosis but are also able to arrest cell growing during interphase. The anticancer drugs, taxanes and vinca alkaloids have established tubulin as important target in cancer therapy. More recently the vascular disrupting agents (VDA) combretastatin analogues were studied for their antimitotics properties. This review will consider the anti mitotic NP and their potential impact in the development of new therapeutic agents.

  3. Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.

    Science.gov (United States)

    Perera, David; Venkitaraman, Ashok R

    2016-07-14

    Oncogenic KRAS induces cell proliferation and transformation, but little is known about its effects on cell division. Functional genetic screens have recently revealed that cancer cell lines expressing oncogenic KRAS are sensitive to interference with mitosis, but neither the mechanism nor the uniformity of anti-mitotic drug sensitivity connected with mutant KRAS expression are yet clear. Here, we report that acute expression of oncogenic KRAS in HeLa cells induces mitotic delay and defects in chromosome segregation through mitogen-activated protein kinase (MAPK) pathway activation and de-regulated expression of several mitosis-related genes. These anomalies are accompanied by increased sensitivity to anti-mitotic agents, a phenotype dependent on the transcription factor MYC and its downstream target anti-apoptotic protein BCL-XL. Unexpectedly, we find no correlation between KRAS mutational status or MYC expression levels and anti-mitotic drug sensitivity when surveying a large database of anti-cancer drug responses. However, we report that the co-existence of KRAS mutations and high MYC expression predicts anti-mitotic drug sensitivity. Our findings reveal a novel function of oncogenic KRAS in regulating accurate mitotic progression and suggest new avenues to therapeutically target KRAS-mutant tumours and stratify patients in ongoing clinical trials of anti-mitotic drugs.

  4. Evaluation of natural anthracene-derived compounds as antimitotic agents.

    Science.gov (United States)

    Badria, Farid A; Ibrahim, Ahmed S

    2013-04-01

    Plants that contain anthracene-derived compounds such as anthraquinones have been reported to act as anticancer besides their use for millennia to treat constipation, but the mechanism of action is still unfolding. Therefore we pursue this study to explore a new horizon in the anticancer property of these agents with relevance to mitotic arrest. To achieve this goal, the antimitotic activity of a series of naturally occurring anthracene-derived anthraquinones including anthrone, alizarin (1,2-dihydroxyanthraquinone), quinizarin (1,4-dihydroxyanthraquinone), rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid), emodin (1,6,8-trihydroxy-3-methylanthraquinone), and aloe emodin (1,8-dihydroxy-3-hydroxymethylanthraquinone) were evaluated using Allium cepa root tips. Initial results revealed that the mitosis was inhibited after 3, 6, and 24 h, respectively, of incubation with 500, 250, and 125 ppm of each compound in a dose-dependent manner. Furthermore, alizarin at 500 ppm was proved to be the most active compound to arrest the mitosis after 24 h followed by emodin, aloe emodin, rhein, and finally quinizarin. Interestingly, this inhibition of mitosis was irreversible in root tips incubated with each compound at concentration of 500 ppm but not with 250 ppm or 125 ppm, where the roots regained their normal mitotic activity after 96 h post-incubation in water. This re-evaluation of an old remedy suggests that several bioactive anthraquinones possess promising anti-mitotic activity that may have the potential to be lead compounds for the development of a new class of multifaceted natural anticancer/antimitotic agents.

  5. Phytochemical screening and antioxidant, antimitotic, and antiproliferative activities of Trichodesma indicum shoot

    Directory of Open Access Journals (Sweden)

    Shweta S Saboo

    2014-01-01

    Full Text Available Background: Traditionally Trichodesma indicum has been used for its therapeutic effect in folk medicine that include anti-inflammatory, analgesic and anticancer properties. In this work, we validate the anticancer potential of the plant. Aims: To screen the shoot extracts T. indicum for their antimitotic and antiproliferative activities. Materials and Methods: The dried aerial parts of T. indicum were successively extracted with petroleum ether, successive chloroform extract (SCH, successive ethanol extract (SEE and water. The plant extracts were subjected to study of in vitro antioxidant activity using 2,2′- diphenyl-1-picrylhydrazyl, 2,2′- azino-bis(3-ethylbenzothiazoline-6-sulphonic acid radical inhibition systems. The extracts were also tested for their in vitro antimitotic activity in Allium cepa root and antiproliferative activity using the yeast model and five human cell lines (MCF-7, HOP-62, MOLT-4, HCT-15 and PRO. Result and Conclusion: The mitotic index for SCH and SEE was found to be 12.01 ± 1.34 and 12.99 ± 0.25 mg/mL, respectively. The IC 50 value in the antiproliferative assay was found to be 30.14-35.36 mg/mL for SCH and SEE respectively. Both SCH and SEE extracts showed significant antimitotic and antiproliferative activity when compared to the standard methothreaxate, vincreastine and adriamycin. Among the extracts, SEE showed strong inhibition against MCF-7 and MOLT-4 cell lines at concentration <30 μg/mL. Phytochemical analysis of extracts indicated the presence of β-sitosterol, gallic acid and catechin. Based on these results, it is concluded that T. indicum may be a good candidate for the treatment of a variety of cancer. Thus, its traditional use is validated.

  6. Antimitotic agents increase the production of doubled-haploid embryos from cork oak anther culture.

    Science.gov (United States)

    Pintos, Beatriz; Manzanera, Jose A; Bueno, Maria A

    2007-12-01

    The objective of this study is to induce the nuclear DNA duplication of anther-derived embryos of cork oak (Quercus suber L.) to obtain doubled-haploid plants. Anther culture of this species produces a low percentage (7.78%) of spontaneous diploids, as assessed by flow cytometry. Therefore, three antimitotic agents, colchicine, oryzalin and amiprophos-methyl (APM), were applied in vitro to anther-derived cork oak haploid embryos from six genotypes at different concentrations and for different treatment durations. Antimitotic toxicity was determined by embryo survival. Efficiency in inducing chromosome doubling of haploid embryos was evaluated by flow cytometry measurements and differences were observed between treatments. Nuclear DNA duplication and embryo survival of cork oak haploid embryos was most efficiently induced with oryzalin 0.01 mM for 48 h. Around 50% diploid embryos were obtained. The rate of chromosome duplication induced by APM 0.01 mM was also acceptable but lower than that induced by oryzalin, regardless of the duration of the treatment. Colchicine 1.3 or 8.8 mM was the least efficient, with the induction of necrosis and only a small rate of nuclear DNA duplication.

  7. Anti-mitotic potential of 7-diethylamino-3(2 Prime -benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Nam Hyun [Department of Pharmacology, Kwandong University College of Medicine, Gangneung 210-701 (Korea, Republic of); Kim, Su-Nam [KIST Gangneung Institute, Gangneung 210-340 (Korea, Republic of); Oh, Joa Sub [College of Pharmacy, Dankook University, Cheonan 330-714 (Korea, Republic of); Lee, Seokjoon [Department of Basic Science, Kwandong University College of Medicine, Gangneung 210-701 (Korea, Republic of); Kim, Yong Kee, E-mail: yksnbk@sookmyung.ac.kr [College of Pharmacy, Sookmyung Women' s University, Seoul 140-742 (Korea, Republic of)

    2012-02-24

    Highlights: Black-Right-Pointing-Pointer DBC exerts antiproliferative potential against 5FU-resistant human gastric cancer cells. Black-Right-Pointing-Pointer This effect is mediated by destabilization of microtubules and subsequent mitotic arrest. Black-Right-Pointing-Pointer DBC enhances apoptosis via caspase activation and downregulation of antiapoptotic genes. -- Abstract: In this study, we investigate an anti-mitotic potential of the novel synthetic coumarin-based compound, 7-diethylamino-3(2 Prime -benzoxazolyl)-coumarin, in 5-fluorouracil-resistant human gastric cancer cell line SNU-620-5FU and its parental cell SNU-620. It exerts the anti-proliferative effects with similar potencies against both cancer cells, which is mediated by destabilization of microtubules and subsequent mitotic arrest. Furthermore, this compound enhances caspase-dependent apoptotic cell death via decreased expression of anti-apoptotic genes. Taken together, our data strongly support anti-mitotic potential of 7-diethylamino-3(2 Prime -benzoxazolyl)-coumarin against drug-resistant cancer cells which will prompt us to further develop as a novel microtubule inhibitor for drug-resistant cancer chemotherapy.

  8. Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity.

    Science.gov (United States)

    Spanò, Virginia; Montalbano, Alessandra; Carbone, Anna; Parrino, Barbara; Diana, Patrizia; Cirrincione, Girolamo; Castagliuolo, Ignazio; Brun, Paola; Issinger, Olaf-Georg; Tisi, Silvia; Primac, Irina; Vedaldi, Daniela; Salvador, Alessia; Barraja, Paola

    2014-03-03

    A new series of pyrrolo[3,4-h]quinazolines was conveniently prepared with a broad substitution pattern. A large number of derivatives was obtained and the cellular cytotoxicity was evaluated in vitro against 5 different human tumor cell lines with GI₅₀ values reaching the low micromolar level (1.3-19.8 μM). These compounds were able to induce cell death mainly by apoptosis through a mitochondrial dependent pathway. Selected compounds showed antimitotic activity and a reduction of tubulin polymerization in a concentration-dependent manner. Moreover, they showed anti-angiogenic properties since reduced in vitro endothelial cell migration and disrupted HUVEC capillary-like tube network in Matrigel.

  9. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.

    Science.gov (United States)

    Vine, K L; Indira Chandran, V; Locke, J M; Matesic, L; Lee, J; Skropeta, D; Bremner, J B; Ranson, M

    2012-01-01

    Tumor-specific delivery of ligand-directed prodrugs can increase the therapeutic window of chemotherapeutics by maintaining efficacy whilst decreasing toxic side effects. We have previously described a series of synthetic N-alkylated isatin cytotoxins that destabilize microtubules and induce apoptosis with 10-fold greater potency than conventional anti-mitotics in vitro. Here, we report the characterization, in vitro cytotoxicity and in vivo efficacy of a lead compound, 5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin (N-AI) conjugated via an esterase-labile linker (N-AIE) to two proven targeting ligands, transferrin (Tf) and plasminogen activator inhibitor type 2 (PAI-2/serpinB2). N-AI was released from N-AIE and the targeting ligands Tf/PAI-2 in an esterase-dependent manner at 37 C and both Tf- and PAI-2-N-AIE conjugates were stable at physiological pH. Human cancer cell lines which vary in their expression levels of Tf receptor (TfR/CD71) and PAI-2 target, receptor bound urokinase (uPA) selectively internalized the conjugates. Tf-N-AIE was up to 24 times more active than the free drug and showed clear selectivity patterns based on TfR levels. PAI-2-N-AIE showed equivalent activity compared to the parent drug and strong selectivity patterns for uPA levels. In preliminary in vivo experiments, the PAI-2- and Tf-N-AIE conjugates were efficacious at 1/20(th) and 1/10(th) of the dose of the free N-AI, respectively, in a metastatic, orthotopic human breast tumor xenograft mouse model. Thus, this strategy specifically delivers and concentrates a novel class of isatin-based, tubulin destabilizing agents to tumors in vivo and warrants further detailed preclinical investigation.

  10. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics

    NARCIS (Netherlands)

    Orth, James D; Kohler, Rainer H; Foijer, Floris; Sorger, Peter K; Weissleder, Ralph; Mitchison, Timothy J

    2011-01-01

    Cancer relies upon frequent or abnormal cell division, but how the tumor microenvironment affects mitotic processes in vivo remains unclear, largely due to the technical challenges of optical access, spatial resolution, and motion. We developed high-resolution in vivo microscopy methods to visualize

  11. Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel.

    Science.gov (United States)

    Fonseca, Joana; Marques, Sandra; Silva, Patrícia M A; Brandão, Pedro; Cidade, Honorina; Pinto, Madalena M; Bousbaa, Hassan

    2016-07-29

    We previously reported that prenylated chalcone 2 (PC2), the O-prenyl derivative (2) of 2'-hydroxy-3,4,4',5,6'-pentamethoxychalcone (1), induced cytotoxicity of tumor cells via disruption of p53-MDM2 interaction. However, the cellular changes through which PC2 exerts its cytotoxic activity and its antitumor potential, remain to be addressed. In the present work, we aimed to (i) characterize the effect of PC2 on mitotic progression and the underlying mechanism; and to (ii) explore this information to evaluate its ability to sensitize tumor cells to paclitaxel in a combination regimen. PC2 was able to arrest breast adenocarcinoma MCF-7 and non-small cell lung cancer NCI-H460 cells in mitosis. All mitosis-arrested cells showed collapsed mitotic spindles with randomly distributed chromosomes, and activated spindle assembly checkpoint. Live-cell imaging revealed that the compound induced a prolonged delay (up to 14 h) in mitosis, culminating in massive cell death by blebbing. Importantly, PC2 in combination with paclitaxel enhanced the effect on cell growth inhibition as determined by cell viability and proliferation assays. Our findings demonstrate that the cytotoxicity induced by PC2 is mediated through antimitotic activity as a result of mitotic spindle damage. The enhancement effects of PC2 on chemosensitivity of cancer cells to paclitaxel encourage further validation of the clinical potential of this combination.

  12. Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel

    Directory of Open Access Journals (Sweden)

    Joana Fonseca

    2016-07-01

    Full Text Available We previously reported that prenylated chalcone 2 (PC2, the O-prenyl derivative (2 of 2′-hydroxy-3,4,4′,5,6′-pentamethoxychalcone (1, induced cytotoxicity of tumor cells via disruption of p53-MDM2 interaction. However, the cellular changes through which PC2 exerts its cytotoxic activity and its antitumor potential, remain to be addressed. In the present work, we aimed to (i characterize the effect of PC2 on mitotic progression and the underlying mechanism; and to (ii explore this information to evaluate its ability to sensitize tumor cells to paclitaxel in a combination regimen. PC2 was able to arrest breast adenocarcinoma MCF-7 and non-small cell lung cancer NCI-H460 cells in mitosis. All mitosis-arrested cells showed collapsed mitotic spindles with randomly distributed chromosomes, and activated spindle assembly checkpoint. Live-cell imaging revealed that the compound induced a prolonged delay (up to 14 h in mitosis, culminating in massive cell death by blebbing. Importantly, PC2 in combination with paclitaxel enhanced the effect on cell growth inhibition as determined by cell viability and proliferation assays. Our findings demonstrate that the cytotoxicity induced by PC2 is mediated through antimitotic activity as a result of mitotic spindle damage. The enhancement effects of PC2 on chemosensitivity of cancer cells to paclitaxel encourage further validation of the clinical potential of this combination.

  13. STUDIES ON THE PHYTOCHEMISTRY, SPECTROSCOPIC CHARACTERIZATION AND SCREENING FOR ANTI-MITOTIC EFFICACY OF SALICORNIA BRACHIATA ROXB

    Directory of Open Access Journals (Sweden)

    G.V.Pavan Kumar

    2014-10-01

    Full Text Available Salicorniabrachiata is a euhalopytic plant belonging to the family Chenopodiaceae. The present study investigates the phytochemistry, characterization and antimitotic activity of ethanolic extract of S.brachiata.Plants popularly known as Sea asparagus are cooked and eaten or pickled. It is also a good fodder for cattle, sheep and goat. Plant material is also used as raw material in paper and board factories. Its seeds yield high quality edible oil which is highly polyunsaturated and similar to safflower oil in fatty acid.S.brachiata was collected from the back waters of Bapatla,Guntur district. The collected plant material was shade dried and pulverized. The plant material Was studied for phytochemistry,spectroscopic analysis i.e.,UV- Visible, FT-IR and anti mitotic activity.S. brachiata has been prescribed in traditional medicines for the treatment of intestinal ailments, nephropathy, and hepatitis in Oriental countries. In addition, S.brachiata has recently reported to be effective on the atherosclerosis, hyperlipidemia, and diabetes. A variety of pharmacological experiments have revealed that solvent-extracted fractions of S.brachiata exhibited anti-oxidative, anti-microbial, anti-proliferative, and anti-inflammatory activities,supporting rationale behind its several traditional uses.The phytochemical analysis indicates the presence of Tannins and Flavonoids in the plant. UV-Vis Spectrum, used for the quantitative analysis of the plant extract showed peaks at 280 and 290 nm. Identification of the functional groups was performed by FT-IR spectroscopy which confirmed the presence of phenolic, alcoholic and aromatic compounds.

  14. Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition.

    Science.gov (United States)

    Kim, Ju-Hwa; Choi, Ae-Ran; Kim, Yong Kee; Yoon, Sungpil

    2013-11-22

    The purpose of this study was to identify conditions that will increase the sensitivity of resistant cancer cells to anti-mitotic drugs. Currently, atovaquine (ATO), chloroquine (CHL), primaquine (PRI), mefloquine (MEF), artesunate (ART), and doxycycline (DOY) are the most commonly used anti-malarial drugs. Herein, we tested whether anti-malarial drugs can sensitize drug-resistant KBV20C cancer cells. None of the six tested anti-malarial drugs was found to better sensitize the drug-resistant cells compared to the sensitive KB cells. With an exception of DOY, all other anti-malarial drugs tested could sensitize both KB and KBV20C cells to a similar extent, suggesting that anti-malarial drugs could be used for sensitive as well as resistant cancer cells. Furthermore, we examined the effects of anti-malarial drugs in combination with an antimitotic drug, vinblastine (VIN) on the sensitisation of resistant KBV20C cells. Using viability assay, microscopic observation, assessment of cleaved PARP, and Hoechst staining, we identified that two anti-malarial drugs, PRI and MEF, highly sensitized KBV20C-resistant cells to VIN treatment. Moreover, PRI- or MEF-induced sensitisation was not observed in VIN-treated sensitive KB parent cells, suggesting that the observed effect is specific to resistant cancer cells. We demonstrated that the PRI and MEF sensitisation mechanism mainly depends on the inhibition of p-glycoprotein (P-gp). Our findings may contribute to the development of anti-malarial drug-based combination therapies for patients resistant to anti-mitotic drugs.

  15. Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.

    Science.gov (United States)

    Romagnoli, Romeo; Baraldi, Pier Giovanni; Salvador, Maria Kimatrai; Prencipe, Filippo; Bertolasi, Valerio; Cancellieri, Michela; Brancale, Andrea; Hamel, Ernest; Castagliuolo, Ignazio; Consolaro, Francesca; Porcù, Elena; Basso, Giuseppe; Viola, Giampietro

    2014-08-14

    A new class of compounds that incorporated the structural motif of the 1-(3',4',5'-trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton was synthesized and evaluated for their antiproliferative activity in vitro, interactions with tubulin, and cell cycle effects. The most active agent, 3c, was evaluated for antitumor activity in vivo. Structure-activity relationships were elucidated with various substituents on the phenyl ring of the anilino moiety at the C-3 position of the 1,2,4-triazole ring. The best results for inhibition of cancer cell growth were obtained with the p-Me, m,p-diMe, and p-Et phenyl derivatives 3c, 3e, and 3f, respectively, and overall, these compounds were more or less as active as CA-4. Their vascular disrupting activity was evaluated in HUVEC cells, with compound 3c showing activity comparable with that of CA-4. Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/c mice, suggesting that 3c could be a new antimitotic agent with clinical potential.

  16. Validation and evaluation of an HPLC methodology for the quantification of the potent antimitotic compound (+)-discodermolide in the Caribbean marine sponge Discodermia dissoluta.

    Science.gov (United States)

    Valderrama, Katherine; Castellanos, Leonardo; Zea, Sven

    2010-08-01

    The sponge Discodermia dissoluta is the source of the potent antimitotic compound (+)-discodermolide. The relatively abundant and shallow populations of this sponge in Santa Marta, Colombia, allow for studies to evaluate the natural and biotechnological supply options of (+)-discodermolide. In this work, an RP-HPLC-UV methodology for the quantification of (+)-discodermolide from sponge samples was tested and validated. Our protocol for extracting this compound from the sponge included lyophilization, exhaustive methanol extraction, partitioning using water and dichloromethane, purification of the organic fraction in RP-18 cartridges and then finally retrieving the (+)-discodermolide in the methanol-water (80:20 v/v) fraction. This fraction was injected into an HPLC system with an Xterra RP-18 column and a detection wavelength of 235 nm. The calibration curve was linear, making it possible to calculate the LODs and quantification in these experiments. The intra-day and inter-day precision showed relative standard deviations lower than 5%. The accuracy, determined as the percentage recovery, was 99.4%. Nine samples of the sponge from the Bahamas, Bonaire, Curaçao and Santa Marta had concentrations of (+)-discodermolide ranging from 5.3 to 29.3 microg/g(-1) of wet sponge. This methodology is quick and simple, allowing for the quantification in sponges from natural environments, in situ cultures or dissociated cells.

  17. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs

    Science.gov (United States)

    2005-07-01

    of the Human Kinetochore Protein CENP-E Isabel Garcia-Saez’, Tim Yen 2, Richard H. Wade’ and Frank Kozielskil* ’Laboratoire de Microscopic The human...kinetochore is a highly complex macromolecular structure Electronique Structurale that connects chromosomes to spindle microtubules (MTs) in order to

  18. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.

    Directory of Open Access Journals (Sweden)

    Xiaolei Wang

    Full Text Available Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to paclitaxel is frequently observed. Thus, new therapy that can overcome paclitaxel resistance will be of significant clinical importance. We evaluated antiproliferative effects of an antimitotic and antivascular agent BPR0L075 in paclitaxel-resistant ovarian cancer cells. BPR0L075 displays potent and broad-spectrum cytotoxicity at low nanomolar concentrations (IC50 = 2-7 nM against both parental ovarian cancer cells (OVCAR-3, SKOV-3, and A2780-1A9 and paclitaxel-resistant sublines (OVCAR-3-TR, SKOV-3-TR, 1A9-PTX10, regardless of the expression levels of the multidrug resistance transporter P-gp and class III β-tubulin or mutation of β-tubulin. BPR0L075 blocks cell cycle at the G2/M phase in paclitaxel-resistant cells while equal concentration of paclitaxel treatment was ineffective. BPR0L075 induces cell death by a dual mechanism in parental and paclitaxel-resistant ovarian cancer cells. In the parental cells (OVCAR-3 and SKOV-3, BPR0L075 induced apoptosis, evidenced by poly(ADP-ribose polymerase (PARP cleavage and DNA ladder formation. BPR0L075 induced cell death in paclitaxel-resistant ovarian cancer cells (OVCAR-3-TR and SKOV-3-TR is primarily due to mitotic catastrophe, evidenced by formation of giant, multinucleated cells and absence of PARP cleavage. Immunoblotting analysis shows that BPR0L075 treatment induced up-regulation of cyclin B1, BubR1, MPM-2, and survivin protein levels and Bcl-XL phosphorylation in parental cells; however, in resistant cells, the endogenous expressions of BubR1 and survivin were depleted, BPR0L075 treatment failed to induce MPM-2 expression and phosphorylation of Bcl-XL. BPR0L075 induced cell death in both parental and paclitaxel-resistant ovarian cancer cells proceed through caspase-3 independent mechanisms. In conclusion, BPR0L075 displays potent cytotoxic effects in ovarian cancer cells with a potential to overcome

  19. Sodium cacodylate as antimitotic agent

    Directory of Open Access Journals (Sweden)

    Jadwiga A. Tarkowska

    2014-01-01

    Full Text Available The effect of pure sodium cacodylate on dividing cells was studied. The root meristematic cells of Allium cepa L. (the roots were squashed in acetoorcein and endosperm cells of Haemanthus katherinae Bak. (in vitro observations were used. Serious disturbances in karyokinesis and cytokinesis were found that led most often to the formation of polyploid or multinucleate (A. cepa cells. These results point to damage of the mitotic spindle and phragmoplast. Careful use of cacodylate buffer in ultrastructural studies of microtubules is advised.

  20. Comparative modelling of human β tubulin isotypes and implications for drug binding

    Science.gov (United States)

    Torin Huzil, J.; Ludueña, Richard F.; Tuszynski, Jack

    2006-02-01

    The protein tubulin is a target for several anti-mitotic drugs, which affect microtubule dynamics, ultimately leading to cell cycle arrest and apoptosis. Many of these drugs, including the taxanes and Vinca alkaloids, are currently used clinically in the treatment of several types of cancer. Another tubulin binding drug, colchicine, although too toxic to be used as a chemotherapeutic agent, is commonly used for the treatment of gout. The main disadvantage that all of these drugs share is that they bind tubulin indiscriminately, leading to the death of both cancerous and healthy cells. However, the broad cellular distribution of several tubulin isotypes provides a platform upon which to construct novel chemotherapeutic drugs that could differentiate between different cell types, reducing the undesirable side effects associated with current chemotherapeutic treatments. Here, we report an analysis of ten human β tubulin isotypes and discuss differences within each of the previously characterized paclitaxel, colchicine and vinblastine binding sites.

  1. Establishment of a drug sensitivity panel using human lung cancer cell lines.

    Directory of Open Access Journals (Sweden)

    Matsushita A

    1999-04-01

    Full Text Available We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.

  2. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.

    Science.gov (United States)

    Ahn, Sunjoo; Kearbey, Jeffrey D; Li, Chien-Ming; Duke, Charles B; Miller, Duane D; Dalton, James T

    2011-04-01

    3-(1H-Indol-2-yl)phenyl)(3,4,5-trimethoxyphenyl)methanone (I-387) is a novel indole compound with antitubulin action and potent antitumor activity in various preclinical models. I-387 avoids drug resistance mediated by P-glycoprotein and showed less neurotoxicity than vinca alkaloids during in vivo studies. We examined the pharmacokinetics and metabolism of I-387 in mice as a component of our preclinical development of this compound and continued interest in structure-activity relationships for antitubulin agents. After a 1 mg/kg intravenous dose, noncompartmental pharmacokinetic analysis in plasma showed that clearance (CL), volume of distribution at steady state (Vd(ss)), and terminal half-life (t(1/2)) of I-387 were 27 ml per min/kg, 5.3 l/kg, and 7 h, respectively. In the in vitro metabolic stability study, half-lives of I-387 were between 10 and 54 min by mouse, rat, dog, monkey, and human liver microsomes in the presence of NADPH, demonstrating interspecies variability. I-387 was most stable in rat liver microsomes and degraded quickly in monkey liver microsomes. Liquid chromatography-tandem mass spectrometry was used to identify phase I metabolites. Hydroxylation, reduction of a ketone group, and O-demethylation were the major metabolites formed by the liver microsomes of the five species. The carbonyl group of I-387 was reduced and identified as the most labile site in human liver microsomes. The results of these drug metabolism and pharmacokinetic studies provide the foundation for future structural modification of this pharmacophore to improve stability of drugs with potent anticancer effects in cancer patients.

  3. Drug: D08679 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gif Catharanthus roseus (Vinca rosea) [TAX:4058] Antineoplastic, antimitotic Same as: C07204 ATC code: L01CA02 Vinca alkaloid...aloids and analogues L01CA02 Vincristine D08679 Vincristine (INN) Target-based clas... ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS L01CA Vinca alk

  4. Activation of JNK triggers release of Brd4 from mitotic chromosomes and mediates protection from drug-induced mitotic stress.

    Science.gov (United States)

    Nishiyama, Akira; Dey, Anup; Tamura, Tomohiko; Ko, Minoru; Ozato, Keiko

    2012-01-01

    Some anti-cancer drugs, including those that alter microtubule dynamics target mitotic cells and induce apoptosis in some cell types. However, such drugs elicit protective responses in other cell types allowing cells to escape from drug-induced mitotic inhibition. Cells with a faulty protective mechanism undergo defective mitosis, leading to genome instability. Brd4 is a double bromodomain protein that remains on chromosomes during mitosis. However, Brd4 is released from mitotic chromosomes when cells are exposed to anti-mitotic drugs including nocodazole. Neither the mechanisms, nor the biological significance of drug-induced Brd4 release has been fully understood. We found that deletion of the internal C-terminal region abolished nocodazole induced Brd4 release from mouse P19 cells. Furthermore, cells expressing truncated Brd4, unable to dissociate from chromosomes were blocked from mitotic progression and failed to complete cell division. We also found that pharmacological and peptide inhibitors of the c-jun-N-terminal kinases (JNK) pathway, but not inhibitors of other MAP kinases, prevented release of Brd4 from chromosomes. The JNK inhibitor that blocked Brd4 release also blocked mitotic progression. Further supporting the role of JNK in Brd4 release, JNK2-/- embryonic fibroblasts were defective in Brd4 release and sustained greater inhibition of cell growth after nocodazole treatment. In sum, activation of JNK pathway triggers release of Brd4 from chromosomes upon nocodazole treatment, which mediates a protective response designed to minimize drug-induced mitotic stress.

  5. Drug Facts

    Medline Plus

    Full Text Available ... The Link Between Drug Use and HIV/AIDS Recovery & Treatment Drug Treatment Facts Does Drug Treatment Work? ... and Family Can Help Find Treatment/Rehab Resources Prevent Drug Use Help Children and Teens Stay Drug- ...

  6. Drug Facts

    Medline Plus

    Full Text Available ... Addiction? Addiction Risk Factors Does Addiction Run in Families? Why Is It So Hard to Quit Drugs? ... Drug Use Hurts Other People Drug Use Hurts Families Drug Use Hurts Kids Drug Use Hurts Unborn ...

  7. Drug Allergy

    Science.gov (United States)

    ... Loss of consciousness Other conditions resulting from drug allergy Less common drug allergy reactions occur days or ... you take the drug. Drugs commonly linked to allergies Although any drug can cause an allergic reaction, ...

  8. Drug Facts

    Medline Plus

    Full Text Available ... Use Hurts Unborn Children Drug Use Hurts Your Health Drug Use Hurts Bodies Drug Use Hurts Brains Drug Use and Mental Health Problems Often Happen Together The Link Between Drug ...

  9. Drug allergies

    Science.gov (United States)

    Allergic reaction - drug (medication); Drug hypersensitivity; Medication hypersensitivity ... A drug allergy involves an immune response in the body that produces an allergic reaction to a medicine. The ...

  10. Drugs and Drug Abuse.

    Science.gov (United States)

    Anastas, Robert, Comp.; And Others.

    GRADES OR AGES: Secondary grades. SUBJECT MATTER: Drugs and drug abuse. ORGANIZATION AND PHYSICAL APPEARANCE: The guide is divided into several sections, each of which is in outline or list form. It is xeroxed and spiral-bound with a paper cover. OBJECTIVES AND ACTIVITIES: No objectives are mentioned. The major portion of the guide contains a…

  11. Club Drugs

    Science.gov (United States)

    ... uses. Other uses of these drugs are abuse. Club drugs are also sometimes used as "date rape" drugs, to make someone unable to say no to or fight back against sexual assault. Abusing these drugs can ...

  12. 抗癌药秋水仙碱及其类似物构效关系研究进展%RECENT PROGRESS IN STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON THE ANTICANCER DRUG COLCHICINE AND ITS ANALOGUES

    Institute of Scientific and Technical Information of China (English)

    潘显道; 方唯硕

    2002-01-01

    @@ Colchicine (1) (Figure 1), the major alkaloid isolated from Colchicum autumnale in 1820, is a potent drug that interferes with microtubules both in vitro and in vivo, thereby causing cells to accumulate in apparent mitotic arrest during the cell cycle. Colchicine has been used in the treatment of acute gout, familial Mediterranean fever, scleroderma, amyloidosis, Behcet's disease and liver disorder, particularly cirrhosis[1]. Although colchicine is a potent antimitotic agent, its medicinal uses are limited due to its high toxicity. Virtually all its therapeutic and toxic effects were believed to be the consequence of its interaction with tubulin. Hence, colchicine has become an attractive molecule that the medicinal chemists were in pursuit of. It is a less toxic and more selective analogue which bind to tubulin.

  13. Drug Reactions

    Science.gov (United States)

    ... problem is interactions, which may occur between Two drugs, such as aspirin and blood thinners Drugs and food, such as statins and grapefruit Drugs and supplements, such as ginkgo and blood thinners ...

  14. Drug Resistance

    Science.gov (United States)

    HIV Treatment Drug Resistance (Last updated 3/2/2017; last reviewed 3/2/2017) Key Points As HIV multiplies in the ... the risk of drug resistance. What is HIV drug resistance? Once a person becomes infected with HIV, ...

  15. Drug Facts

    Medline Plus

    Full Text Available ... abuse, addiction, and treatment. Watch Videos Information About Drugs Alcohol Bath Salts Cocaine Heroin Marijuana MDMA Meth ... 662-HELP (4357) at any time to find drug treatment centers near you. I want my daughter ...

  16. Drugged Driving

    Science.gov (United States)

    ... Parents & Educators Children & Teens Search Connect with NIDA : Google Plus Facebook LinkedIn Twitter YouTube Flickr RSS Menu ... misuse of prescription drugs can make driving a car unsafe—just like driving after drinking alcohol. Drugged ...

  17. Prescription Drugs

    Science.gov (United States)

    ... Skippy, The Smart Drug, Vitamin R, Bennies, Black Beauties, Roses, Hearts, Speed, Uppers Prescription drug misuse has ... body, especially in brain areas involved in the perception of pain and pleasure. Prescription stimulants , such as ...

  18. Study Drugs

    Science.gov (United States)

    ... study drugs: amphetamines like Adderall, Dexedrine, or Vyvanse methylphenidates like Ritalin or Concerta Most people get study ... How Much Sleep Do I Need? Prescription Drug Abuse How to Make Homework Less Work Organizing Schoolwork & ...

  19. Drug Facts

    Science.gov (United States)

    ... drug. "Max" was addicted to prescription drugs. The addiction slowly took over his life. I need different people around me. To stop using marijuana, "Cristina" is making positive changes in her life. She finds support from ...

  20. Drug Facts

    Medline Plus

    Full Text Available ... Marijuana (Weed, Pot) Facts MDMA (Ecstasy, Molly) Facts Meth (Crank, Ice) Facts Pain Medicine (Oxy, Vike) Facts ... Drugs Alcohol Bath Salts Cocaine Heroin Marijuana MDMA Meth Pain Medicines Spice (K2) Tobacco/Nicotine Other Drugs ...

  1. Drugs (image)

    Science.gov (United States)

    ... Drugs for fever, cough, stuffy nose, runny nose, diarrhea, and allergies are common drugs which are especially helpful during times of illness. All medications should be kept out of the reach of children.

  2. Drug allergy

    Directory of Open Access Journals (Sweden)

    Warrington Richard

    2011-11-01

    Full Text Available Abstract Drug allergy encompasses a spectrum of immunologically-mediated hypersensitivity reactions with varying mechanisms and clinical presentations. This type of adverse drug reaction (ADR not only affects patient quality of life, but may also lead to delayed treatment, unnecessary investigations, and even mortality. Given the myriad of symptoms associated with the condition, diagnosis is often challenging. Therefore, referral to an allergist experienced in the identification, diagnosis and management of drug allergy is recommended if a drug-induced allergic reaction is suspected. Diagnosis relies on a careful history and physical examination. In some instances, skin testing, graded challenges and induction of drug tolerance procedures may be required. The most effective strategy for the management of drug allergy is avoidance or discontinuation of the offending drug. When available, alternative medications with unrelated chemical structures should be substituted. Cross-reactivity among drugs should be taken into consideration when choosing alternative agents. Additional therapy for drug hypersensitivity reactions is largely supportive and may include topical corticosteroids, oral antihistamines and, in severe cases, systemic corticosteroids. In the event of anaphylaxis, the treatment of choice is injectable epinephrine. If a particular drug to which the patient is allergic is indicated and there is no suitable alternative, induction of drug tolerance procedures may be considered to induce temporary tolerance to the drug. This article provides a backgrounder on drug allergy and strategies for the diagnosis and management of some of the most common drug-induced allergic reactions, such allergies to penicillin, sulfonamides, cephalosporins, radiocontrast media, local anesthetics, general anesthetics, acetylsalicylic acid (ASA and non-steroidal anti-inflammatory drugs.

  3. Anti-mitotic activity towards sea urchin eggs of dichloromethane fraction obtained from Allamanda schottii Pohl (Apocynaceae Atividade anti-mitótica da fração diclorometano obtida de Allamanda schottii Pohl (Apocynaceae sobre ovos do ouriço do mar

    Directory of Open Access Journals (Sweden)

    Louisa M. A. Sousa

    2009-06-01

    Full Text Available Allamanda (Apocynaceae is a genus of climbing shrubs known for producing compounds with a range of biological activities. Previous works have shown the anti-proliferative effect of the ethanolic extract of Allamanda schottii on leukemic cells. The present work was conducted to evaluate the effects of dichloromethane fraction, obtained from Allamanda schottii, on sea urchin Echinometra lucunter eggs, as a multicellular model for evaluating anti-tumor activity. Our results show an inhibition of sea urchin development in a dose-dependent manner in the presence of dichloromethane fraction. The IC50 values for first and third cleavage and blastulae stage were 103.7 µg/mL, 33.1 µg/mL and 10.2 µg/mL, respectively. These results also demonstrate the cumulative effect of this fraction on sea urchin embryos. In the present work, the expressive anti-mitotic activity of dichloromethane fraction towards sea urchin eggs, a multicellular model, reinforces the anti-tumor potential of the Allamanda schotti.Allamanda (Apocynacea é um gênero de arbustos escandentes conhecido por produzir compostos com várias atividades biológicas. Trabalhos anteriores têm mostrado um efeito anti-proliferativo do extrato etanólico de Allamanda schottii sobre células leucêmicas. O presente trabalho foi realizado para avaliar o efeito da fração diclorometano, obtida de Allamanda schotti, sobre os ovos de ouriço-do-mar de Echinometra lucunter, como um modelo multicelular para estudar atividade anti-tumoral. Nossos resultados mostram uma inibição do desenvolvimento dos ovos de uma maneira dose-dependente na presença da fração diclorometano. Os valores de IC50 para a primeira e terceira clivagem e para o estágio de blástula foram de 103,7 µg/mL, 33.1 µg/mL e 10,2 µg/mL, respectivamente. Estes resultados também demonstram um efeito acumulativo da fração sobre os embriões do ouriço-do-mar. No presente trabalho, esta expressiva atividade anti-mitótica da fra

  4. In vitro haematic proteins adsorption and cytocompatibility study on acrylic copolymer to realise coatings for drug-eluting stents

    Energy Technology Data Exchange (ETDEWEB)

    Gagliardi, Mariacristina, E-mail: mariacristina.gagliardi@iit.it

    2012-12-01

    In the present paper, a preliminary in vitro analysis of biocompatibility of newly-synthesised acrylic copolymers is reported. In particular, with the aim to obtain coatings for drug-eluting stents, blood protein absorption and cytocompatibility were studied. For protein absorption tests, bovine serum albumin and bovine plasma fibrinogen were considered. Cytocompatibility was tested using C2C12 cell line as model, analysing the behaviour of polymeric matrices and of drug-eluting systems, obtained loading polymeric matrices with paclitaxel, an anti-mitotic drug, in order to evaluate the efficacy of a pharmacological treatment locally administered from these materials. Results showed that the amount of albumin absorbed was greater than the amount of fibrinogen (comprised in the range of 70%-85% and 10%-22% respectively) and it is a good behaviour in terms of haemocompatibility. Cell culture tests showed good adhesion properties and a relative poor proliferation. In addition, a strong effect related to drug elution and a correlation with the macromolecular composition were detected. In this preliminary analysis, tested materials showed good characteristics and can be considered possible candidates to obtain coatings for drug-eluting stents. Highlights: Black-Right-Pointing-Pointer Preliminary evaluation of haemo- and cytocompatibility of newly-synthesised acrylic copolymers Black-Right-Pointing-Pointer Materials adsorb higher amounts of albumin and with a faster rate than fibrinogen. Black-Right-Pointing-Pointer Protein adsorption depended on the macromolecular composition and surface properties. Black-Right-Pointing-Pointer Cell viability on pure samples and efficacy of paclitaxel release were verified in C2C12 cultures.

  5. Orphan drugs

    Directory of Open Access Journals (Sweden)

    Goločorbin-Kon Svetlana

    2013-01-01

    Full Text Available Introduction. Drugs used for treatment of rare diseases are known worldwide under the term of orphan drugs because pharmaceutical companies have not been interested in ”adopting” them, that is in investing in research, developing and producing these drugs. This kind of policy has been justified by the fact that these drugs are targeted for small markets, that only a small number of patients is available for clinical trials, and that large investments are required for the development of drugs meant to treat diseases whose pathogenesis has not yet been clarified in majority of cases. The aim of this paper is to present previous and present status of orphan drugs in Serbia and other countries. The beginning of orphan drugs development. This problem was first recognized by Congress of the United States of America in January 1983, and when the ”Orphan Drug Act” was passed, it was a turning point in the development of orphan drugs. This law provides pharmaceutical companies with a series of reliefs, both financial ones that allow them to regain funds invested into the research and development and regulatory ones. Seven years of marketing exclusivity, as a type of patent monopoly, is the most important relief that enables companies to make large profits. Conclusion. There are no sufficient funds and institutions to give financial support to the patients. It is therefore necessary to make health professionals much more aware of rare diseases in order to avoid time loss in making the right diagnosis and thus to gain more time to treat rare diseases. The importance of discovery, development and production of orphan drugs lies in the number of patients whose life quality can be improved significantly by administration of these drugs as well as in the number of potential survivals resulting from the treatment with these drugs. [Projekat Ministarstva nauke Republike Srbije, br. III 41012

  6. Club Drugs

    Science.gov (United States)

    ... Anabolic) Synthetic Cannabinoids (K2/Spice) Synthetic Cathinones (Bath Salts) Tobacco/Nicotine Other Drugs Related Topics Addiction Science Adolescent Brain Comorbidity College-Age & Young Adults ...

  7. Herbal drugs and drug interactions

    OpenAIRE

    Gül Dülger

    2014-01-01

    Herbal drugs are defined as any form of a plant or plant product that contains a single herb or combinations of herbs that are believed to have complementary effects. Although they are considered to be safe, because they are natural, they may have various adverse effects, and may interact with other herbal products or conventional drugs. These interactions are especially important for drugs with narrow therapeutic indices.In the present study, pharmacokinetic and pharmacodynamic interactions ...

  8. Drugged Driving

    Science.gov (United States)

    ... Age Adults in 2015 Teens and E-cigarettes Abuse of Prescription (Rx) Drugs Affects Young Adults Most Substance Use in Women and Men View All NIDA's Publication Series Brain Power DrugFacts Mind Over Matter Research Reports NIDA Home ...

  9. Drug treatment

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    2010263 Drug resistance mechanism of non-small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib.JU Lixia(鞠立霞),et al. Dept Oncol,Shanghai Pulm Hosp,Tongji Univ,Shanghai 200433. Chin J Tuberc Respir Dis 2010;33(5):354-358. Objective To

  10. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.

    Science.gov (United States)

    Aneja, Ritu; Vangapandu, Surya N; Lopus, Manu; Chandra, Ramesh; Panda, Dulal; Joshi, Harish C

    2006-06-01

    We have shown previously that an antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans. Structure-function analyses pointed to a proton at position-9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Thus, many noscapine analogs with different functional moieties at position-9 were synthesized. Those analogs that kill human cancer cells resistant to other antimicrotubule agents, vincas and taxanes, were screened. Here, we present one such analog, 9-nitro-noscapine (9-nitro-nos), which binds tubulin and induces apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine, and teniposide. 9-Nitro-nos treatment at doses as high as 100 microM did not affect the cell cycle profile of normal human fibroblasts. This selectivity of 9-nitro-nos for cancer cells represents a unique edge over the other available antimitotics. 9-Nitro-nos perturbs the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive cells. Thus, we conclude that 9-nitro-nos has great potential to be a novel therapeutic agent for ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.

  11. Identification of novel and improved antimitotic agents derived from noscapine.

    Science.gov (United States)

    Anderson, James T; Ting, Anthony E; Boozer, Sherry; Brunden, Kurt R; Crumrine, Chris; Danzig, Joel; Dent, Tom; Faga, Laurel; Harrington, John J; Hodnick, William F; Murphy, Steven M; Pawlowski, Gary; Perry, Robert; Raber, Amy; Rundlett, Stephen E; Stricker-Krongrad, Alain; Wang, Jianmin; Bennani, Youssef L

    2005-11-17

    Analogues of the natural product noscapine were synthesized and their potential as antitumor agents evaluated. The discovery of a novel regioselective O-demethylation facilitated the synthesis of the potent aniline 6, which arrests mammalian cells in the G2/M phase of the cell cycle at 0.1 microM and also affects tubulin polymerization. Aniline 6 is orally bioavailable and is 250-fold more potent than noscapine in reducing cell proliferation in rapidly dividing cells.

  12. Drug Facts

    Medline Plus

    Full Text Available ... That People Abuse Alcohol Facts Bath Salts Facts Cocaine (Coke, Crack) Facts Heroin (Smack, Junk) Facts Marijuana ( ... Watch Videos Information About Drugs Alcohol Bath Salts Cocaine Heroin Marijuana MDMA Meth Pain Medicines Spice (K2) ...

  13. Antiretroviral drugs.

    Science.gov (United States)

    De Clercq, Erik

    2010-10-01

    In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'-dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The INIs (i.e. raltegravir) represent the most recent advance in the search for effective and selective anti-HIV agents. Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one.

  14. Drug Addiction

    Science.gov (United States)

    ... stimulants Stimulants include amphetamines, meth (methamphetamine), cocaine and methylphenidate (Ritalin). They are often used and abused in ... a medication, talk to your doctor. Preventing drug abuse in children and teenagers Take these steps to ...

  15. Drug-drug interactions: antiretroviral drugs and recreational drugs.

    Science.gov (United States)

    Staltari, Orietta; Leporini, Christian; Caroleo, Benedetto; Russo, Emilio; Siniscalchi, Antonio; De Sarro, Giovambattista; Gallelli, Luca

    2014-01-01

    With the advances in antiretroviral (ARV) therapy, patients with Human Immunodeficiency Virus (HIV) infection are living longer, however, some patients encounter co- morbidities which sometimes require treatment. Therefore, during the treatment with ARV drugs these patients could take several recreational drugs (e.g. amphetamines, hallucinogenes, opiates, or alcohol) with a possible development of drug-drug interactions (DDIs). In particular, Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are mainly excreted through the kidney and are not substrates of the cytochrome P450 or P-glycoprotein, therefore the DDIs during this treatment are minimal. In contrast, the other ARV drugs (i.e. non-nucleoside reversetranscriptase inhibitors, Protease inhibitors, Integrase inhibitors, chemokine receptor 5 antagonists and HIV-fusion inhibitors) are an important class of antiretroviral medications that are frequent components of HAART regimens but show several DDIs related to interaction with the cytochrome P450 or P-glycoprotein. In this paper we will review data concerning the possibility of DDI in HIV patients treated with ARV and taking recreational drugs.

  16. COPD - control drugs

    Science.gov (United States)

    Chronic obstructive pulmonary disease - control drugs; Bronchodilators - COPD - control drugs; Beta agonist inhaler - COPD - control drugs; Anticholinergic inhaler - COPD - control drugs; Long-acting inhaler - COPD - ...

  17. Herbal drugs and drug interactions

    Directory of Open Access Journals (Sweden)

    Gül Dülger

    2012-01-01

    Full Text Available Herbal drugs are defined as any form of a plant or plant product that contains a single herb or combinations of herbs that are believed to have complementary effects. Although they are considered to be safe, because they are natural, they may have various adverse effects, and may interact with other herbal products or conventional drugs. These interactions are especially important for drugs with narrow therapeutic indices.In the present study, pharmacokinetic and pharmacodynamic interactions of some most commanly used herbals (St John's wort, ginkgo biloba, ginseng, ginger, garlic, echinacea, ephedra and valerian with the conventional drugs were reviewed. Pharmacokinetic interactions involve mainly induction or inhibition of the cytochrome P450 isozymes and p-glycoproteins by the herbal medicine, thus changing the absorption and/or elimination rate and consequently the efficacy of the concommitantly used drugs. St John's wort, a well known enzyme inducer, decreases the efficacy of most of the other drugs that are known to be the substrates of these enzymes.Pharmacodynamic interactions may be due to additive or synergistic effects which results in enhanced effect or toxicity, or herbal medicines with antagonistic properties reduce drug efficacy and result in therapeutic failure. For exampla, St John's wort may have synergistic effects with other antidepressant drugs used by the patient, resulting in increased CNS effects.Herbals like ginseng, ginkgo, garlic, ginger were reported to increase bleeding time, thus potentiating the effect of anticoagulant and antithrombotic agents. In conclusion, patients should be warned against the interaction between the herbal products and conventional medicines.

  18. Mucoactive drugs

    Directory of Open Access Journals (Sweden)

    R. Balsamo

    2010-06-01

    Full Text Available Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Airway mucosal infection and/or inflammation associated with these diseases often gives rise to inflammatory products, including neutrophil-derived DNA and filamentous actin, in addition to bacteria, apoptotic cells and cellular debris, that may collectively increase mucus production and viscosity. Mucoactive agents have been the medication of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Many mucoactive drugs are currently available and can be classified according to their putative mechanism of action. Mucoactive medications include expectorants, mucoregulators, mucolytics and mucokinetics. By developing our understanding of the specific effects of mucoactive agents, we may result in improved therapeutic use of these drugs. The present review provides a summary of the most clinically relevant mucoactive drugs in addition to their potential mechanism of action.

  19. Drug resistance

    NARCIS (Netherlands)

    Gorter, J.A.; Potschka, H.; Noebels, J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V.

    2012-01-01

    Drug resistance remains to be one of the major challenges in epilepsy therapy. Identification of factors that contribute to therapeutic failure is crucial for future development of novel therapeutic strategies for difficult-to-treat epilepsies. Several clinical studies have shown that high seizure f

  20. Drug signs and teenagers

    Science.gov (United States)

    ... use in teenagers; Drug abuse - teenagers; Substance abuse - teenagers Images Signs of drug abuse References National Council on Alcoholism and Drug Dependence. Talking with Children. www.ncadd. ...

  1. Drug resistance and antiretroviral drug development

    OpenAIRE

    Shafer, Robert W.; Jonathan M Schapiro

    2005-01-01

    As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible fo...

  2. [Emergent drugs (I): smart drugs].

    Science.gov (United States)

    Burillo-Putze, G; Díaz, B Climent; Pazos, J L Echarte; Mas, P Munné; Miró, O; Puiguriguer, J; Dargan, P

    2011-01-01

    In recent years, a series of new drugs, known as smart drugs or legal highs, have gaining in popularity. They are easily obtainable through online shops. This is happening amongst younger segments of the population and is associated with recreational consumption, at weekends. In general, they are synthetic derivatives of natural products. There has been hardly any clinical research into them and they are not detectable in hospital laboratories. Three of these products, BZP (1- benzylpiperazine), mefedrone (4-methylmethcathinone) and Spice are probably the most widely used in Europe. The first two are consumed as an alternative to ecstasy and cocaine and are characterized by their producing a clinical profile of a sympathetic mimetic type; on occasion, they have serious consequences, with convulsions and even death. Spice (a mixture of herbs with synthetic cannabinoids such as JWH-018, JWH-073 and CP 47497-C8) is giving rise to profiles of dependence and schizophrenia. Although the emergent drugs have an aura of safety, there is an increasing amount of experience on their secondary effects.

  3. Drugs Approved for Retinoblastoma

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for retinoblastoma. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries.

  4. Drugs Approved for Neuroblastoma

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for neuroblastoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  5. Drug Plan Coverage Rules

    Science.gov (United States)

    ... works with other insurance Find health & drug plans Drug plan coverage rules Note Call your Medicare drug ... shingles vaccine) when medically necessary to prevent illness. Drugs you get in hospital outpatient settings In most ...

  6. Urine drug screen

    Science.gov (United States)

    Drug screen -- urine ... detect the presence of illegal and some prescription drugs in your urine. Their presence indicates that you recently used these drugs. Some drugs may remain in your system for ...

  7. National Drug Code Directory

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs...

  8. National Drug Code Directory

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured,...

  9. Medication/Drug Allergy

    Science.gov (United States)

    ... Science Education & Training Home Conditions Medication/Drug Allergy Medication/Drug Allergy Make an Appointment Find a Doctor ... immediate or delayed. What Is an Allergy to Medication/Drugs? Allergies to drugs/medications are complicated, because ...

  10. Drug Preferences of Multiple Drug Abusers.

    Science.gov (United States)

    Harford, Robert J.

    1978-01-01

    Examined drug preferences of a group of active multiple drug abusers referred for treatment. Nearly half the respondents preferred drugs other than type they most frequently used. Preferences were related to method of administration. Results suggest preference is one among several determinants of drug use. (Author/BEF)

  11. Personality, Drug Preference, Drug Use, and Drug Availability

    Science.gov (United States)

    Feldman, Marc; Boyer, Bret; Kumar, V. K.; Prout, Maurice

    2011-01-01

    This study examined the relationship between drug preference, drug use, drug availability, and personality among individuals (n = 100) in treatment for substance abuse in an effort to replicate the results of an earlier study (Feldman, Kumar, Angelini, Pekala, & Porter, 2007) designed to test prediction derived from Eysenck's (1957, 1967)…

  12. AIDSinfo Drug Database

    Science.gov (United States)

    ... U V W X Y Z All Drugs Drug News Thursday, February 2, 2017 Sustiva Drug Label Updated ... Drug Label Updated Tuesday, January 31, 2017 Stribild Drug Label Updated More News Mobile Apps iPhone/iPad App Android App Back ...

  13. Drug-drug interactions between clopidogrel and novel cardiovascular drugs.

    Science.gov (United States)

    Pelliccia, Francesco; Rollini, Fabiana; Marazzi, Giuseppe; Greco, Cesare; Gaudio, Carlo; Angiolillo, Dominick J

    2015-10-15

    The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events. These two agents act in concert to ameliorate the prothrombotic processes stimulated by plaque rupture and vessel injury complicating cardiovascular disease. Guidelines recommend the use of clopidogrel in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention, and the drug remains the most utilized P2Y12 receptor inhibitor despite the fact that newer antiplatelet agents are now available. In recent years, numerous studies have shown inconsistency in the efficacy of clopidogrel to prevent atherothrombotic events. Studies of platelet function testing have shown variability in the response to clopidogrel. One of the major reason for this phenomenon lies in the interaction between clopidogrel and other drugs that may affect clopidogrel absorption, metabolism, and ultimately its antiplatelet action. Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia. Previous systematic reviews have focused on drug-drug interactions between clopidogrel and specific pharmacologic classes, such as proton pump inhibitors, calcium channel blockers, and statins. However, more recent pieces of scientific evidence show that clopidogrel may also interact with newer drugs that are now available for the treatment of cardiovascular patients. Accordingly, the aim of this review is to highlight and discuss recent data on drug-drug interactions between clopidogrel and third-generation proton pump inhibitors, pantoprazole and lansoprazole, statins, pitavastatin, and antianginal drug, ranolazine.

  14. Attitudes towards drug legalization among drug users.

    Science.gov (United States)

    Trevino, Roberto A; Richard, Alan J

    2002-01-01

    Research shows that support for legalization of drugs varies significantly among different sociodemographic and political groups. Yet there is little research examining the degree of support for legalization of drugs among drug users. This paper examines how frequency and type of drug use affect the support for legalization of drugs after adjusting for the effects of political affiliation and sociodemographic characteristics. A sample of 188 drug users and non-drug users were asked whether they would support the legalization of marijuana, cocaine, and heroin. Respondents reported their use of marijuana, crack, cocaine, heroin, speedball, and/or methamphetamines during the previous 30 days. Support for legalization of drugs was analyzed by estimating three separate logistic regressions. The results showed that the support for the legalization of drugs depended on the definition of "drug user" and the type of drug. In general, however, the results showed that marijuana users were more likely to support legalizing marijuana, but they were less likely to support the legalization of cocaine and heroin. On the other hand, users of crack, cocaine, heroin, speedball, and/or methamphetamines were more likely to support legalizing all drugs including cocaine and heroin.

  15. KEGG DRUG / Acutect (TN) [KEGG DRUG

    Lifescience Database Archive (English)

    Full Text Available DRUG: D06027 Entry D06027Drug Name Technetium Tc 99m apcitide (USP); Acutect (TN) F... 1 838085 1 848586 1 857781 1 868182 1 878280 1 888687 1 898288 2 908689 2 918390 1 929091 2 939092 1 949495 2 KEGG DRUG / Acutect (TN) ...

  16. Drug-induced hepatitis

    Science.gov (United States)

    Toxic hepatitis ... to get liver damage. Some drugs can cause hepatitis with small doses, even if the liver breakdown ... liver. Many different drugs can cause drug-induced hepatitis. Painkillers and fever reducers that contain acetaminophen are ...

  17. Prescription Drug Abuse

    Science.gov (United States)

    ... Whether they're using street drugs or medications, drug abusers often have trouble at school, at home, with ... a short period of time may make a drug abuser aggressive or paranoid. Although stimulant abuse might not ...

  18. Drugs of Abuse Testing

    Science.gov (United States)

    ... may be used for: Medical screening Legal or forensic information Employment drug testing Sports/athletics testing Monitoring ... article Emergency and Overdose Drug Testing . Legal or Forensic Testing Drug testing for legal purposes primarily aims ...

  19. Drugs Approved for Melanoma

    Science.gov (United States)

    ... Ask about Your Treatment Research Drugs Approved for Melanoma This page lists cancer drugs approved by the ... that are not listed here. Drugs Approved for Melanoma Aldesleukin Cobimetinib Cotellic (Cobimetinib) Dabrafenib Dacarbazine DTIC-Dome ( ...

  20. Drug Interaction API

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Interaction API is a web service for accessing drug-drug interactions. No license is needed to use the Interaction API. Currently, the API uses DrugBank for its...

  1. Drug Retention Times

    Energy Technology Data Exchange (ETDEWEB)

    Center for Human Reliability Studies

    2007-05-01

    The purpose of this monograph is to provide information on drug retention times in the human body. The information provided is based on plausible illegal drug use activities that might be engaged in by a recreational drug user

  2. Drugs: Shatter the Myths

    Science.gov (United States)

    ... ML. Tobacco, alcohol, and other risk behaviors in film: how well do MPAA ratings distinguish content? J ... about drugs and drug abuse. NDFW includes local school and community events and Drug Facts Chat Day, ...

  3. Drug Retention Times

    Energy Technology Data Exchange (ETDEWEB)

    Center for Human Reliability Studies

    2007-05-01

    The purpose of this monograph is to provide information on drug retention times in the human body. The information provided is based on plausible illegal drug use activities that might be engaged in by a recreational drug user.

  4. Drug Development Process

    Science.gov (United States)

    ... Device Approvals The Drug Development Process The Drug Development Process Share Tweet Linkedin Pin it More sharing ... Pin it Email Print Step 1 Discovery and Development Discovery and Development Research for a new drug ...

  5. Drug: D06912 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nese Medicine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs for removing blood stasis D06912 *Quercus cortex; Bokusoku Drug...s for external use Drugs for external use D06912 *Quercu

  6. Drug: D06717 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 0 Crude drugs D06717 Safflower (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs... for removing blood stasis D06717 *Safflower; Safflower Drugs for external use Drugs

  7. Drug: D06770 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ommia family) Eucommia bark (dried) Major component: Gutta-percha Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D0...e Drugs Drugs for Qi Drugs for replenishing Qi D06770 Eucommia bark Crude drugs [BR:br08305] Dicot plants: a

  8. CONCEPT OF DRUG INTERACTION

    Directory of Open Access Journals (Sweden)

    Singh Nidhi

    2012-07-01

    Full Text Available Drug interaction is an increasingly important cause of adverse reactions (ADR, and is the modification of the effect of one drug (object by the prior or concomitant administration of another drug (precipitant drug. Drug interaction may either enhance or diminish the intended effect of one or both drugs. For example severe haemorrhage may occur if warfarin and salicylates (asprin are combined. Precipitant drugs modify the object drug's absorption, distribution, metabolism, excretion or actual clinical effect. Nonsteroidal anti-inflammatory drugs, antibiotics and, in particular, rifampin are common precipitant drugs prescribed in primary care practice. Drugs with a narrow therapeutic range or low therapeutic index are more likely to be the objects for serious drug interactions. Object drugs in common use include warfarin, fluoroquinolones, antiepileptic drugs, oral contraceptives, cisapride and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Many other drugs, act as precipitants or objects, and a number of drugs act as both. The aim of present review is to throw light on the concept of drug interaction.

  9. Drugs and Young People

    Science.gov (United States)

    Drug abuse is a serious public health problem. It affects almost every community and family in some way. Drug abuse in children and teenagers may pose a ... of young people may be more susceptible to drug abuse and addiction than adult brains. Abused drugs ...

  10. Fighting the Drug War.

    Science.gov (United States)

    The Journal of State Government, 1990

    1990-01-01

    All nine articles in this periodical issue focus on the theme of the war against illegal drug use, approaching the topic from a variety of perspectives. The articles are: "The Drug War: Meeting the Challenge" (Stanley E. Morris); "Ways to Fight Drug Abuse" (Bruce A. Feldman); "Treatment Key to Fighting Drugs" (Stan…

  11. Utah Drug Use Questionnaire.

    Science.gov (United States)

    Governor's Citizen Advisory Committee on Drugs, Salt Lake City, UT.

    This questionnaire assesses drug use practices in junior and senior high school students. The 21 multiple choice items pertain to drug use practices, use history, available of drugs, main reason for drug use, and demographic data. The questionnaire is untimed, group administered, and may be given by the classroom teacher in about 10 minutes. Item…

  12. New drug update: 2010.

    Science.gov (United States)

    Hussar, Daniel A

    2010-10-01

    Five new drugs that are used for medical problems often encountered in the elderly have been selected for consideration in this review. The uses and most important properties of these agents are considered, and a rating for each new drug is determined using the New Drug Comparison Rating (NDCR) system developed by the author. In the NDCR system, a rating from 1 to 5 (5 being the highest rating) is assigned for each new drug. The rating is based on a comparison of the new drug with related drugs already marketed. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating.

  13. 2016 New Drug Update.

    Science.gov (United States)

    Hussar, Daniel A

    2016-04-01

    Six new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating (NDCR) system developed by the author. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating. The drugs include a hypnotic, an anticoagulant, two drugs for heart failure, and two drugs to reduce low-density lipoprotein cholesterol.

  14. New drug update: 2011.

    Science.gov (United States)

    Hussar, Daniel A

    2012-04-01

    Five new drugs that are used for medical problems often encountered in the elderly have been selected for consideration in this review. The uses and most important properties of these agents are considered, and a rating for each new drug is determined using the New Drug Comparison Rating (NDCR) system developed by the author. In the NDCR system, a rating from 1 to 5 (5 being the highest rating) is assigned for each new drug. The rating is based on a comparison of the new drug with related drugs already marketed. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating.

  15. New drug update: 2012.

    Science.gov (United States)

    Hussar, Daniel A

    2013-04-01

    Five new drugs that are used for medical problems often experienced by the elderly have been selected for consideration in this review. The uses and most important properties of these agents are considered, and a rating for each new drug is determined. The rating is based on a comparison of the new drug with related drugs already marketed. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating.

  16. Food and drugs

    OpenAIRE

    Đaković-Švajcer Kornelija

    2002-01-01

    Food can exert a significant influence on the effects of certain drugs. The interactions between food and drugs can be pharmacokinetic and pharmacodynamic. Pharmacokinetic interactions most often take place on absorption and drug metabolism levels. Absorption can be either accelerated or delayed, increased or decreased, while drug metabolism can be either stimulated or inhibited. The factors which influence food-drug interactions are as follows: composition and physic-chemical properties of d...

  17. Drug interactions with oral sulphonylurea hypoglycaemic drugs.

    Science.gov (United States)

    Hansen, J M; Christensen, L K

    1977-01-01

    The effect of the oral sulphonylurea hypoglycaemic drugs may be influenced by a large number of other drugs. Some of these combinations (e.g. phenylbutazone, sulphaphenazole) may result in cases of severe hypoglycaemic collapse. Tolbutamide and chlorpropamide should never be given to a patient without a prior careful check of which medicaments are already being given. Similarly, no drug should be given to a diabetic treated with tolbutamide and chlorpropamide without consideration of the possibility of interaction phenomena.

  18. Drug: D06742 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Crude drugs D06742 Houttuynia herb (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drug...s for clearing heat D06742 *Houttuynia herb; Houttuynia harb Drugs... for pus discharge Drugs for pus discharge D06742 *Houttuynia herb; Houttuynia harb Crude drugs [B

  19. Drug: D06803 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 10 Crude drugs 5100 Crude drugs D06803 Nelumbo seed (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for Qi Drugs for replenishing Qi D06803 Nelumbo seed Crude dr

  20. Drug: D06749 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs 5100 Crude drugs D06749 Nuphar rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for blood Drugs for removing blood stasis D06749 Nuphar rhizome; Nup

  1. Drug: D06706 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 06706 Immature orange (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs... for regulating Qi D06706 *Immature orange; Kijitsu Drugs for pus discharge Drugs

  2. Drug: D06736 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ehmannia root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for replenishing Ying Drugs... for replenishing Ying D06736 *Rehmannia root; Rehmannia root Drugs for blood Drugs for replenishin

  3. Drug: D06813 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nent: Scopoletin [CPD:C01752] Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Stomachic and a...ntidiarrheal drugs Stomachic and antidiarrheal drugs D06813 *Dolichos seed Drugs for dampness Drugs

  4. Drug: D06767 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gs D06767 Benincasa seed (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs... for removing blood stasis D06767 *Benincasa seed Drugs for pus discharge Drugs

  5. Drug: D09185 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Stomachic and antidiarrheal drugs Stomachic ...and antidiarrheal drugs D09185 *Myrica Drugs for external use Drugs for external use D09185 *Myrica Crude dr

  6. Drug: D03404 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs D03404 Cardamon (JP16); Cardamom seed (NF) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for dampness Drugs for resolving dampness D03404 Cardamon; Cardamom seed; Cardamon Crude drugs [B

  7. Drug: D04705 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 05 Lithospermum root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for clearing heat Drugs for clearing heat D04705 *Lithospermum root; Lithospermum root Drugs for external use Drugs

  8. Drug: D06697 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 00 Crude drugs D06697 Polygonum root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs... Drugs for blood Drugs for replenishing blood D06697 Polygonum root Crude drugs [BR

  9. Drug: D05431 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (NF) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Diaphoretic d...rugs Diaphoretic drugs pungent in flavor and cool in property D05431 *Peppermint; Peppermint Drugs for external use Drugs

  10. Drug: D06894 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available daisy family) Artemisia leaf (dried) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs... for replenishing blood D06894 *Artemisiae folium; Gaiyo Drugs for external use Drugs

  11. Drug: D06772 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Stomachic an...d antidiarrheal drugs Stomachic and antidiarrheal drugs D06772 *Ginseng; Powdered ginseng; Ginseng Drugs for Qi Drugs

  12. Drug: D09151 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available raditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs for regulating Qi D09151 Sw...eetflag rhizome Other drugs Drugs for resuscitation D09151 Acorus gramineus rhizo

  13. Drug: D06689 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs...lodendron bark; Phellodendron bark Drugs for external use Drugs for external use D06689 *Phellodendron bark;

  14. Medicaid Drug Rebate Program Data

    Data.gov (United States)

    U.S. Department of Health & Human Services — Product Data for Drugs in the Medicaid Drug Rebate Program. The rebate drug product data file contains the active drugs that have been reported by participating drug...

  15. Food-drug interactions

    DEFF Research Database (Denmark)

    Schmidt, Lars E; Dalhoff, Kim

    2002-01-01

    Interactions between food and drugs may inadvertently reduce or increase the drug effect. The majority of clinically relevant food-drug interactions are caused by food-induced changes in the bioavailability of the drug. Since the bioavailability and clinical effect of most drugs are correlated......, the bioavailability is an important pharmacokinetic effect parameter. However, in order to evaluate the clinical relevance of a food-drug interaction, the impact of food intake on the clinical effect of the drug has to be quantified as well. As a result of quality review in healthcare systems, healthcare providers...... are increasingly required to develop methods for identifying and preventing adverse food-drug interactions. In this review of original literature, we have tried to provide both pharmacokinetic and clinical effect parameters of clinically relevant food-drug interactions. The most important interactions are those...

  16. Drug: D06732 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available r component: Loganin [CPD:C01433] Powdered product: Standards for non-pharmacopoeial crude drugs Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs...ine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs for replenishing Qi D06732 Cornus fruit; Sanshuyu Crude drugs... 5100 Crude drugs D06732 Cornus fruit (JP16) Traditional Chinese Medic

  17. Drug development, radiolabelled drugs and PET

    NARCIS (Netherlands)

    Vaalburg, W; Hendrikse, NH; de Vries, EFJ

    1999-01-01

    Positron emission tomography (PET) provides noninvasive in vivo quantitative pharmacokinetic and pharmacodynamic information on novel and established drugs. Because only very low amounts of the (potential) drug have to be administered, far below toxicity levels, human studies can be carried out even

  18. Drugs and drug policy in the Netherlands

    NARCIS (Netherlands)

    Leuw, Ed.

    1991-01-01

    The Dutch parliament enacted the revised Opium Act in 1976. This penal law is part of the Dutch drug policy framework that includes tolerance for nonconforming lifestyles, risk reduction in regard to the harmful health and social consequences of drug taking, and penal measures directed against illeg

  19. Antiepileptic drugs: newer targets and new drugs

    Directory of Open Access Journals (Sweden)

    Vihang S. Chawan

    2016-06-01

    Full Text Available Epilepsy is a common neurological disorder affecting 0.5-1% of the population in India. Majority of patients respond to currently available antiepileptic drugs (AEDs, but a small percentage of patients have shown poor and inadequate response to AEDs in addition to various side effects and drug interactions while on therapy. Thus there is a need to develop more effective AEDs in drug resistant epilepsy which have a better safety profile with minimal adverse effects. The United States food and drug administration (USFDA has approved eslicarbazepine acetate, ezogabine, perampanel and brivaracetam which have shown a promising future as better AEDs and drugs like ganaxolone, intranasal diazepam, ICA- 105665, valnoctamide, VX-765, naluzotan are in the pipeline. [Int J Basic Clin Pharmacol 2016; 5(3.000: 587-592

  20. IMPROVING ACCESS TO DRUGS

    Directory of Open Access Journals (Sweden)

    Max Joseph Herman

    2012-11-01

    Full Text Available Although essentially not all therapies need drug intervention, drugs is still an important components in health sector, either in preventive, curative, rehabilitative or promotion efforts. Hence the access to drugs is a main problem, either in international or national scale even to the smallest unit. The problem on access to drugs is very complicated and cannot be separated especially from pharmacy management problems; moreover in general from the overall lack of policy development and effective of health policy, and also the implementation process. With the policy development and effective health policy, rational drug uses, sufficient health service budget so a country can overcome the health problems. Besides infrastructures, regulations, distribution and cultural influences; the main obstacles for drug access is drugs affordability if the price of drugs is an important part and determined by many factors, especially the drug status whether is still patent orgenerics that significantly decrease cost of health cares and enhance the drugs affordability. The determination of essential drug prices in developing countries should based on equity principal so that poor people pay cheaper and could afford the essential drugs. WHO predicts two third of world population can not afford the essential drugs in which in developing countries, some are because of in efficient budget allocation in consequence of drug distribution management, including incorrect selection and allocation and also irrational uses. In part these could be overcome by enhancing performances on the allocation pharmacy needs, including the management of information system, inventory management, stock management and the distribution. Key words: access, drugs, essential drugs, generic drugs

  1. Drug Facts: Anabolic Steroids

    Science.gov (United States)

    ... and Over-the-Counter Medications Stimulant ADHD Medications: Methylphenidate and Amphetamines Synthetic Cannabinoids Synthetic Cathinones ("Bath Salts") Effects of Drug Abuse Comorbidity: Addiction and Other Mental Disorders Drug Use ...

  2. Street Drugs and Pregnancy

    Science.gov (United States)

    ... premature birth Zika virus and pregnancy Folic acid Medicine safety and pregnancy Birth defects prevention Learn how ... Is it safe? > Street drugs and pregnancy Street drugs and pregnancy E-mail to a friend Please ...

  3. Life after Drugs

    Institute of Scientific and Technical Information of China (English)

    LIUDONGPING

    2004-01-01

    THE famous Kunming Drug Rehabilitation Center, founded in 1989, is located in the suburbs of Kunming City. Yunnan Province. It is the first drug rehabilitation center in China and the biggest in Asia.Covering 200 hectares, the center is

  4. Prescription Drug Abuse

    Science.gov (United States)

    ... what the doctor prescribed, it is called prescription drug abuse. It could be Taking a medicine that ... purpose, such as getting high Abusing some prescription drugs can lead to addiction. These include opioids, sedatives, ...

  5. Drugs@FDA Database

    Data.gov (United States)

    U.S. Department of Health & Human Services — Information about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of...

  6. Drug use first aid

    Science.gov (United States)

    ... or extreme social withdrawal. Cannabis drugs such as marijuana may cause relaxation, impaired motor skills, and increased appetite. When prescription drugs are taken in higher than normal amounts, serious side effects may occur.

  7. CMS Drug Spending

    Data.gov (United States)

    U.S. Department of Health & Human Services — CMS has released several information products that provide spending information for prescription drugs in the Medicare and Medicaid programs. The CMS Drug Spending...

  8. National Drug IQ Challenge

    Science.gov (United States)

    ... Reto nacional del coeficiente intelectual (CI) sobre las drogas y el alcohol 2016 National Drug IQ Challenge ... Reto nacional del coeficiente intelectual (CI) sobre las drogas y el alcohol 2015 National Drug IQ Challenge ...

  9. Prescription Drug Profiles PUF

    Data.gov (United States)

    U.S. Department of Health & Human Services — This release contains the Prescription Drug Profiles Public Use Files (PUFs) drawn from Medicare prescription drug claims for the year of the date on which the...

  10. Drugs to be Discontinued

    Data.gov (United States)

    U.S. Department of Health & Human Services — Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (as amended by the Food and Drug Administration Safety and...

  11. Drugs in sport

    OpenAIRE

    Mottram, David R

    2007-01-01

    This new edition includes fresh information regarding drugs use and abuse in sport and the updated worldwide anti-doping laws, and changes to the prohibited and therapeutic use exemption lists. The objectives of the book are to review/discuss the latest information on drugs in sport by considering i) actions of drugs and hormones, ii) medication and nutritional supplements in sport, iii) the latest doping control regulations of the WADA, iv) the use of banned therapeutic drugs in sport, v) an...

  12. Drug: D06718 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ied) Major component: Ginsenoside [CPD:C08944 C08945] Powdered product: Standards for non-pharmacopoeial crude drugs... Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D06718 Red ginseng (JP16) Crude drugs

  13. Drug: D06680 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available eaf Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drug...s 5100 Crude drugs D06680 Sweet hydrangea leaf (JP16); Powdered sweet hydrangea leaf (JP16) Crude drugs

  14. Drug: D06731 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fruit (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs fo...r clearing heat D06731 *Gardenia fruit; Powdered gardenia fruit; Gerenia fruit Drugs... for Qi Sedative drugs D06731 *Gardenia fruit; Powdered gardenia fruit; Gerenia fruit Drugs for external use Drugs

  15. Drug: D06688 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs for clearing heat D06688 *Scute...eal drugs Stomachic and antidiarrheal drugs D06688 *Scutellaria root; Powdered scutellaria root; Scutellaria root Drugs... for pus discharge Drugs for pus discharge D06688 *Scutellaria root; Powdered scutellaria root; S

  16. Drug: D06911 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ude drugs 510 Crude drugs 5100 Crude drugs D06911 Lilium bulb (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs... Drugs for replenishing Ying Drugs for replenishing Ying D06911 *Lilii bulbus; Lily bulb; Byakugo Drugs

  17. Drug: D06695 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available in [CPD:C10443] Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs for regula...ting Qi D06695 *Termeric; Turmeric rhizome Drugs for blood Drugs for removing blood stasis D06695 *Termeric; Turmeric rhizome Drugs... for external use Drugs for external use D06695 *Termeric;

  18. Drug: D06798 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available R:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D...06798 Coix seed (JP16); Powdered coix seed (JP16) 59 Other crude drugs and Chinese medicine formula...tions 590 Other crude drugs and Chinese medicine formulations 5900 Other crude drugs and Chinese medicine formula

  19. Rational Use of Drugs: Pharmaceutical Aspects of the Drug Selection

    Directory of Open Access Journals (Sweden)

    Natalya B. Rostova, PhD, ScD

    2012-09-01

    Full Text Available In this article, the problems encountered in the rational use of drugs are discussed, one of the areas of optimization of drug supply being the rational choice of drugs, particularly, a regulatory activity regarding the approach to the selection of standardized drug lists (drug formulary for public drug supply, according to government guarantees and programs. The clinical aspects of the drug selection are expounded in detail. The characteristics of the drugs (original or generic drug (generics, the origin of drugs and the breadth of therapeutic index, have been taken into account. Certain stages have been analyzed, particularly drug use in individual diseases, drug selection, expert drug evaluation, and expert recommendations to include specific drugs in the drug list. Organizational steps have been proposed to implement the rational choice of drugs to be included in the drug formulary.

  20. Writing Drug Cultures

    DEFF Research Database (Denmark)

    Nissen, Morten

    2012-01-01

    The paper juxtaposes the cultural mediation of experience through drugs with that performed with text. As a sample of the currently radically changing relations between professional and lay knowledge in the field of drug interventions, the website of a Copenhagen institution for young drug users...

  1. [Fluoroquinolones. Drug interactions].

    Science.gov (United States)

    Rusu, G; Dănilă, G

    2000-01-01

    This review summarizes clinically relevant drug-drug interactions for fluoroquinolones: antiacids containing aluminum and magnesium salts, iron or zinc preparations, sucralfate, cimetidine, ranitidine, warfarina, cyclosporin, rifampin, oral contraceptive steroids, benzodiazepine, probenecid, beta-lactam antibiotics, nonsteroidal anti-inflammatory drugs, metronidazole, theophylline, caffeine.

  2. Teenage Drug Use

    Science.gov (United States)

    1991-01-01

    W 4. 0 10 n Used Sws Oduor Nick Drug Note "Other illcilt" drugs includes cocaine, halucinogens, heroin, and the nonmedical use of psycho- therapeutics...Washington, D.C.: Congressional Research Service, May 1988. Strasburger, Victor . "Sex, Drugs, Rock ’n’ Roll: An Introduction." Pediat- rics, 76:4 (Oct. 1985

  3. Drug: D06715 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory family) Pharbitis seed Major component: Pharbitin Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs... D06715 Pharbitis seed (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Purgative drugs... Purgative drugs D06715 Pharbitis seed; Pharbitis seed Crude drugs [B

  4. Drug: D06765 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ponent: Vanillyl alcohol [CPD:C06317] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and ...Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06765 Gastrodia tuber (JP16) ...Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Sedative drugs... D06765 Gastrodia tuber; Tianma Crude drugs [BR:br08305] Monocot plants Orchidaceae (orchid family) D06765 Gastrodia tuber PubChem: 47208416 ...

  5. Drug: D06741 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :C17056] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D06741 Plantago herb (JP16) Trad...itional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs D06741 Plantago... herb; Plantago herb Crude drugs [BR:br08305] Dicot plants: asterids Plantaginaceae (plantain family) D06741 Plantago herb PubChem: 47208392 ...

  6. Drug: D06756 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nt: Sennoside [CPD:C10404 C13526 C16797 C16798] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06756 Rhubarb (JP16...); Powdered rhubarb (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Purgative drugs... Purgative drugs D06756 Rhubarb; Powdered rhubarb; Rhubarb Crude drugs [BR:br08305

  7. Drug: D06909 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available data rhizome Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs an...d Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06909 Aralia rhizome (JP16)... Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Antirheumatic drugs D0690...9 Araliae cardatae rhizoma; Dokkatsu Crude drugs [BR:br08305] Dicot plants: asterids Araliaceae (ginseng family) D06909 Aralia rhizome PubChem: 51091251 ...

  8. Drug: D06787 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (carrot family) Saposhnikovia root Major component: Fraxidin [CPD:C17479] Therapeutic category of drugs in ...Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs...:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and warm in property D06787 Sapo...shnikovia root; Fangfeng Crude drugs [BR:br08305] Dicot plants: asterids Apiaceae (carrot family) D06787 Saposhnikovia root PubChem: 47208438 ...

  9. Drug: D06707 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ategory: 5100 Apiaceae (carrot family) Notopterygium rhizome Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06707 ...rude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and warm in property D06707 Notopterygium rhizome Crude drugs...Notopterygium rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] C

  10. Drug: D06782 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Therapeutic category: 5100 Arecaceae (palm family) Areca seed Major component: Arecoline [CPD:C10129] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs... 5100 Crude drugs D06782 Areca (JP16) Traditional Chinese Medici...ne in Japan [BR:br08304] Crude Drugs Drugs for expelling parasites Anthelmintic drugs D06782 Areca; Areca Crude drugs

  11. Drug: D06723 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ponent: Palmitic acid [CPD:C00249] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chi...nese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06723... Burdock fruit (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs... pungent in flavor and cool in property D06723 Burdock fruit Crude drugs [BR:br08305] Dicot plan

  12. Drug: D06762 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ry: 5100 Rubiaceae (madder family) Uncaria hook Major component: Rhyncophylline [CPD:C09236] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D06762 Uncaria hook (JP16) Traditional Chinese Medicine ...in Japan [BR:br08304] Crude Drugs Drugs for Qi Sedative drugs D06762 Uncaria hook Crude drugs [BR:br08305] D

  13. Drug: D06783 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available [CPD:C14495] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs an...d Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06783 Poria sclerotium (JP1...6); Powdered poria sclerotium (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs... D06783 Poria sclerotium; Powdered poria sclerotium; Hoelen Crude drugs

  14. 2015 new drug update.

    Science.gov (United States)

    Hussar, Daniel A

    2015-04-01

    Six new drugs approved within the last two years, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating. The drugs include two antidiabetic agents, one bronchodilator, one antidepressant, one for erectile dysfunction, and one for menopause-associated conditions.

  15. Rational drug design.

    Science.gov (United States)

    Mandal, Soma; Moudgil, Mee'nal; Mandal, Sanat K

    2009-12-25

    In this article, current knowledge of drug design is reviewed and an approach of rational drug design is presented. The process of drug development is challenging, expensive, and time consuming, although this process has been accelerated due to the development of computational tools and methodologies. The current target based drug design approach is incomplete because most of the drugs developed by structure guided approaches have been shown to have serious toxic side effects. Otherwise these drugs would have been an ideal choice for the treatment of diseases. Hence, rational drug design would require a multidisciplinary approach. In this regard, incorporation of gene expression technology and bioinformatics tools would be indispensable in the structure based drug design. Global gene expression data and analysis of such data using bioinformatics tools will have numerous benefits such as efficiency, cost effectiveness, time saving, and will provide strategies for combination therapy in addition to overcoming toxic side effects. As a result of incorporation of gene expression data, partial benefit of the structure based drug design is slowly emerging and rapidly changing the approach of the drug development process. To achieve the full benefit of developing a successful drug, multidisciplinary approaches (approaches such as computational chemistry and gene expression analysis, as discussed in this article) would be necessary. In the future, there is adequate room for the development of more sophisticated methodologies.

  16. Drug Retention Times

    Energy Technology Data Exchange (ETDEWEB)

    None, None

    2007-05-01

    The purpose of this monograph is to provide information on drug retention times in the human body. The information provided is based on plausible illegal drug use activities that might be engaged in by a recreational drug user. Based on anecdotal evidence, most people “party” during extended time away from the work environment. Therefore, the following scenarios were envisioned: (1) a person uses an illicit drug at a party on Saturday night (infrequent user); (2) a person uses a drug one time on Friday night and once again on Saturday night (infrequent user); and (3) a person uses a drug on Friday night, uses a drug twice on Saturday night, and once again on Sunday (frequent user).

  17. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... the Link - Drugs and HIV Learn the Link - Drugs and HIV Email Facebook Twitter 2005 –Ongoing Behaviors ... GA: CDC, DHHS. Retrieved June 2012 How are Drug Abuse and HIV Related? Drug abuse and addiction ...

  18. Drugs Approved for Liver Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for liver cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries.

  19. Drugs Approved for Vulvar Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for vulvar cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  20. Drugs Approved for Esophageal Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for esophageal cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  1. Drugs Approved for Vaginal Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) to prevent vaginal cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries.

  2. Drugs Approved for Endometrial Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for endometrial cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  3. Drugs Approved for Penile Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for penile cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries.

  4. Drug: D06709 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available amily) Lycium mature fruit Major component: Betaine [CPD:C00719] Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for replenishing Ying Drugs for replenishing Ying D06709 Lycium fruit Crude drugs

  5. Drug: D06761 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available pan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs for clearing heat D06761 Anemarrhena rhizome; Ane... Crude drugs D06761 Anemarrhena rhizome (JP16) Traditional Chinese Medicine in Ja

  6. Drug: D09520 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nensis carapace; Standards for non-pharmacopoeial crude drugs Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for replenishing Ying Drugs for replenishing Ying D09520 A

  7. Drug: D06794 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gs Drugs for dampness Diuretic drugs D06794 Akebia stem; Akebiae caulis Crude drugs...gs 5100 Crude drugs D06794 Akebia stem (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Dru

  8. Drug: D06799 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available icine in Japan [BR:br08304] Crude Drugs Drugs for Qi Sedative drugs D06799 Longgu; Fossilized mammal bones Crude drugs [BR:br08305] Animals Mammals D06799 Longgu PubChem: 47208450 ...

  9. Drug: D09127 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rmacopoeial crude drugs Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for clearing heat Drugs for clearing heat D09127 Scrophularia root; Ningpo figwort root Crude dr

  10. Drug: D06775 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available r (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for replenishing Ying Drugs fo...r replenishing Ying D06775 *Ophiopogon tuber; Ophiopogonis tuber Drugs for dampness Cough suppressants and e

  11. Drug: D06703 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Cough suppr...essants and expectorants D06703 *Platycodon root; Powdered platycodon root; Platycodon root Drugs for pus discharge Drugs

  12. Drug: D06750 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cine in Japan [BR:br08304] Crude Drugs Drugs for external use Drugs for external use D06750 Toad venom Crude drugs [BR:br08305] Animals Amphibians D06750 Toad venom PubChem: 47208401 ...

  13. Drugs Approved for Skin Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for skin cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  14. Drugs Approved for Kaposi Sarcoma

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Kaposi sarcoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  15. Drugs Approved for Bone Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for bone cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.

  16. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Drugs of Abuse Commonly Abused Drugs Charts Emerging Trends and Alerts Alcohol Club Drugs Cocaine Hallucinogens Heroin ... Misuse Mental Health Military Naloxone Pain Prevention Treatment Trends & Statistics Women and Drugs Publications Funding Funding Opportunities ...

  17. Drug: D01729 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ategory of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radioacti...ve drugs D01729 3-Iodobenzylguanidine (123I) (JAN) Anato

  18. Drug: D08762 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radioact...ive drugs D08762 Technetium (99mTc) labelled macroaggreg

  19. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Nicotine Other Drugs Related Topics Addiction Science Adolescent Brain Comorbidity College-Age & Young Adults Criminal Justice Drugged Driving Drug Testing Drugs and the Brain Genetics Global Health Hepatitis (Viral) HIV/AIDS Health ...

  20. Drug: D08765 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available category: 4300 ATC code: V09BA03 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radio...active drugs 430 Radioactive drugs 4300 Radioactive drugs

  1. Drug: D08766 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radio...active drugs 4300 Radioactive drugs D08766 Sodium phytate hydrate - technetium (99mTc)

  2. Drug: D08761 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tegory: 4300 ATC code: V09GA06 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radio...active drugs 430 Radioactive drugs 4300 Radioactive drugs D08

  3. Drug: D04163 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available THER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS R03BX Other drugs for obstructive airway...MIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DX Other systemic drugs for obstructive airway diseases R03DX03

  4. Incidence of potential drug-drug interactions with antidiabetic drugs.

    Science.gov (United States)

    Samardzic, I; Bacic-Vrca, V

    2015-06-01

    In an effort to achieve normoglycemia more than one antidiabetic agent is usually needed. Diabetes is associated with several comorbidities and patients with diabetes are often treated with multiple medications. Therefore, patients with diabetes are especially exposed to drug-drug interactions (DDIs). The aim of this study was to analyse the incidence and type of potential DDIs of antidiabetic drugs in patients with diabetes. This retrospective study analyzed pharmacy record data of 225 patients with diabetes mellitus. Both type 1 and type 2 diabetic patients who were taking at least one antidiabetic agent during the period of six months were included. We investigated associated therapy in that period in order to identify potential DDIs with antidiabetic therapy. Potential interactions were identified by Lexicomp Lexi-Interat Online (Lexi-Comp, Inc., Hudson, USA) software which categorizes potential DDIs according to clinical significance in five types (A, B, C, D and X). Categories C, D and X are of clinical concern and always require medical attention (therapy monitoring, therapy modification or avoiding combination). We found that 80.9% of patients had at least one potential category C interaction while there were no D and X interactions. Most frequently encountered potential DDI (n = 176) included antidiabetic drugs and thiazide or thiazide like diuretics. Patients with diabetes are exposed to a large number of potential clinically significant DDIs that may require appropriate monitoring. Using databases of DDIs could be helpful in reducing the risk of potential clinically significant DDIs.

  5. Drug-induced hyperkalemia.

    Science.gov (United States)

    Ben Salem, Chaker; Badreddine, Atef; Fathallah, Neila; Slim, Raoudha; Hmouda, Houssem

    2014-09-01

    Hyperkalemia is a common clinical condition that can be defined as a serum potassium concentration exceeding 5.0 mmol/L. Drug-induced hyperkalemia is the most important cause of increased potassium levels in everyday clinical practice. Drug-induced hyperkalemia may be asymptomatic. However, it may be dramatic and life threatening, posing diagnostic and management problems. A wide range of drugs can cause hyperkalemia by a variety of mechanisms. Drugs can interfere with potassium homoeostasis either by promoting transcellular potassium shift or by impairing renal potassium excretion. Drugs may also increase potassium supply. The reduction in renal potassium excretion due to inhibition of the renin-angiotensin-aldosterone system represents the most important mechanism by which drugs are known to cause hyperkalemia. Medications that alter transmembrane potassium movement include amino acids, beta-blockers, calcium channel blockers, suxamethonium, and mannitol. Drugs that impair renal potassium excretion are mainly represented by angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, heparin and derivatives, aldosterone antagonists, potassium-sparing diuretics, trimethoprim, and pentamidine. Potassium-containing agents represent another group of medications causing hyperkalemia. Increased awareness of drugs that can induce hyperkalemia, and monitoring and prevention are key elements for reducing the number of hospital admissions, morbidity, and mortality related to drug-induced hyperkalemia.

  6. Drug: D06702 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06702 Crude, Drug Processed ginger (JP16) [6]-Shogaol [CPD:C10494], [6]-Gingerol [...icine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06702 Processed ginger (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for warming the interior Drugs for warming the interior D06702 Processed ginger Crude drugs [BR:br08305] Monocot plants Zingiberaceae (ginger family) D06702 Processed ginger PubChem: 47208353 ...

  7. Drug: D06730 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available bin [CPD:C17449] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06730 Smilax rhizome (J...izome; Smilax rhizome Crude drugs [BR:br08305] Monocot plants Smilacaceae (catbrier famly) D06730 Smilax rhizome PubChem: 47208381 ...

  8. Drug: D04388 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available monene [CPD:C06078] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D04388 Bitter orange peel (JP16) Crude drugs

  9. Drug: D06760 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Major component: Chikusetsusaponin [CPD:C17539 C17540 C17543 C17544 C17545] Therapeutic category of drugs i...n Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs... D06760 Panax rhizome (JP16); Powdered panax rhizome (JP16) Crude drugs [

  10. Drug: D04360 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available raniaceae (geranium family) Geranium thunbergii aerial part Major component: Geraniin [CPD:C10230] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D04360 Geranium herb (JP16); Powdered geranium herb (JP16) Crude drugs

  11. Drug: D06777 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ent: Imperatorin [CPD:C09269] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06777 Glehnia root (JP16) Crude dru...gs [BR:br08305] Dicot plants: asterids Apiaceae (carrot family) D06777 Glehnia root PubChem: 47208428 ...

  12. Drug: D01728 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ponent: Calcium sulfate [DR:D09201] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D0172... for clearing heat D01728 Gypsum; Calcium sulfate; Gypsum fibrosum Crude drugs [BR:br08305] Others Minerals D01728 Gypsum PubChem: 7848791 ...

  13. Drug: D06716 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ae (gentian family) Gentiana lutea root and rhizome Major component: Gentiopicrin [CPD:C09782] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D06716 Gentian (JP16); Powdered gentian (JP16) Crude drugs

  14. Drug related critical incidents.

    Science.gov (United States)

    Khan, F A; Hoda, M Q

    2005-01-01

    Drug related incidents are a common form of reported medical errors. This paper reviews the critical incidents related to drug errors reported from the main operating theatre suite in a teaching hospital in a developing country from January 1997 to December 2002. Each report was evaluated individually by two reviewers using a structured process. During this period, 44 874 anaesthetics were administered; 768 critical incidents were reported, 165 (21%) of which were related to drug errors. Underdosage, side-effect/drug reaction and syringe swap were the most common. A total of 76% were classified as preventable; 56% due to human error and 19% due to system error. High risk incidents accounted for 10% of all drug errors and most of these were related to the use of neuromuscular blocking drugs. This analysis has been found useful in addressing some issues about priorities.

  15. Discontinued drugs in 2012: cardiovascular drugs.

    Science.gov (United States)

    Zhao, Hong-Ping; Jiang, Hong-Min; Xiang, Bing-Ren

    2013-11-01

    The continued high rate of cardiovascular morbidity and mortality has attracted wide concern and great attention of pharmaceutical industry. In order to reduce the attrition of cardiovascular drug R&D, it might be helpful recapitulating previous failures and identifying the potential factors to success. This perspective mainly analyses the 30 cardiovascular drugs dropped from clinical development in 2012. Reasons causing the termination of the cardiovascular drugs in the past 5 years are also tabulated and analysed. The analysis shows that the attrition is highest in Phase II trials and financial and strategic factors and lack of clinical efficacy are the principal reasons for these disappointments. To solve the four problems (The 'better than the Beatles' problem, the 'cautious regulator' problem, the 'throw money at it' tendency and the 'basic researchbrute force' bias) is recommended as the main measure to increase the number and quality of approvable products.

  16. New Drugs for CML

    Science.gov (United States)

    2007-02-01

    AD_________________ Award Number: W81XWH-06-1-0232 TITLE: New Drugs for CML PRINCIPAL...TYPE Final 3. DATES COVERED 1 Feb 2006– 31 Jan 2007 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER New Drugs for CML 5b. GRANT NUMBER W81XWH...Deisseroth A. Use of combinatorial structural variation of top design new drugs for CML. Mol Cancer Ther, 6: 655-666, 2007. Novel compounds with

  17. Vaccines for Drug Abuse

    Science.gov (United States)

    Shen, Xiaoyun; Orson, Frank M.; Kosten, Thomas R.

    2012-01-01

    Current medications for drug abuse have had only limited success. Anti-addiction vaccines to elicit antibodies that block the pharmacological effects of drugs have great potential for treating drug abuse. We review the status for two vaccines that are undergoing clinical trials (cocaine and nicotine) and two that are still in pre-clinical development (methamphetamine and heroin). We also outline the challenges and ethical concerns for anti-addiction vaccine development and their use as future therapeutics. PMID:22130115

  18. Drug-induced diarrhoea.

    Science.gov (United States)

    Chassany, O; Michaux, A; Bergmann, J F

    2000-01-01

    Diarrhoea is a relatively frequent adverse event, accounting for about 7% of all drug adverse effects. More than 700 drugs have been implicated in causing diarrhoea; those most frequently involved are antimicrobials, laxatives, magnesium-containing antacids, lactose- or sorbitol-containing products, nonsteroidal anti-inflammatory drugs, prostaglandins, colchicine, antineoplastics, antiarrhythmic drugs and cholinergic agents. Certain new drugs are likely to induce diarrhoea because of their pharmacodynamic properties; examples include anthraquinone-related agents, alpha-glucosidase inhibitors, lipase inhibitors and cholinesterase inhibitors. Antimicrobials are responsible for 25% of drug-induced diarrhoea. The disease spectrum of antimicrobial-associated diarrhoea ranges from benign diarrhoea to pseudomembranous colitis. Several pathophysiological mechanisms are involved in drug-induced diarrhoea: osmotic diarrhoea, secretory diarrhoea, shortened transit time, exudative diarrhoea and protein-losing enteropathy, and malabsorption or maldigestion of fat and carbohydrates. Often 2 or more mechanisms are present simultaneously. In clinical practice, 2 major types of diarrhoea are seen: acute diarrhoea, which usually appears during the first few days of treatment, and chronic diarrhoea, lasting more than 3 or 4 weeks and which can appear a long time after the start of drug therapy. Both can be severe and poorly tolerated. In a patient presenting with diarrhoea, the medical history is very important, especially the drug history, as it can suggest a diagnosis of drug-induced diarrhoea and thereby avoid multiple diagnostic tests. The clinical examination should cover severity criteria such as fever, rectal emission of blood and mucus, dehydration and bodyweight loss. Establishing a relationship between drug consumption and diarrhoea or colitis can be difficult when the time elapsed between the start of the drug and the onset of symptoms is long, sometimes up to several

  19. Pharmacology and drug distribution

    Energy Technology Data Exchange (ETDEWEB)

    Morgan, L.R.; Weatherall, T.J.

    1979-08-01

    An overview of the pharmacology of drugs in the treatment of cancer is presented. The discussion begins with the simplest relationship of drugs and particles to one another then proceeds to demonstrate the interrelationship in a biologic system to produce a chemobiodynamic response. The basic principles of pharmacokinetics are reviewed and their correlation with investigational and standard drug therapies is discussed. Voids in the consideration of interactions between chemotherapy and radiotherapy are discussed.

  20. Single compartment drug delivery

    OpenAIRE

    Cima, Michael J.; Lee, Heejin; Daniel, Karen; Tanenbaum, Laura M.; Mantzavinou, Aikaterini; Spencer, Kevin C.; Ong, Qunya; Sy, Jay C.; Santini, John; Schoellhammer, Carl M.; Blankschtein, Daniel; Langer, Robert S.

    2014-01-01

    Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modi...

  1. Academic Drug Discovery Centres

    DEFF Research Database (Denmark)

    Kirkegaard, Henriette Schultz; Valentin, Finn

    2014-01-01

    Academic drug discovery centres (ADDCs) are seen as one of the solutions to fill the innovation gap in early drug discovery, which has proven challenging for previous organisational models. Prior studies of ADDCs have identified the need to analyse them from the angle of their economic and organi......Academic drug discovery centres (ADDCs) are seen as one of the solutions to fill the innovation gap in early drug discovery, which has proven challenging for previous organisational models. Prior studies of ADDCs have identified the need to analyse them from the angle of their economic...... their performance....

  2. Drug-induced diarrhea

    Science.gov (United States)

    ... cancer Drugs used to treat heartburn and stomach ulcers, such as omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), rabeprazole (AcipHex), pantoprazole (Protonix), cimetidine (Tagamet), ranitidine ( ...

  3. Metallomics in drug development

    DEFF Research Database (Denmark)

    Nguyen, Trinh Thi Nhu Tam; Ostergaard, Jesper; Stürup, Stefan;

    2013-01-01

    A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation...... to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before...... and will improve characterization of liposomal drugs during drug development and in studies on kinetics....

  4. How to Misuse Drugs

    Directory of Open Access Journals (Sweden)

    I.R. Edwards

    1978-09-01

    Full Text Available Most of us, during our training, are taught about the actions of drugs and their side-effects, but very few of us are taught how to misuse drugs. However, this is an art that seems to be acquired through practice in handling drugs, by various members of the medical and nursing professions, as well as by the general population. The purpose of this paper is to demonstrate a few of the ways in which drugs can be, and are, misused.

  5. Microwave Assisted Drug Delivery

    DEFF Research Database (Denmark)

    Jónasson, Sævar Þór; Zhurbenko, Vitaliy; Johansen, Tom Keinicke

    2014-01-01

    In this work, the microwave radiation is adopted for remote activation of pharmaceutical drug capsules inside the human body in order to release drugs at a pre-determined time and location. An array of controllable transmitting sources is used to produce a constructive interference at a certain...... focus point inside the body, where the drugs are then released from the specially designed capsules. An experimental setup for microwave activation has been developed and tested on a body phantom that emulates the human torso. A design of sensitive receiving structures for integration with a drug...

  6. Intracellular drug release nanosystems

    Directory of Open Access Journals (Sweden)

    Fenghua Meng

    2012-10-01

    Full Text Available In order to elicit therapeutic effects, many drugs including small molecule anticancer drugs, proteins, siRNA, and DNA have to be delivered and released into the specific cellular compartments typically the cytoplasm or nucleus of target cells. Intracellular environment-responsive nanosystems that exhibit good extracellular stability while rapidly releasing drugs inside cancer cells have been actively pursued for effective cancer therapy. Here, we highlight novel designs of smart nanosystems that release drugs in response to an intracellular biological signal of cancer cells such as acidic pH in endo/lysosomal compartments, enzymes in lysosomes, and redox potential in cytoplasm and the cell nucleus.

  7. State Drug Control and Illicit Drug Participation

    OpenAIRE

    Henry Saffer; Frank Chaloupka

    1999-01-01

    The purpose of this paper is to estimate the effect of state criminal justice expenditures and state public health expenditures on deterring illicit drug use. The empirical model is based on a demand and supply model of drug markets. The effect of a given expenditure on criminal justice or public health programs is dependent on the magnitude of the resulting shifts in the two functions and the demand price elasticity. A reduced form of the demand and supply model is also estimated. The data e...

  8. Drug-drug co-crystals

    Directory of Open Access Journals (Sweden)

    Bhupinder Singh Sekhon

    2012-10-01

    Full Text Available Active pharmaceutical ingredients (APIs are most conveniently developed and delivered orally as solid dosage forms that contain a defined crystalline form of an API. Co-crystal is a crystalline entity formed by two different or more molecular entities where the intermolecular interactions are weak forces like hydrogen bonding and pi-pi stacking. Co-crystals are an enabling technology that is used in new or existing drug delivery systems by majority of pharmaceutical companies in formulation and drug development.

  9. Drug: D06906 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ri, or other related species larval exuvia; Standards for non-pharmacopoeial crude drugs Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs...n Japan [BR:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and cool in property ...D06906 Cicadae periostracum; Cicada slough; Zentai Crude drugs [BR:br08305] Animals Insects D06906 Cicada larva exuvia PubChem: 51091248 ...

  10. Drug: D06721 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available attle family) Oriental bezoar Major component: Bile acid [CPD:C01558] Powdered product: Standards for non-pharmacopoeial crude drugs... Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06721 Oriental ...bezoar (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Other drugs Drugs for resuscita...tion D06721 Oriental bezoar Crude drugs [BR:br08305] Animals Mammals D06721 Oriental bezoar PubChem: 47208372 ...

  11. Drug: D06785 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available menium stem and rhizome Major component: Sinomenine [CPD:C09643] Powdered product: Standards for non-pharmacopoeial crude drugs... Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06785 Sinomenium ste...m (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs D0...6785 Sinomenium stem; Fangji Crude drugs [BR:br08305] Dicot plants: others Menispermaceae (moonseed family) D06785 Sinomenium stem PubChem: 47208436 ...

  12. The relationship between rational drug design and drug side effects.

    Science.gov (United States)

    Wang, Juan; Li, Zhi-xin; Qiu, Cheng-xiang; Wang, Dong; Cui, Qing-hua

    2012-05-01

    Previous analysis of systems pharmacology has revealed a tendency of rational drug design in the pharmaceutical industry. The targets of new drugs tend to be close with the corresponding disease genes in the biological networks. However, it remains unclear whether the rational drug design introduces disadvantages, i.e. side effects. Therefore, it is important to dissect the relationship between rational drug design and drug side effects. Based on a recently released drug side effect database, SIDER, here we analyzed the relationship between drug side effects and the rational drug design. We revealed that the incidence drug side effect is significantly associated with the network distance of drug targets and diseases genes. Drugs with the distances of three or four have the smallest incidence of side effects, whereas drugs with the distances of more than four or smaller than three show significantly greater incidence of side effects. Furthermore, protein drugs and small molecule drugs show significant differences. Drugs hitting membrane targets and drugs hitting cytoplasm targets also show differences. Failure drugs because of severe side effects show smaller network distances than approved drugs. These results suggest that researchers should be prudent on rationalizing the drug design. Too small distances between drug targets and diseases genes may not always be advantageous for rational design for drug discovery.

  13. DRUGS IN SPORT

    Directory of Open Access Journals (Sweden)

    David R. Mottram

    2005-12-01

    Full Text Available This new edition includes fresh information regarding drugs use and abuse in sport and the updated worldwide anti-doping laws, and changes to the prohibited and therapeutic use exemption lists. The objectives of the book are to review/discuss the latest information on drugs in sport by considering i actions of drugs and hormones, ii medication and nutritional supplements in sport, iii the latest doping control regulations of the WADA, iv the use of banned therapeutic drugs in sport, v an assessment of the prevalence of drug taking in sport. FEATURES A common, uniform strategy and evidence-based approach to organizing and interpreting the literature is used in all chapters. This textbook is composed of twelve parts with sub-sections in all of them. The topics of the parts are: i An introduction to drugs and their use in sport, ii Drug use and abuse in sport, iii Central nervous system stimulants, iv WADA regulations in relation to drugs used in the treatment of respiratory tract disorders, v Androgenic anabolic steroids, vi Peptide and glycoprotein hormones and sport, vii Blood boosting and sport, viii Drug treatment of inflammation in sports injuries, ix Alcohol, anti-anxiety drugs and sport, x Creatine, xi Doping control and sport, xii Prevalence of drug misuse in sport. Each specific chapter has been systematically developed from the data available in prospective, retrospective, case-control, and cross-sectional studies. The tables and figures are numerous, helpful and very useful. AUDIENCE The book provides a very useful resource for students on sports related courses, coaches and trainers, researchers, nutritionists, exercise physiologists, pharmacologists, healthcare professionals in the fields of sports medicine and those involved in the management and administration side of sport. The readers are going to discover that this is an excellent reference book. Extensively revised new edition of this book is also a first-rate resource for

  14. Drug-nutrient interactions.

    Science.gov (United States)

    Chan, Lingtak-Neander

    2013-07-01

    Drug-nutrient interactions are defined as physical, chemical, physiologic, or pathophysiologic relationships between a drug and a nutrient. The causes of most clinically significant drug-nutrient interactions are usually multifactorial. Failure to identify and properly manage drug-nutrient interactions can lead to very serious consequences and have a negative impact on patient outcomes. Nevertheless, with thorough review and assessment of the patient's history and treatment regimens and a carefully executed management strategy, adverse events associated with drug-nutrient interactions can be prevented. Based on the physiologic sequence of events after a drug or a nutrient has entered the body and the mechanism of interactions, drug-nutrient interactions can be categorized into 4 main types. Each type of interaction can be managed using similar strategies. The existing data that guide the clinical management of most drug-nutrient interactions are mostly anecdotal experience, uncontrolled observations, and opinions, whereas the science in understanding the mechanism of drug-nutrient interactions remains limited. The challenge for researchers and clinicians is to increase both basic and higher level clinical research in this field to bridge the gap between the science and practice. The research should aim to establish a better understanding of the function, regulation, and substrate specificity of the nutrient-related enzymes and transport proteins present in the gastrointestinal tract, as well as assess how the incidence and management of drug-nutrient interactions can be affected by sex, ethnicity, environmental factors, and genetic polymorphisms. This knowledge can help us develop a true personalized medicine approach in the prevention and management of drug-nutrient interactions.

  15. Drugs and brain death: drug assay perspectives.

    Science.gov (United States)

    Morris, R G

    1996-08-01

    The ability to make any meaningful interpretation of a drug assay result is very dependent upon a knowledge of the limitations of the method(s) used (sensitivity, specificity etc.), and the concentration that may be measured in plasma and its relationship to CNS effects. We need more information about 'critical' concentrations for each drug and sedation in the setting of the brain-injured patient before meaningful interpretation can be applied to such data. While the above discussion is critical of screen-type assays, the alternative specific assays are not easily provided for, as obviously the resourcing of laboratories to be able to deliver such specialized services for a range of therapeutic drugs, in addition to 'social' drugs or other toxins (e.g. glues, pesticides, solvents, environmental substances etc), becomes an increasingly complex issue in the current economic climate. Hence, the analytical laboratory can offer valuable support to the clinical team however, the interpretation of such results must be assessed in the light of many limitations of such assay methods and not seen as the 'gold standard' for assessment of brain function.

  16. Drug: D06774 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rds for non-pharmacopoeial crude drugs Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and... Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D0...ss Cough suppressants and expectorants D06774 Fritillaria bulb Crude drugs [BR:br08305] Monocot plants Liliaceae (lily family) D06774 Fritillaria bulb PubChem: 47208425 ...

  17. Drug: D06896 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory: 5100 Cucurbitaceae (cucumber family) Trichosanthes seed; Standards for non-pharmacopoeial crude drugs M...ajor component: Trichosanic acid [CPD:C08364] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs... for dampness Cough suppressants and expectorants D06896 Trichosanthis semen; Karonin Crude drugs [BR:br0830

  18. Drug: D06766 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available or component: Asparagine [CPD:C16438] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and ...Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06766 Asparagus tuber (JP16) ...hing Ying Drugs for replenishing Ying D06766 Asparagus tuber Crude drugs [BR:br08305] Monocot plants Asparagaceae (asparagus family) D06766 Asparagus tuber PubChem: 47208417 ...

  19. Drug: D04365 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available s D04365 Glycyrrhiza (JP16); Powdered glycyrrhiza (JP16); Licorice (NF) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drug...rrhiza; Licorice; Powdered glycyrrhiza; Glycyrrhiza Drugs for Qi Drugs for replen...ishing Qi D04365 *Glycyrrhiza; Licorice; Powdered glycyrrhiza; Glycyrrhiza Drugs for pus discharge Drugs for... pus discharge D04365 *Glycyrrhiza; Licorice; Powdered glycyrrhiza; Glycyrrhiza Drugs for external use Drugs

  20. Ayurvedic drug discovery.

    Science.gov (United States)

    Balachandran, Premalatha; Govindarajan, Rajgopal

    2007-12-01

    Ayurveda is a major traditional system of Indian medicine that is still being successfully used in many countries. Recapitulation and adaptation of the older science to modern drug discovery processes can bring renewed interest to the pharmaceutical world and offer unique therapeutic solutions for a wide range of human disorders. Eventhough time-tested evidences vouch immense therapeutic benefits for ayurvedic herbs and formulations, several important issues are required to be resolved for successful implementation of ayurvedic principles to present drug discovery methodologies. Additionally, clinical examination in the extent of efficacy, safety and drug interactions of newly developed ayurvedic drugs and formulations are required to be carefully evaluated. Ayurvedic experts suggest a reverse-pharmacology approach focusing on the potential targets for which ayurvedic herbs and herbal products could bring tremendous leads to ayurvedic drug discovery. Although several novel leads and drug molecules have already been discovered from ayurvedic medicinal herbs, further scientific explorations in this arena along with customization of present technologies to ayurvedic drug manufacturing principles would greatly facilitate a standardized ayurvedic drug discovery.

  1. Newer antithrombotic drugs

    Science.gov (United States)

    Sikka, Pranav; Bindra, V. K.

    2010-01-01

    Thromboembolic disorders are one of the disorders for which we are still on the look out for a safe and efficient drug. Despite the widespread use of antithrombotic drugs for the prevention and treatment of arterial and venous thrombosis, thromboembolic diseases continue to be a major cause of death and disability worldwide. This shows our inefficiency in searching efficacious and safe antithrombotic drugs. We have reached the basic mechanism of thrombus formation and by interrupting various steps of this mechanism, we can prevent as well as treat thromboembolic disorders. In continuation of Aspirin, now, we are using Clopidogrel, Ticlopidine and GpIIb/IIIa inhibitors (Abciximab, Tirofiban and Eptifibatide). Warfarin is an old antithrombotic drug which is still being used; but due to various side effects and drug interactions, we are bound to use newer drugs. Newer antiplatelet drugs include Prasugrel, Ticagrelor and Cangrelor, whereas newer thrombin inhibitors are Ximelgatran and Dabigatran. Apixaban is also a newer entry in this category as factor Xa inhibitor. Idrabiotaparinux is an indirect inhibitor of Xa as it accelerates the activity of antithrombin. Moreover, researches and trials for better and safe drugs are ongoing. PMID:21572750

  2. Club Drug Use

    Science.gov (United States)

    ... person is thirsty, give him or her a sports drink (like Gatorade), not plain water. If the person doesn’t start feeling better, get medical help right away. PreventionHow can I prevent someone from giving me a club drug?Club drugs often are used as “date ...

  3. The Drug War.

    Science.gov (United States)

    DeCrosta, Anthony

    1989-01-01

    The role of teachers in helping fight against drug abuse is discussed stressing the teacher's ability to see changes in the students and the potential for positive influence. A vital school role involves teaching life skills and wellness principles. Information on commonly abused drugs and their effects is presented. (SM)

  4. Interoception and drug addiction.

    Science.gov (United States)

    Paulus, Martin P; Stewart, Jennifer L

    2014-01-01

    The role of interoception and its neural basis with relevance to drug addiction is reviewed. Interoception consists of the receiving, processing, and integrating body-relevant signals with external stimuli to affect ongoing motivated behavior. The insular cortex is the central nervous system hub to process and integrate these signals. Interoception is an important component of several addiction relevant constructs including arousal, attention, stress, reward, and conditioning. Imaging studies with drug-addicted individuals show that the insular cortex is hypo-active during cognitive control processes but hyperactive during cue reactivity and drug-specific, reward-related processes. It is proposed that interoception contributes to drug addiction by incorporating an "embodied" experience of drug uses together with the individual's predicted versus actual internal state to modulate approach or avoidance behavior, i.e. whether to take or not to take drugs. This opens the possibility of two types of interventions. First, one may be able to modulate the embodied experience by enhancing insula reactivity where necessary, e.g. when engaging in drug seeking behavior, or attenuating insula when exposed to drug-relevant cues. Second, one may be able to reduce the urge to act by increasing the frontal control network, i.e. inhibiting the urge to use by employing cognitive training. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

  5. Drug-induced lupus.

    Science.gov (United States)

    Rubin, Robert L

    2005-04-15

    Autoantibodies and, less commonly, systemic rheumatic symptoms are associated with treatment with numerous medications and other types of ingested compounds. Distinct syndromes can be distinguished, based on clinical and laboratory features, as well as exposure history. Drug-induced lupus has been reported as a side-effect of long-term therapy with over 40 medications. Its clinical and laboratory features are similar to systemic lupus erythematosus, except that patients fully recover after the offending medication is discontinued. This syndrome differs from typical drug hypersensitivity reactions in that drug-specific T-cells or antibodies are not involved in induction of autoimmunity, it usually requires many months to years of drug exposure, is drug dose-dependent and generally does not result in immune sensitization to the drug. Circumstantial evidence strongly suggests that oxidative metabolites of the parent compound trigger autoimmunity. Several mechanisms for induction of autoimmunity will be discussed, including bystander activation of autoreactive lymphocytes due to drug-specific immunity or to non-specific activation of lymphocytes, direct cytotoxicity with release of autoantigens and disruption of central T-cell tolerance. The latter hypothesis will be supported by a mouse model in which a reactive metabolite of procainamide introduced into the thymus results in lupus-like autoantibody induction. These findings, as well as evidence for thymic function in drug-induced lupus patients, support the concept that abnormalities during T-cell selection in the thymus initiate autoimmunity.

  6. Dimensions of Drug Information

    Science.gov (United States)

    Sharp, Mark E.

    2011-01-01

    The high number, heterogeneity, and inadequate integration of drug information resources constitute barriers to many drug information usage scenarios. In the biomedical domain there is a rich legacy of knowledge representation in ontology-like structures that allows us to connect this problem both to the very mature field of library and…

  7. Effect of Drug Loading Method on Drug Content and Drug Release from Calcium Pectinate Gel Beads

    OpenAIRE

    2010-01-01

    Drug-loaded calcium pectinate gel (CaPG) beads were prepared by either mixing, absorption, or swelling method. The effects of drug loading method as well as the drug loading factors (i.e., drug concentration, soaking time in drug solution, type of solvent) on drug content and drug release were investigated. The amount of drug uptake (i.e., drug content) into CaPG beads increased as the initial drug concentration increased and varied depending on the loading method. The in vitro release studie...

  8. Impact and Roles of Drug Information in Drug Education

    Science.gov (United States)

    Goodstadt, Michael S.

    1975-01-01

    Evidence is presented elucidating the role of knowledge about drugs in facilitating or impeding drug use. The issues considered include (1) the role of drug information in previous "education" programs, (2) the source and uses of drug information, (3) the impact of this information, and (4) the alternative roles for drug information. (Author)

  9. Computational drug discovery

    Institute of Scientific and Technical Information of China (English)

    Si-sheng OU-YANG; Jun-yan LU; Xiang-qian KONG; Zhong-jie LIANG; Cheng LUO; Hualiang JIANG

    2012-01-01

    Computational drug discovery is an effective strategy for accelerating and economizing drug discovery and development process.Because of the dramatic increase in the availability of biological macromolecule and small molecule information,the applicability of computational drug discovery has been extended and broadly applied to nearly every stage in the drug discovery and development workflow,including target identification and validation,lead discovery and optimization and preclinical tests.Over the past decades,computational drug discovery methods such as molecular docking,pharmacophore modeling and mapping,de novo design,molecular similarity calculation and sequence-based virtual screening have been greatly improved.In this review,we present an overview of these important computational methods,platforms and successful applications in this field.

  10. Parents who use drugs

    DEFF Research Database (Denmark)

    Rhodes, Tim; Bernays, Sarah; Houmøller, Kathrin

    2010-01-01

    Parents who use drugs parent in a context of heightened concern regarding the damaging effects of parental drug use on child welfare and family life. Yet there is little research exploring how parents who use drugs account for such damage and its limitation. We draw here upon analyses of audio......-recorded depth qualitative interviews, conducted in south-east England between 2008 and 2009, with 29 parents who use drugs. Our approach to thematic analysis treated accounts as co-produced and socially situated. An over-arching theme of accounts was 'damage limitation'. Most damage limitation work centred...... on efforts to create a sense of normalcy of family life, involving keeping drug use secret from children, and investing heavily in strategies to maintain ambiguity regarding children's awareness. Our analysis highlights that damage limitation strategies double-up in accounts as resources of child protection...

  11. Drug Pricing Reforms

    DEFF Research Database (Denmark)

    Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas;

    2015-01-01

    Reference price systems for prescription drugs have found widespread use as cost containment tools. Under such regulatory regimes, patients co-pay a fraction of the difference between pharmacy retail price of the drug and a reference price. Reference prices are either externally (based on drug...... prices in other countries) or internally (based on domestic drug prices) determined. In a recent study, we analysed the effects of a change from external to internal reference pricing in Denmark in 2005, finding that the reform led to substantial reductions in prices, producer revenues, and expenditures...... for patients and the health insurance system. We also estimated an increase in consumer welfare but the size effect depends on whether or not perceived quality differences between branded and other drugs are taken into account....

  12. Layer-by-layer assembled multilayers and polymeric nanoparticles for drug delivery in tissue engineering applications

    Science.gov (United States)

    Mehrotra, Sumit

    Tissues and organs in vivo are structured in three dimensional (3-D) ordered assemblies to maintain their metabolic functions. In the case of an injury, certain tissues lack the regenerative abilities without an external supportive environment. In order to regenerate the natural in vivo environment post-injury, there is a need to design three-dimensional (3-D) tissue engineered constructs of appropriate dimensions along with strategies that can deliver growth factors or drugs at a controlled rate from such constructs. This thesis focuses on the applications of hydrogen bonded (H-bonded) nanoscale layer-by-layer (LbL) assembled multilayers for time controlled drug delivery, fabrication of polymeric nanoparticles as drug delivery carriers, and engineering 3-D cellular constructs. Axonal regeneration in the central nervous system after spinal cord injury is often disorganized and random. To support linear axonal growth into spinal cord lesion sites, certain growth factors, such as brain-derived neurotrophic factor (BDNF), needs to be delivered at a controlled rate from an array of uniaxial channels patterned in a scaffold. In this study, we demonstrate for the first time that H-bonded LbL assembled degradable thin films prepared over agarose hydrogel, whereby the protein was loaded separately from the agarose fabrication, provided sustained release of protein under physiological conditions for more than four weeks. Further, patterned agarose scaffolds implanted at the site of a spinal cord injury forms a reactive cell layer of leptomeningeal fibroblasts in and around the scaffold. This limits the ability of axons to reinnervate the spinal cord. To address this challenge, we demonstrate the time controlled release of an anti-mitotic agent from agarose hydrdgel to control the growth of the reactive cell layer of fibroblasts. Challenges in tissue engineering can also be addressed using gene therapy approaches. Certain growth factors in the body are known to inhibit

  13. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing

    OpenAIRE

    Lucreţia Udrescu; Laura Sbârcea; Alexandru Topîrceanu; Alexandru Iovanovici; Ludovic Kurunczi; Paul Bogdan; Mihai Udrescu

    2016-01-01

    Analyzing drug-drug interactions may unravel previously unknown drug action patterns, leading to the development of new drug discovery tools. We present a new approach to analyzing drug-drug interaction networks, based on clustering and topological community detection techniques that are specific to complex network science. Our methodology uncovers functional drug categories along with the intricate relationships between them. Using modularity-based and energy-model layout community detection...

  14. Drug: D06790 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available herapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medi...cine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06790 Oyster shell (JP16); Powdered oyste...r shell (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Sedative drugs D0...6790 Oyster shell; Powdered oyster shell; Oyster shell Crude drugs [BR:br08305] Animals Mollusks D06790 Oyster shell PubChem: 47208441 ... ...: E00159 Therapeutic category: 5100 Osteridae Oyster shell Major component: Calcium carbonate [CPD:C08129] T

  15. Drug: D05525 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available antain family) Plantago mature seed (dried) Major component: Aucubin [CPD:C09771] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs... 5100 Crude drugs D05525 Plantago seed (JP16/USP) Anatomical Therapeutic Chemical (AT...Plantago seed (JP16/USP) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs... D05525 Plantago seed; Ispaghula; Plantago seed Crude drugs [BR:br08305] Dicot plants: asterids Plantaginaceae (plantain family) D05525 Plantago seed PubChem: 17398302 ...

  16. Drug: D06763 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available category: 5100 Polyporaceae (Polypore) Polyporus sclerotium Major component: Ergosterol [CPD:C01694] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs... 5100 Crude drugs D06763 Polyporus sclerotium (JP16); Powdered pol...yporus sclerotium (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs... D06763 Polyporus sclerotium; Powdered polyporus sclerotium; Chuling Crude drugs [BR:br08305] Fungi Basidiomycetes D06763 Polyporus sclerotium PubChem: 47208414 ...

  17. Drug: D06738 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available mponent: Kaempferol [CPD:C05903] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chine...se medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06738 Tribulus fruit (JP16) Tradit...ional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Sedative drugs... D06738 Tribulus fruit Crude drugs [BR:br08305] Dicot plants: rosids Zygophyllaceae (creosote-bush family) D06738 Tribulus fruit PubChem: 47208389 ...

  18. Drug: D06793 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available mp fruit Major component: Palmitic acid [CPD:C00249] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs... D06793 Hemp fruit (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Purgative drugs Purgative drugs... D06793 Hemp fruit Crude drugs [BR:br08305] Dicot plants: rosids Cannabaceae (hop family) D06793 Hemp fruit PubChem: 47208444 ...

  19. Drug: D06693 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5100 Fabaceae (pea family) Pueraria root Major component: Puerarin [CPD:C10524] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs...:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and cool in property D06693 Puer...aria root; Pueraria root Crude drugs [BR:br08305] Dicot plants: rosids Fabaceae (pea family) D06693 Pueraria root PubChem: 47208344 ...

  20. Drug: D06786 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nt: Cylindrin [CPD:C17534] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese med...icine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06786 Imperat...a rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Other drugs Hemostatic drugs... D06786 Imperata rhizome; Imperatae rhizoma Crude drugs [BR:br08305] Monocot plants Poaceae (grass family) D06786 Imperata rhizome PubChem: 47208437 ...

  1. Drug: D06910 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Hordeum vulgare seed Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06910 Malt (JP16) PubChem: 51091252 ...

  2. Drug: D06903 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available heaceae (tea family) Tea leaf Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese ...medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06903 Theae folium PubChem: 51091245 ...

  3. Drug: D07153 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available amily) Cinchona bark Major component: Quinine [CPD:C06526] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D07153 Cinchona bark PubChem: 51091492 ...

  4. Drug: D06892 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gs Drugs for replenishing Ying Drugs for replenishing Yi...ng D06892 *Asini corii collas; Ass-hide glue; Donkey-hide glue; Akyo; Gelatin Drugs for blood Drugs for repl...dae Equus asinus hide glue; Standards for non-pharmacopoeial crude drugs Traditional Chinese Medicine in Japan [BR:br08304] Crude Dru

  5. Drug: D04674 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs for clearing heat D0...4674 *Forsythia fruit; Forsythia fruit Drugs for pus discharge Drugs for pus discharge D04674 *Forsythia fru

  6. Drug: D06748 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 6748 Cnidium rhizome (JP16); Powdered cnidium rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for blood Drugs for removing blood stasis D06748 *Cnidium rhizome; Powdered cnidium rhizome; Cnidii rhizoma Dru...gs for pus discharge Drugs for pus discharge D06748 *Cni

  7. Drug: D06764 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs for regulating Qi D06764 *Citrus... unshiu peel; Citrus unshiu peel Drugs for dampness Drugs for resolving dampness D06764 *Citrus unshiu peel;

  8. Drug: D06694 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gs D06694 Clematis root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for damp...ness Antirheumatic drugs D06694 *Clematis root; Irei-sen Drugs for external use Drugs for external use D0669

  9. Drug: D06740 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for Qi Drugs for replenishing Qi D06740 *Cnidium monnieri fruit Dru...gs for external use Drugs for external use D06740 *Cnidium monnieri fruit Crude dru

  10. Drug: D06739 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs for replenishing bl...ood D06739 *Peony root; Powdered peony root; Peony root Drugs for pus discharge Drugs for pus discharge D067

  11. Drug: D06710 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ); Powdered sophora root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs... for clearing heat D06710 *Sophora root; Powdered sophora root; Sophora root Drugs... for external use Drugs for external use D06710 *Sophora root; Powdered sophora root; Sopho

  12. Drug: D00092 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (JP16); Powdered coptis rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs... rhizome; Powdered coptis rhizome; Coptis rhizome Drugs for external use Drugs for external use D00092 *Copt

  13. Drug: D06768 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cine in Japan [BR:br08304] Crude Drugs Drugs for blood Drugs for replenishing blood D06768 *Japanese angelic...a root; Powdered japanese angelica root; Japanese angelica root Drugs for external use Drugs for external us

  14. Drug: D06758 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Stomachic and antidiarrheal drugs St...omachic and antidiarrheal drugs D06758 *Jujube; Jujube Drugs for Qi Drugs for replenishing Qi D06758 *Jujube

  15. Drug: D06727 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5100 Crude drugs D06727 Bupleurum root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for clearing heat Drugs for clearing heat D06727 Bupleurum root; Bupleurum root Crude drugs [BR:br083

  16. Drugs Approved for Hodgkin Lymphoma

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Hodgkin lymphoma. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.

  17. Drugs Approved for Multiple Myeloma

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for multiple myeloma and other plasma cell neoplasms. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.

  18. Drugs Approved for Myeloproliferative Neoplasms

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for myeloproliferative neoplasms. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.

  19. Drug: D07152 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07152 Crude, Drug Processed aconite root Aconitine [CPD:C06091], Jesaconitine [CPD...Same as: E00256 Therapeutic category: 5100 Ranunculaceae (buttercup family) Processed... drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D07152 Processed aconite root PubChem: 51091491 ...

  20. Drug: D06800 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06800 Crude, Drug Japanese gentian (JP16); Powdered japanese gentian (JP16); Genti...gs 5100 Crude drugs D06800 Japanese gentian (JP16); Powdered japanese gentian (JP16) Traditional Chinese Med...icine in Japan [BR:br08304] Crude Drugs Drugs for clearing heat Drugs for clearing heat D06800 Japanese gentian; Powdered japanese

  1. Intracerebroventricular administration of drugs.

    Science.gov (United States)

    Cook, Aaron M; Mieure, Katherine D; Owen, Robert D; Pesaturo, Adam B; Hatton, Jimmi

    2009-07-01

    Intracerebroventricular drug administration is a method that bypasses the blood-brain barrier and other mechanisms that limit drug distribution into the brain, allowing high drug concentrations to enter the central compartment. Instillation of drugs directly into the ventricles of the brain must be done carefully and with full consideration of factors affecting the efficacy and safety of this route of administration. These factors include the osmolarity, pH, volume, and presence of preservatives and diluents of the drug solution being administered. Very few studies have formally investigated intraventricular therapies, and dosing recommendations may vary widely depending on the agent and the patient. Many antimicrobials have been given intraventricularly, although very few prospective studies have evaluated this strategy. There are wide variations among the reports regarding dosage regimens and the pharmacokinetics of the antimicrobials used. Guidance on appropriate formulations and their use is lacking. Clinicians should be aware of their patients' ongoing disease processes and neurologic status, as well as pertinent physiochemical properties of drugs when formulating them for intracerebroventricular administration; a high index of suspicion should be maintained when monitoring patients for adverse drug events after instillation.

  2. Drug abuse in athletes

    Directory of Open Access Journals (Sweden)

    Reardon CL

    2014-08-01

    Full Text Available Claudia L Reardon, Shane Creado Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Abstract: Drug abuse occurs in all sports and at most levels of competition. Athletic life may lead to drug abuse for a number of reasons, including for performance enhancement, to self-treat otherwise untreated mental illness, and to deal with stressors, such as pressure to perform, injuries, physical pain, and retirement from sport. This review examines the history of doping in athletes, the effects of different classes of substances used for doping, side effects of doping, the role of anti-doping organizations, and treatment of affected athletes. Doping goes back to ancient times, prior to the development of organized sports. Performance-enhancing drugs have continued to evolve, with “advances” in doping strategies driven by improved drug testing detection methods and advances in scientific research that can lead to the discovery and use of substances that may later be banned. Many sports organizations have come to ban the use of performance-enhancing drugs and have very strict consequences for people caught using them. There is variable evidence for the performance-enhancing effects and side effects of the various substances that are used for doping. Drug abuse in athletes should be addressed with preventive measures, education, motivational interviewing, and, when indicated, pharmacologic interventions. Keywords: doping, athletes, steroids, drug abuse, mental illness

  3. Herb-drug interactions.

    Science.gov (United States)

    Fugh-Berman, A

    2000-01-08

    Concurrent use of herbs may mimic, magnify, or oppose the effect of drugs. Plausible cases of herb-drug interactions include: bleeding when warfarin is combined with ginkgo (Ginkgo biloba), garlic (Allium sativum), dong quai (Angelica sinensis), or danshen (Salvia miltiorrhiza); mild serotonin syndrome in patients who mix St John's wort (Hypericum perforatum) with serotonin-reuptake inhibitors; decreased bioavailability of digoxin, theophylline, cyclosporin, and phenprocoumon when these drugs are combined with St John's wort; induction of mania in depressed patients who mix antidepressants and Panax ginseng; exacerbation of extrapyramidal effects with neuroleptic drugs and betel nut (Areca catechu); increased risk of hypertension when tricyclic antidepressants are combined with yohimbine (Pausinystalia yohimbe); potentiation of oral and topical corticosteroids by liquorice (Glycyrrhiza glabra); decreased blood concentrations of prednisolone when taken with the Chinese herbal product xaio chai hu tang (sho-salko-to); and decreased concentrations of phenytoin when combined with the Ayurvedic syrup shankhapushpi. Anthranoid-containing plants (including senna [Cassia senna] and cascara [Rhamnus purshiana]) and soluble fibres (including guar gum and psyllium) can decrease the absorption of drugs. Many reports of herb-drug interactions are sketchy and lack laboratory analysis of suspect preparations. Health-care practitioners should caution patients against mixing herbs and pharmaceutical drugs.

  4. Bioequivalence of generic drugs.

    Science.gov (United States)

    Andrade, Chittaranjan

    2015-09-01

    Generic drugs are bioequivalent to the original brand; this is a prerequisite for marketing approval. It is theoretically possible that one generic drug may overestimate the pharmacokinetic (PK) parameters of the original and another generic may underestimate these PK parameters; in consequence, these 2 generics may not be bioequivalent between themselves. The result could be loss of efficacy or development of drug-related adverse effects if these generics are interchanged in stable patients. In a recent study involving 292 indirect comparisons of generic formulations of 9 different drugs, mathematical modeling showed that in most cases (87.0% for maximum concentration, 90.1% for area under the curve, and 80.5% for both) generic drugs are bioequivalent to each other. These reassuring findings notwithstanding, prudence dictates that, in stable patients, generic drugs should be interchanged only if there is a good reason for it. This is because bioequivalent brands of drugs may differ in their excipient content, and this can result in variations in safety profiles.

  5. Drug-induced gynecomastia.

    Science.gov (United States)

    Eckman, Ari; Dobs, Adrian

    2008-11-01

    Gynecomastia is caused by drugs in 10 - 25% of all cases. The pathophysiologic mechanism for some drugs includes exogenous estrogens exposure, medications that cause hypogonadism, anti-androgenic effects and hyperprolactinemia. This manuscript reviews common examples of drug-induced gynecomastia, discussing the mechanisms and possible treatments. Discontinuing the medication is always the best choice; however, if this is not possible, then testosterone replacement therapy may be needed for hypogonadism. When a man is euogonadal, a trial of the anti-estrogen, tamoxifen or an aromatase inhibitor may be an option.

  6. Drugs Approved for Thyroid Cancer

    Science.gov (United States)

    ... Ask about Your Treatment Research Drugs Approved for Thyroid Cancer This page lists cancer drugs approved by the ... that are not listed here. Drugs Approved for Thyroid Cancer Cabozantinib-S-Malate Caprelsa (Vandetanib) Cometriq (Cabozantinib-S-Malate) Doxorubicin ...

  7. Drug: D06722 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 722 Achyranthes root (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for blood Drugs for removing blood stasis D06722 Achyranthes root; Achyranthese root Crude d

  8. Drug: D06754 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apan [BR:br08304] Crude Drugs Drugs for blood Drugs for removing blood stasis D06...5 Fabaceae (pea family) Sappan wood Major component: Brazilin [CPD:C09920] Traditional Chinese Medicine in J

  9. Drug: D06801 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ly) Alpinia Officinarum Rhizome Major component: Cineole [CPD:C09844] Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs... Drugs for warming the interior Drugs for warming the interior D06801 Alpinia offcin

  10. Drugs Approved for Lung Cancer

    Science.gov (United States)

    ... Ask about Your Treatment Research Drugs Approved for Lung Cancer This page lists cancer drugs approved by the ... listed here. Drugs Approved for Non-Small Cell Lung Cancer Abitrexate (Methotrexate) Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation) ...

  11. Drugs Approved for Bladder Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for bladder cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.

  12. Drugs Approved for Breast Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for breast cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.

  13. Drugs Approved for Pancreatic Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for pancreatic cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.

  14. Drug: D04403 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04403 Drug Guar gum (NF) Pharmaceutic aid [tablet binder]; Pharmaceutic aid [table...NG DRUGS, EXCL. INSULINS A10BX Other blood glucose lowering drugs, excl. insulins A10BX01 Guar gum D04403

  15. State Drug Utilization Data 2012

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  16. Drug: D07379 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 02 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES... R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DX Other systemic drugs

  17. Drug: D01828 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISE...ASES R03DX Other systemic drugs for obstructive airway diseases R03DX01 Amlexanox D

  18. Drug: D08767 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available n [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radioa...ctive drugs D08767 Benzoylmercaptoacetylglycylglycylglycine - mercaptoacetylglycylglycylglycine technetium (99mTc) mixt PubChem: 96025450 ...

  19. Drug: D09125 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rt Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Drugs for resolving dam...705] Pogostemon cablin [TAX:28511] Same as: E00188 Lamiaceae (mint family) Pogostemon cablin above ground pa

  20. State Drug Utilization Data 1992

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  1. State Drug Utilization Data 2007

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  2. State Drug Utilization Data 1998

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  3. State Drug Utilization Data 2006

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  4. State Drug Utilization Data 2008

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  5. State Drug Utilization Data 2009

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  6. State Drug Utilization Data 2005

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  7. State Drug Utilization Data 1999

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  8. State Drug Utilization Data 1994

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  9. State Drug Utilization Data 1996

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  10. State Drug Utilization Data 2000

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  11. State Drug Utilization Data 2014

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  12. State Drug Utilization Data 2010

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  13. State Drug Utilization Data 2011

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  14. State Drug Utilization Data 2002

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  15. State Drug Utilization Data 2003

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  16. State Drug Utilization Data 2015

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  17. State Drug Utilization Data 1993

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  18. State Drug Utilization Data 1991

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  19. State Drug Utilization Data 2001

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  20. State Drug Utilization Data 1997

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  1. State Drug Utilization Data 2013

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  2. State Drug Utilization Data 1995

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  3. Drug: D06905 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06905 Crude, Drug Peucedanum root (JP16); Peucedani radix; Zenko (Pd-Ia, II,III, I... Crude Drugs Drugs for dampness Cough suppressants and expectorants D06905 *Peucedani radix; Hogfennel root;

  4. Drug: D08546 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ISM A02 DRUGS FOR ACID RELATED DISORDERS A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (...GORD) A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (G

  5. State Drug Utilization Data 2004

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  6. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Adolescent Brain Comorbidity College-Age & Young Adults Criminal Justice Drugged Driving Drug Testing Drugs and the Brain ... Meetings & Events Media Guide About NIDA Director's Page Organization Legislative Activities Advisory Boards & Groups Working at NIDA ...

  7. State Drug Utilization Data 2016

    Data.gov (United States)

    U.S. Department of Health & Human Services — Drug utilization data are reported by states for covered outpatient drugs that are paid for by state Medicaid agencies since the start of the Medicaid Drug Rebate...

  8. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Related Topics Addiction Science Adolescent Brain Comorbidity College-Age & Young Adults Criminal Justice Drugged Driving Drug Testing ... please visit: http://www.cdc.gov/hiv/risk/age/youth/index.html​ . Resources Publications Drug Facts: HIV/ ...

  9. Vitiligo, drug induced (image)

    Science.gov (United States)

    ... this person's face have resulted from drug-induced vitiligo. Loss of melanin, the primary skin pigment, occasionally ... is the case with this individual. The typical vitiligo lesion is flat and depigmented, but maintains the ...

  10. Food and Drug Administration

    Science.gov (United States)

    ... trials, Critical Path Initiative and more Icon for Business & Industry section. For Industry Guidance, registration and listing, ... Map Nondiscrimination Website Policies U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 ...

  11. Cholesterol - drug treatment

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/patientinstructions/000314.htm Cholesterol - drug treatment To use the sharing features on ... treatment; Hardening of the arteries - statin Statins for Cholesterol Statins reduce your risk of heart disease, stroke, ...

  12. Medicaid Drug Claims Statistics

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Medicaid Drug Claims Statistics CD is a useful tool that conveniently breaks up Medicaid claim counts and separates them by quarter and includes an annual count.

  13. Drug-induced catatonia.

    Science.gov (United States)

    Duggal, Harpreet S; Singh, Ira

    2005-09-01

    Catatonia is a heterogeneous syndrome that varies in etiology, presentation, course and sequelae. Initially conceptualized as a subtype of schizophrenia, catatonia is now recognized to occur not only with other psychiatric conditions but also with medical conditions and drug-induced and toxic states. While drug-induced catatonia is now a recognized entity, most studies club it with catatonia due to general medical conditions or organic catatonia, thus precluding any meaningful interpretation of such cases. The literature on drug-induced catatonia mostly draws from scattered case reports. This article attempts to review the available literature in this realm and integrate the information in an attempt to explore the epidemiology, etiology, mechanism and treatment of drug-induced catatonia.

  14. Drug therapy smartens up

    Science.gov (United States)

    Martin, Christian

    2015-11-01

    The submission of the first 'smart pill' for market approval, combined with progress in the European nanomedicine landscape, illustrates the positive outlook for drug therapy and health monitoring, explains Christian Martin.

  15. MSIS Drug Utilization Datamart

    Data.gov (United States)

    U.S. Department of Health & Human Services — This page provides background needed to take advantage of the capabilities of the MSIS Drug Utilization Datamart. This mart allows the user to develop high-level...

  16. Mucoadhesive drug delivery systems

    Directory of Open Access Journals (Sweden)

    Rahamatullah Shaikh

    2011-01-01

    Full Text Available Mucoadhesion is commonly defined as the adhesion between two materials, at least one of which is a mucosal surface. Over the past few decades, mucosal drug delivery has received a great deal of attention. Mucoadhesive dosage forms may be designed to enable prolonged retention at the site of application, providing a controlled rate of drug release for improved therapeutic outcome. Application of dosage forms to mucosal surfaces may be of benefit to drug molecules not amenable to the oral route, such as those that undergo acid degradation or extensive first-pass metabolism. The mucoadhesive ability of a dosage form is dependent upon a variety of factors, including the nature of the mucosal tissue and the physicochemical properties of the polymeric formulation. This review article aims to provide an overview of the various aspects of mucoadhesion, mucoadhesive materials, factors affecting mucoadhesion, evaluating methods, and finally various mucoadhesive drug delivery systems (buccal, nasal, ocular, gastro, vaginal, and rectal.

  17. Professional thieves and drugs.

    Science.gov (United States)

    Inciardi, J A; Russe, B R

    1977-12-01

    The "professional thief" is a highly specialized predatory offender with a history that dates back to Elizabethan England. Although this type of criminal is generally associated with narcotic addiction, his drug-taking typically involved the use of heroin, morphine, and cocaine on an intermittent basis. However, trafficking in drugs was common to the "professional" underworld, and as a result this deviant fraternity had a notable impact on the impressment of a criminal model of drug use on twentieth century conceptions of the addict. The concept of "professional" theft is reviewed, the use of drugs by professional thieves is discussed, and the interaction between this underworld group and the early Federal Bureau of Narcotics is examined.

  18. The drug swindlers.

    Science.gov (United States)

    Silverman, M; Lydecker, M; Lee, P R

    1990-01-01

    In a number of important developing nations--among them Indonesia, India, and Brazil--clinical pharmacologists and other drug experts are revealing mounting concern over the marketing of fraudulent drug products. These are shaped, colored, flavored, marked, and packaged to mimic the real product. They may contain the actual antibiotic or other drug indicated on the label, but so "cut" that the product provides only a small fraction of the labeled amount, or they may contain only useless flour or starch. At best, they are worthless. At the worst, they can kill. In most instances, it is believed that these "drugs" are produced and marketed by local or domestic fly-by-night groups and not by multinational pharmaceutical firms. Blame for these practices is placed on inadequate or unenforced laws, only trivial punishments, bribery and corruption, and the fact that generally "nobody inspects the inspectors."

  19. Bugs, Drugs, and Computers

    OpenAIRE

    Kilroy, John E.; Campbell, Bruce D.; Mathewson, Herbert O.; Scarafile, Peter D.; Solomon, Stuart H.

    1983-01-01

    The paper describes the development, implementation, and review of a daily reporting system using data from two modules of a hospital information system: Kirby-Bauer sensitivity results from Microbiology, and patient drug profiles from Pharmacy.

  20. Information for Consumers (Drugs)

    Science.gov (United States)

    ... Advertising: Questions to Ask Yourself Sample Prescription Drug Advertisements Give Us Feedback Resources for You Report a ... feeds Follow FDA on Twitter Follow FDA on Facebook View FDA videos on YouTube View FDA photos ...

  1. Drug-Food Interactions

    Science.gov (United States)

    ... t stir medicine into your food or take capsules apart (unless your doctor tells you to) because this may change the way the drug works.Don’t take vitamin pills at the same time you take medicine ...

  2. Animal Drug Safety FAQs

    Science.gov (United States)

    ... and controls used for the manufacturing, processing and packaging of the drug are adequate to preserve its ... have a complaints regarding veterinary standard of care issues? Complaints and questions about standard of care issues ...

  3. Drug: D06778 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ategory: 5100 Araceae (arum family) Pinellia tuber Major component: Homogentisic acid [CPD:C00544] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs... 5100 Crude drugs D06778 Pinellia tuber (JP16) Traditional Chinese M...llia tuber; Pineliae tuber Crude drugs [BR:br08305] Monocot plants Araceae (arum family) D06778 Pinellia tuber PubChem: 47208429 ...

  4. Drug: D01033 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available th stem exudation Major component: Tragacanthic acid Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D01033 Tragacan...th (JP16/NF); Powdered tragacanth (JP16) Crude drugs [BR:br08305] Dicot plants: rosids Fabaceae (pea family) D01033 Tragacanth PubChem: 7848096 ...

  5. Drug: D01032 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 100 Gelidiaceae Gelidium amansii mucous (freeze dry) Major component: Agarose [CPD:C01399] Therapeutic category of drugs... in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs... 510 Crude drugs 5100 Crude drugs D01032 Agar (JP16/NF); Powdered agar (JP16) Crude drugs [BR:br08305] Algae Red algae D01032 Agar PubChem: 7848095 ...

  6. Epigenetic Drugs for Multiple Sclerosis

    OpenAIRE

    Peedicayil, Jacob

    2016-01-01

    There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses ...

  7. Prediction of drug-drug interactions from chemogenomic and gene-gene interactions and analysis of drug-drug interactions

    OpenAIRE

    2013-01-01

    The interactions between multiple drugs administered to an organism concurrently, whether in the form of synergy or antagonism, are of clinical relevance. Moreover, un-derstanding the mechanisms and nature of drug-drug interactions is of great practical and theoretical interest. Work has previously been done on gene-gene and gene-drug interactions, but the prediction and rationalization of drug-drug interactions from this data is not straightforward. We present a strategy for attacking this p...

  8. FDA relations during drug development

    OpenAIRE

    Mitchel, Jules T.

    2000-01-01

    Working closely and cooperatively with regulatory authorities during drug development is vital to successful drug development programs. In the United States, the drug development team includes not only members of the key disciplines of drug discovery, clinical research, regulatory affairs, marketing, chemistry, toxicology, and legal aspects, but also the Food and Drug Administration (FDA). New regulations encourage meetings at the pre-investigational new drug (pre-IND), end-of-phase-2, and pr...

  9. Optimizing HIV drug therapy

    OpenAIRE

    Calmy, Alexandra

    2010-01-01

    The spectrum of drugs used in HIV-infected patients has dramatically changed since triple antiretroviral combinations were introduced, albeit at the expense of some severe adverse events, in 1996. Long term complications of antiretroviral drug exposure, such as HIV lipodystrophy, as well as organ-specific disease of heart and bone are, therefore, a critical issue when designing antiretroviral regimens. Because it is difficult to predict the occurrence of lipodystrophy, and because there is no...

  10. New drugs for migraine

    OpenAIRE

    Stovner, Lars Jacob; Tronvik, Erling; Hagen, Knut

    2009-01-01

    After the triptans, a calcitonin gene-related peptide blocker (telcagepant) is the first acute medicine that has been developed primarily for treatment of acute migraine. Otherwise, the new drugs have been developed first for other purposes, like anticonvulsants, antihypertensives and antidepressants used for migraine prophylaxis. For acute attacks, a new way to administer a traditional drug like dihydroergotamine is under way, and documentation of efficacy in migraine has been gained for som...

  11. Chemoinformatics and Drug Discovery

    Directory of Open Access Journals (Sweden)

    Arnold Hagler

    2002-08-01

    Full Text Available This article reviews current achievements in the field of chemoinformatics and their impact on modern drug discovery processes. The main data mining approaches used in cheminformatics, such as descriptor computations, structural similarity matrices, and classification algorithms, are outlined. The applications of cheminformatics in drug discovery, such as compound selection, virtual library generation, virtual high throughput screening, HTS data mining, and in silico ADMET are discussed. At the conclusion, future directions of chemoinformatics are suggested.

  12. Sociology of Drug Consumption

    Directory of Open Access Journals (Sweden)

    2004-02-01

    Full Text Available In this article which is a review of sociological ideas and studies of drug abusers in social situation, drug addiction steps (particularly alcohol, heroin and cocaine consumption are revised and some explanations are made. Also, the role of some sociological ideas in drug addiction is considered in which Anomie Theory reads: "because of such duality, the individuals who are not satisfied with their role are in hurt." According to this theory, drug users choose seclusion and neglecting usual social aims as well as competitive situations. Association of Differentiation Theory claims that drug use behavior is a learned behavior and the first learning occurs in a friendly small group (i.e. youngsters. Social Control theory believes that one can predict normal and abnormal behaviors through the rate of individuals' social commitments. Internal and external controls also determine commitment rate. Micro-cultural theory considers drug use as a compatibility with abnormal micro-culture rules. Symbolic Mutual Action Believes that the etiquettes which society attribute to individuals/behaviors determine their acquired social reactions rather than any inherited acquisition.

  13. New drugs of abuse.

    Science.gov (United States)

    Rech, Megan A; Donahey, Elisabeth; Cappiello Dziedzic, Jacqueline M; Oh, Laura; Greenhalgh, Elizabeth

    2015-02-01

    Drug abuse is a common problem and growing concern in the United States, and over the past decade, novel or atypical drugs have emerged and have become increasingly popular. Recognition and treatment of new drugs of abuse pose many challenges for health care providers due to lack of quantitative reporting and routine surveillance, and the difficulty of detection in routine blood and urine analyses. Furthermore, street manufacturers are able to rapidly adapt and develop new synthetic isolates of older drugs as soon as law enforcement agencies render them illegal. In this article, we describe the clinical and adverse effects and purported pharmacology of several new classes of drugs of abuse including synthetic cannabinoids, synthetic cathinones, salvia, desomorphine, and kratom. Because many of these substances can have severe or life-threatening adverse effects, knowledge of general toxicology is key in recognizing acute intoxication and overdose; however, typical toxidromes (e.g., cholinergic, sympathomimetic, opioid, etc.) are not precipitated by many of these agents. Medical management of patients who abuse or overdose on these drugs largely consists of supportive care, although naloxone may be used as an antidote for desomorphine overdose. Symptoms of aggression and psychosis may be treated with sedation (benzodiazepines, propofol) and antipsychotics (haloperidol or atypical agents such as quetiapine or ziprasidone). Other facets of management to consider include treatment for withdrawal or addiction, nutrition support, and potential for transmission of infectious diseases.

  14. [Drug use in pregnancy].

    Science.gov (United States)

    von Mandach, U

    2005-01-01

    Drug use in pregnancy is associated with a number of serious complications for mother and fetus. There are safe data on destructive effects of alcohol, cocain, marijuana and tobacco on pregnancy and neonatal outcome. Of importance is the fact that for many drugs similar effects on pregnancy could be observed: vasoconstriction of the placental vessels resulting in placental abruption, preterm labour (mother), spontaneous abortion, intrauterine growth retardation, low birth weight, preterm delivery and stillbirth (fetus). Symptoms of withdrawal and neurodevelopmental disorders are the most important problems of the neonate. However, only small data exist about the effects of recently popular party drugs like ecstasy or LSD. In addition, from most drugs, with exception of alcohol, safe information about the risk of congenital malformations doesn't exist. Nevertheless they may be a useful guide in the diagnostic of potential malformations by ultrasound. Most of pregnant women using drugs are poly-drug users and are often in reduced general condition. They need therefore the intensive care of the obstetrician in cooperation with other specialists (internal medicine, psychiatry).

  15. Drug: D06759 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gs in Japan [BR:br08301] 5 Crude drugs and Chinese medic...ine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06759 Alisma rhizome (JP16); Powdered alis...ma rhizome (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Diuretic drugs... D06759 Alisma rhizome; Powdered alisma rhizome; Alisma rhizome Crude drugs...Alismataceae (water-plantain family) Thrumwort rhizome Major component: Alisol [CPD:C17459 C17460 C17461] Therapeutic category of dru

  16. Drugs affecting the eye.

    Science.gov (United States)

    Taylor, F

    1985-08-01

    This discussion reviews drugs that affect the eye, including antihyperglycemic agents; corticosteroids; antirheumatic drugs (quinolines, indomethacin, and allopurinol); psychiatric drugs (phenothiazine, thioridazine, and chlorpromazine); drugs used in cardiology (practolol, amiodarone, and digitalis gylcosides); drugs implicated in optic neuritis and atrophy, drugs with an anticholinergic action; oral contraceptives (OCs); and topical drugs and systemic effects. Refractive changes, either myopic or hypermetropic, can occur as a result of hyperglycemia, and variation in vision is sometimes a presenting symptom in diabetes mellitus. If it causes a change in the refraction, treatment of hyperglycemia almost always produces a temporary hypermetropia. A return to the original refractive state often takes weeks, sometimes months. There is some evidence that patients adequately treated with insulin improve more rapidly than those taking oral medication. Such patients always should be referred for opthalmological evaluation as other factors might be responsible, but it might not be possible to order the appropriate spectacle correction for some time. The most important ocular side effect of the systemic adiministration of corticosteroids is the formation of a posterior subcapsular cataract. Glaucoma also can result from corticosteroids, most often when they are applied topically. Corticosteroids have been implicated in the production of benign intracranial hypertension, which is paradoxical because they also are used in its treatment. The most important side effect of drugs such as chloroquine and hydroxychloroquine is an almost always irreversible maculopathy with resultant loss of central vision. Corneal and retinal changes similar to those caused by the quinolines have been reported with indomethacin, but there is some question about a cause and effect relationship. The National Registry of Drug Induced Ocular Side Effects in the US published 30 case histories of

  17. Youth, drugs, and biopolitics

    Directory of Open Access Journals (Sweden)

    Alcides Jose Sanches Vergara

    2011-07-01

    Full Text Available In this article, we tackle the issue of youth and drugs as something linked to biopower and biopolitics, both concepts developed by Michael Foucault. Youth and drugs are taken and analyzed in situations involving the management of crime linked to the risks and deviations from the law, abuse and dependence. The youth; irreverent, courageous, healthy, idealistic, and that wanted to change the world for the better as we have seen in the past, is now strongly related to violence, dangerous activities, moral and social risks, drug addiction, criminality, and others negative images. To deal with these young people, tolerance and small punishments of yore are not enough anymore. The young people emerge as a segment of the population subject to various actions and programs. The drugs now are seen as matters of security and public health. There is a shifting and repositioning in the discourse about the young - from minor, drugged, and criminal to lawbreaker, user and drug addict. The change is subtle, but represents a modulation in the devices of social control. Beyond the consent of the young to get rid of drugs, there is a search for the creation of a wide area of monitoring of their behavior through the activation of community protection networks. The belief that the young are more impressionable and vulnerable, and that action on the cause of the problem or risk reduction are the most efficient ways of management, taking responsibility away from personal and family sphere and transferring it to the State, contributes to the increasing control of young people nowadays.

  18. New Drugs and Drug Resistance in Malaria: Molecular Genetic Analysis.

    Science.gov (United States)

    1996-06-26

    heterologous expressions system in yeast for potential drug target enzymes. The yeast expression system should allow rapid screening of new drugs , greatly...medication yet the world faces a crisis-drug resistance is emerging and spreading faster than drugs are being developed and the flow in the pipeline of new ... drugs has all but stopped. This represents a particular threat to the US Military. In a short time there may be parts of the world where no effective

  19. Drug development and immunotoxicity

    Institute of Scientific and Technical Information of China (English)

    SugiY; IzumM

    2002-01-01

    Immunotoxicity of drugs has to be evaluated same as other kinds of toxicities,since the functions of the immune system are vital to human survival,consisting of the protection of the body from invading pathogens and to provide immune surveillance against arising tumor cells.A given drug's effect on the immune system can be classified as (1)immuno-suppression/activation.(2)antigenicity and hypersensitivity,(3)autoimmunity.The guidance of immumotoxicity has highlighted on immuno-suppression in Harmonizing Congress among EC,USA and Japan.In this paper,the strategy and methods to evaluate immunotoxicity,mainly immuno-suppression,of the drugs will be show.complexity and variety of immuno-systems make assessment of immumotoxicity complex.The testing in rats to assess immune function is thought to be the first choice for immunotoxicity evaluation in a drug development,and then other suitable testing should be added depending on the mature of drugs.

  20. Magnetic targeted drug delivery

    Directory of Open Access Journals (Sweden)

    Timothy Wiedmann

    2009-10-01

    Full Text Available Lung cancer is the most common cause of death from cancer in both men and women. Treatment by intravenous or oral administration of chemotherapy agents results in serious and often treatment-limiting side effects. Delivery of drugs directly to the lung by inhalation of an aerosol holds the promise of achieving a higher concentration in the lung with lower blood levels. To further enhance the selective lung deposition, it may be possible to target deposition by using external magnetic fields to direct the delivery of drug coupled to magnetic particles. Moreover, alternating magnetic fields can be used to induce particle heating, which in turn controls the drug release rate with the appropriate thermal sensitive material.With this goal, superparamagetic nanoparticles (SPNP were prepared and characterized, and enhanced magnetic deposition was demonstrated in vitro and in vivo. SPNPs were also incorporated into a lipid-based/SPNP aerosol formulation, and drug release was shown to be controlled by thermal activation. Because of the inherent imaging potential of SPNPs, this use of nanotechnology offers the possibility of coupling the diagnosis of lung cancer to drug release, which perhaps will ultimately provide the “magic bullet” that Paul Ehrlich originally sought.

  1. DRUGS AND SMOKING

    Directory of Open Access Journals (Sweden)

    J. V. Lukina

    2015-12-01

    Full Text Available Smoking is a well – known risk factor of many diseases. It influences the efficacy and safety of drug treatment by affecting the course of different physiological processes and modifying the metabolism of drugs. The number of researches showed decrease in efficacy of some cardiovascular drugs in smokers.Aim. To compare efficacy and safety of selective and non-selective beta–adrenoceptor blockers in smokers and nonsmokers with chronic ischemic disease.Material and Methods. Antianginal efficacy of drugs in patients of both groups was evaluated by burden tests on treadmill, effective doses of bisoprolol and propranolol were adjusted.Results. The result shows that smokers two times more often need prescription of double doses of drugs. Depressed antianginal activity of both beta-adrenoceptor blockers, especially of non-selective propranolol, in smokers was revealed. When evaluating the parameters of spirography, it was found that non-selective beta-adrenoceptor blocker propranol statistically significant decreases figures of bronchial passage, irrespective of the status of smoking. Moreover, with propranol treatment, bigger number of side effects is registered in both groups, demonstrating 30% more in smokers compared to nonsmokers.Conclusion. Smoking attenuates efficacy and safety of beta-blockers, especially these of non-selective ones.

  2. Drug: D08760 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e pentaacetic acid technetium (99mTc) Therapeutic category: 4300 Therapeutic category of drugs in Japan [BR:...br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs... 4300 Radioactive drugs D08760 Diethylenetriamine pentaacetic acid - diethylenetriamine pentaacetic acid technetium (99mTc) mixt PubChem: 96025443 ...

  3. Drug: D08757 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Neurolite (TN) C12H21N2O5S2. Tc. 433.9956 436.3417 Therapeutic category: 4300 Therapeutic category of drugs... in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radioactive drugs

  4. Drug: D06679 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs for dampness Cough suppressants a...nd expectorants D06679 Gambir; Powdered gambir; Gamibir Drugs for external use Drugs for external use D06679

  5. Drug: D06696 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (laurel family) Lindera root Major component: Linderol [CPD:C01766] Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs... Drugs for Qi Drugs for regulating Qi D06696 Lindera root Crude drugs [BR:br08305] Ot

  6. Drug: D07154 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07154 Persimmon calyx (non-JP) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Drugs... for Qi Drugs for regulating Qi D07154 Kaki calyx Crude drugs [BR:br08305] Dicot plants: asterids Ebenaceae (ebony family) D07154 Kaki calyx PubChem: 51091493 ...

  7. Drug: D06734 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available yphus jujuba [TAX:326968] Same as: E00105 Therapeutic category: 5100 Rhamnaceae (buckthorn...08304] Crude Drugs Drugs for Qi Sedative drugs D06734 Jujube seed Crude drugs [BR:br08305] Dicot plants: rosids Rhamnaceae (buckthorn family) D06734 Jujube seed PubChem: 47208385 ...

  8. Drug: D04526 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (USP); Indium oxine In 111 (TN) (C9H6NO)3. In 543.0399 547.2681 D04526.gif Diagnostic aid; Radioactive agent... Therapeutic category: 4300 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive... drugs 430 Radioactive drugs 4300 Radioactive drugs D04526

  9. Drug: D08669 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available br08303] N NERVOUS SYSTEM N07 OTHER NERVOUS SYSTEM DRUGS N07B DRUGS USED IN ADDICTIVE DISORDERS N07BA Drugs used in nicotine dependen...ce N07BA03 Varenicline D08669 Varenicline (INN) USP drug classification [BR:br08302

  10. Drug: D02102 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available BR:br08303] N NERVOUS SYSTEM N07 OTHER NERVOUS SYSTEM DRUGS N07B DRUGS USED IN ADDICTIVE DISORDERS N07BC Drugs used in opioid depende...nce N07BC02 Methadone D02102 Methadone hydrochloride (JAN/USP) USP drug classificat

  11. Drug: D06791 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available in flavor and warm in property D06791 Ephedra herb; Ephedrae Herba Crude drugs [BR:br08305] Naked-seed plants Ephedraceae (ephedra family) D06791 Ephedra herb PubChem: 47208442 ... ...) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent

  12. Drug: D06746 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available in Japan [BR:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and warm in prope...rty D06746 Magnolia flower Crude drugs [BR:br08305] Other flowering plants Magnoliaceae (magnolia family) D06746 Magnolia flower PubChem: 47208397 ...

  13. Drug: D08758 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apeutic category: 4300 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radio...active drugs 430 Radioactive drugs 4300 Radioactive drugs D08758 Technetium (99mTc) N-pyridoxyl-5-methyltryptophan PubChem: 96025441 ...

  14. Drug: D02006 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ron (TN) SrCl2 158.8452 158.526 D02006.gif Antineoplastic; Radioactive agent Therapeutic category: 4300 ATC ...code: V10BX01 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radio...active drugs 4300 Radioactive drugs D02006 Strontium (89

  15. Drug: D06339 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06339 Drug Xenon Xe 133 (JAN/USP/INN); Xenon (133Xe); Xenon Xe 133 (TN) Xe 132.9059 131.293 D06339.gif Radi...gory of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radio

  16. Drug: D08764 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apeutic category: 4300 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radio...active drugs 430 Radioactive drugs 4300 Radioactive drugs D08764 Technetium (99mTc) hydroxymethylene diphosphonate PubChem: 96025447 ...

  17. Drug: D05189 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Meditec (TN) TcO4. Na 185.8757 185.8936 D05189.gif Radioactive agent Therapeutic category: 4300 ATC code: V...09FX01 Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radio...active drugs 4300 Radioactive drugs D05189 Sodium pertechnetate

  18. Drug: D07520 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07520 Drug Bepridil (INN); Bepadin (TN) C24H34N2O 366.2671 366.5396 D07520.gif Antiarrhythmic...; Calcium antagonist; Coronary vasodilator Same as: C06847 ATC code: C08EA02 Class IV antiarrhythmic...36 Calcium channel blocking drugs map07037 Antiarrhythmic drugs map07231 Sodium channel blocking drugs Anato

  19. Drug: D06779 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06779 Crude, Drug Angelica dahurica root (JP16); Angelica dahuricae radix (TN) Bya...PD:C10451], Caryophyllene [CPD:C09629], Ligustilide [CPD:C16987], Osthol [CPD:C09280], Isoimperatorin [CPD:C16976] Angelica... dahurica [TAX:48101] Same as: E00149 Therapeutic category: 5100 Angelica dahurica root Major...:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06779 Angelica...c drugs Diaphoretic drugs pungent in flavor and warm in property D06779 Angelica dahurica root; Angelica dah

  20. Drug: D06724 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06724 Crude, Drug Schisandra fruit (JP16); Schisandra fruit (TN) Schizandrin [CPD:...[CPD:C09635], beta-Chamigrene [CPD:C09637], Chamigrenal, Fumarate [CPD:C00122], Schizandrel A, B Schisandra ...chinensis [TAX:50507] Same as: E00096 Therapeutic category: 5100 Schisandraceae (schisand...in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06724 Schisand...R:br08304] Crude Drugs Drugs for dampness Cough suppressants and expectorants D06724 Schisandra fruit; Schisand

  1. Drug: D06744 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06744 Crude, Drug Ginger (JP16); Powdered ginger (JP16); Ginger (TN) Zingiberene [...77 C11392], Myrcene [CPD:C06074], [6]-Gingerol [CPD:C10462], [8]-Gingerol [CPD:C17495], [10]-Ginger...) Zingiber officinale rhizome Major component: Gingerol [CPD:C10462 C17495 C17496...de drugs 510 Crude drugs 5100 Crude drugs D06744 Ginger (JP16); Powdered ginger (JP16) Traditional Chinese M...edicine in Japan [BR:br08304] Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and warm in property D06744 *Ginger

  2. Drug: D03868 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 8 Ipecac (JP16/USP); Powdered lpecac (JP16) Crude drugs [BR:br08305] Dicot plants: asterids Rubiaceae (madder family) D03868 Ipecac CAS: 8012-96-2 PubChem: 17397952 ... ...D03868 Crude, Drug Ipecac (JP16/USP); Powdered lpecac (JP16); Ipsatol (TN) Emetine ...ry: 5100 ATC code: R05CA04 V03AB01 Rubiaceae (madder family) Cephaelis root Major component: Emetine [CPD:C0...9421] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Cru...de drugs 5100 Crude drugs D03868 Ipecac (JP16/USP); Powdered

  3. Drug abuse among the students

    OpenAIRE

    2015-01-01

    ABSTRACT:Drug abuse is the willful misuse of either licit or illicit drugs for the purpose of recreation, perceived necessity or convenience. Drug abuse is a more intense and often willful misuse of drugs often to the point of addiction. In the eastern world the incidence shows a decline or a static pattern but the number of drug addicts is still enormous.. The major drug of abuse are heroin and marijuana but designer drugs are shown to be on the increase. The aim of the study is to determine...

  4. Genomics and drug discovery.

    Science.gov (United States)

    Haseltine, W A

    2001-09-01

    Genomics, the systematic study of all the genes of an organism, offers a new and much-needed source of systematic productivity for the pharmaceutical industry. The isolation of the majority of human genes in their most useful form is leading to the creation of new drugs based on human proteins, antibodies, peptides, and genes. Human Genome Sciences, Inc, was the first company to use the systematic, genomics approach to discovering drugs, and we have placed 4 of these in clinical trials. Two are described: repifermin (keratinocyte growth factor-2, KGF-2) for wound healing and treatment of mucositis caused by cancer therapy, and B lymphocyte stimulator (BLyS) for stimulation of the immune system. An anti-BLyS antibody drug is in advanced preclinical development for treatment of autoimmune diseases.

  5. [Chirality and drugs].

    Science.gov (United States)

    Testa, B; Reist, M; Carrupt, P A

    2000-07-01

    The two enantiomers of a chiral drug may have vastly different pharmacodynamic and pharmacokinetic properties. As a result, the research and development of chiral drugs raises specific problems some of which are discussed here. Thus, various pharmacokinetic interactions may involve two enantiomers, as seen for example when one enantiomer inhibits the metabolism of the other and modifies its effects. A different situation occurs when a third compound stereoselectively inhibits the metabolism of one of the two enantiomers. Another problem examined here results from the lack of configurational stability of some chiral drugs, a little known phenomenon whose consequences can be of pharmacological or pharmaceutical significance depending on the rate of the reaction of racemization or epimerisation. In-depth investigations are needed before choosing between a eutomer or a racemate.

  6. Storytelling in drug treatment

    DEFF Research Database (Denmark)

    Andersen, Ditte

    2014-01-01

    Professionals who provide drug treatment to young people regularly encounter what they conceive to be inauthentic client claims, that is, claims not in accordance with reality. Earlier research demonstrates how authenticity remains a key concern within drug treatment, but it has not sufficiently...... of ulterior motives, clients are interpreted as making inauthentic claims because they want to obtain something externally from drug treatment (e.g., avoid prison or work training programs), and (3) the story of disorders explains inauthenticity as a result of pathology. The study illuminates how...... professionals assert narrative control through storytelling and how specific stories carry specific consequences and may ultimately contribute to the exclusion of some clients from treatment....

  7. Drug delivery goes supercritical

    Directory of Open Access Journals (Sweden)

    Patrick J. Ginty

    2005-08-01

    Full Text Available In the field of drug delivery, the ability to control the size, morphology, and release of drug particles is fundamental to good targeting, but is often hampered by harsh processing conditions or inadequate methods; likewise for the processing of polymeric controlled-release systems. However, the use of supercritical fluids such as supercritical CO2 (scCO2 has provided a ‘clean’ and effective alternative to traditional methods of drug and polymer processing. In particular, scCO2 has a number of unique properties that make it possible to process both bioactive molecules and amorphous polymers without using toxic organic solvents or elevated temperatures. Here, we review the positive impact that supercritical fluids have had on the micronization, encapsulation, and impregnation of molecules of interest to both the pharmaceutical and biotechnology industries.

  8. Anesthetics drug pharmacodynamics.

    Science.gov (United States)

    Bischoff, P; Schneider, G; Kochs, E

    2008-01-01

    Anesthesia cannot be defined in an unambiguous manner. The essential components of general anesthesia are absence of consciousness and pain. This translates into two particular qualities: (1) sedation and hypnosis, i.e., mental blockade and (2) analgesia/antinociception, i.e., sensory blockade. Anesthetic actions on these two subcomponents are difficult to separate. On the one hand, very few anesthetics act exclusively on one of these components. On the other hand, these components are closely related to each other. Unconsciousness prevents (conscious) perception of pain, and nociception may serve as an arousal stimulus and change the level of sedation and hypnosis. The art of anesthesia lies in adequate dosing of drugs to reach both mental and sensory blockade. Drug administration can be based on pharmacokinetic considerations. Pharmacokinetic models allow an estimation of what happens to the administered drug in the body. Models with an effect site compartment may facilitate a tailored administration of anesthetic drugs. Finally, the quantification of pharmacodynamic effects allows a precise titration of drugs. Clinical assessment of mental blockade is often dichotomous, and therefore not very helpful to guide drug administration. Several scoring systems exist, but once consciousness is lost they become less reliable, in particular because reaction to stimuli is assessed, which mixes assessment of mental blockade with assessment of sensory blockade. Clinical assessment of analgesia requires a conscious patient, so antinociception is difficult to measure. Several methods of objective quantification on the basis of electrical brain activity are discussed including EEG and evoked potentials. Despite numerous indexes of the hypnotic component of anesthesia, there is no parameter that unambiguously quantifies the level of mental or sensory blockade.

  9. Kinetically Controlled Drug Resistance

    DEFF Research Database (Denmark)

    Sun, Xin E.; Hansen, Bjarne Gram; Hedstrom, Lizbeth

    2011-01-01

    The filamentous fungus Penicillium brevicompactum produces the immunosuppressive drug mycophenolic acid (MPA), which is a potent inhibitor of eukaryotic IMP dehydrogenases (IMPDHs). IMPDH catalyzes the conversion of IMP to XMP via a covalent enzyme intermediate, E-XMP*; MPA inhibits by trapping E...... of resistance is not apparent. Here, we show that, unlike MPA-sensitive IMPDHs, formation of E-XMP* is rate-limiting for both PbIMPDH-A and PbIMPDH-B. Therefore, MPA resistance derives from the failure to accumulate the drug-sensitive intermediate....

  10. Drugs and medical ethics.

    Science.gov (United States)

    Somogyi, E

    1993-01-01

    Naturopathy has received considerable interest all over the world recently. The use of its methods and its consequences have raised legal and ethical problems. This article reports on the use of two 'oncolytic' drugs. Neither of them was produced by cancer researchers and neither passed the analytic examination required in pharmaceutical research. During their use--they were prescribed and applied by physicians--conventional treatment was withdrawn. The ethical responsibility of doctors using fringe medicine drugs is dealt with. Naturopathy may, however, have a role in official medicine in certain cases.

  11. Metrology for drug delivery.

    Science.gov (United States)

    Lucas, Peter; Klein, Stephan

    2015-08-01

    In various recently published studies, it is argued that there are underestimated risks with infusion technology, i.e., adverse incidents believed to be caused by inadequate administration of the drugs. This is particularly the case for applications involving very low-flow rates, i.e., metrological infrastructure for low-flow rates. Technical challenges such as these were the reason a European research project "Metrology for Drug Delivery" was started in 2011. In this special issue of Biomedical Engineering, the results of that project are discussed.

  12. Thoughts on Drug Policies

    Institute of Scientific and Technical Information of China (English)

    韦兴宁

    2013-01-01

    Through the book“The economics of Public Issues”,in chapter 6,the author discussed why the government could not easily get spectacular success in the il egal commodity such as sex,booze,and drugs in economic way.In normal market, according to the law of demand,when the price of good is rising,the consumed amount wil decrease.However,the government has executed a lot of policies to reduce supply of drugs, but the consequence is not as good as they expected. Economics can help to find the answer to the phenomenon and improve the government's decision.

  13. Drug use as consumer behavior.

    Science.gov (United States)

    Foxall, Gordon Robert; Sigurdsson, Valdimar

    2011-12-01

    Seeking integration of drug consumption research by a theory of memory function and emphasizing drug consumption rather than addiction, Müller & Schumann (M&S) treat drug self-administration as part of a general pattern of consumption. This insight is located within a more comprehensive framework for understanding drug use as consumer behavior that explicates the reinforcement contingencies associated with modes of drug consumption.

  14. Drug: D05157 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05157 Drug Nicotine polacrilex (USAN); Nicorette (TN) Smoking cessation adjunct AT... NERVOUS SYSTEM DRUGS N07B DRUGS USED IN ADDICTIVE DISORDERS N07BA Drugs used in nicotine dependence N07BA01 Nicotine D05157 Nicotine...Anti-Addiction/Substance Abuse Treatment Agents Smoking Cessation Agents Nicotine D05157 Nicotine polacrilex (USAN) CAS: 96055-45-7 PubChem: 47206881 DrugBank: DB00184 ...

  15. Drug: D06050 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available kit (TN) map04976 Bile secretion Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 43 Radio...active drugs 430 Radioactive drugs 4300 Radioactive drugs D...trofosmin 99mTc-complex Radioactive agent Therapeutic category: 4300 ATC code: V09GA02 Component of Myoview ...D06050 Drug Technetium Tc 99m tetrofosmin (USP); Technetium (99mTc) tetrofosmin; Te

  16. Drug: D06699 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06699 Crude, Drug Japanese valerian (JP16); Powdered japanese valerian (JP16); Val... hypnotics and sedatives N05CM09 Valerian radix D06699 Japanese valerian (JP16); Powdered japanese valerian ...erian (JP16); Powdered japanese valerian (JP16) Anatomical Therapeutic Chemical (ATC) classification [BR:br0... drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06699 Japanese val

  17. Smart drugs: green shuttle or real drug?

    Science.gov (United States)

    Cornara, L; Borghesi, B; Canali, C; Andrenacci, M; Basso, M; Federici, S; Labra, M

    2013-11-01

    We have combined morphological, molecular, and chemical techniques in order to identify the plant and chemical composition of some last-generation smart drugs, present on the market under the following names: Jungle Mistic Incense, B-52, Blendz, and Kratom 10x. Micromorphological analyses of botanical fragments allowed identification of epidermal cells, stomata, trichomes, starch, crystals, and pollen. DNA barcoding was carried out by the plastidial gene rbcL and the spacer trnH-psbA as universal markers. The combination of morphological and molecular data revealed a mixture of plants from different families, including aromatic species, viz., Lamiaceae and Turneraceae. GC-MS and LC-MS analyses on ethanol or methanol extracts showed the presence of synthetic cannabinoids, including JWH-250 in Jungle, JWH-122 in B-52, and JWH-073 and JWH-018 in Blendz. In Kratom 10x, only the indole alkaloid mitragynine was detected. All the identified synthetic cannabinoids, apart from mitragynine, are under the restriction of law in Italy (TU 309/90). Synthetic cannabinoid crystals were also identified by scanning electron microscopy and energy dispersive X-ray spectroscopy, which also detected other foreign organic chemicals, probably preservatives or antimycotics. In Kratom only leaf fragments from Mitragyna speciosa, containing the alkaloid mitragynine, were found. In the remaining products, aromatic plant species have mainly the role of hiding synthetic cannabinoids, thus acting as a "green shuttle" rather than as real drugs. Such a multidisciplinary approach is proposed as a method for the identification of herbal blends of uncertain composition, which are widely marketed in "headshops" and on the Internet, and represent a serious hazard to public health.

  18. Ingestion of drugs by "parachuting": a unique drug delivery technique.

    Science.gov (United States)

    Kenerson, Katherine L; Lear-Kaul, Kelly C

    2012-06-01

    "Parachuting" is a technique of drug delivery where medications or illicit drugs are ingested by wrapping the drug of choice in a covering, which then will dissolve or unravel in the gastrointestinal tract, thereby releasing the drug for absorption. Parachuting of drugs can entail crushing of a pill prior to packaging to theoretically increase the surface area for absorption or may involve the packaging of a higher than usual dose of a drug in attempts to attain a sustained-release effect as the "parachute" dissolves or unravels. A case is presented in which a prescription drug abuser known to parachute his medications dies from obstruction of his airway by the inhaled packet. Risks of parachuting any drug would include overdose and fatal toxic effect from the drug itself and adverse effects from the packaging including bowel obstruction or perforation, or airway obstruction.

  19. The metaphorical nature of drugs and drug taking.

    Science.gov (United States)

    Montagne, M

    1988-01-01

    An inquiry into the role metaphor plays in personal and societal conceptions of drugs and drug taking reveals that drug metaphors and symbols are quite pervasive in individual thinking, social discourse, and the cultural media. They appear to influence beliefs and attitudes regarding drugs, the nature and meaning of drug experiences, and the reasons behind drug-taking behaviors. Some drug metaphors are common to different cultures and historical periods, while others are specific and exclusive to particular individuals and groups or drug-taking situations. These metaphors can carry positive as well as negative connotations. Further study is needed to delineate the metaphorical structuring of our thinking about drugs, and the process whereby these metaphors are generated and spread throughout society.

  20. Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs

    DEFF Research Database (Denmark)

    Sulochana, Suresh P; Syed, Muzeeb; Chandrasekar, Devaraj V

    2016-01-01

    of drugs. This review covers several category of drugs such as non-steroidal anti-inflammatory drugs, fluoroquinolones, histamine H2-receptor blockers, macrolides, anti-fungals, anti-diabetics, salicylic acid derivatives, steroidal anti-inflammatory drugs and provides pharmacokinetic data summary along...

  1. 77 FR 43337 - Drugs for Human Use; Drug Efficacy Study Implementation; Certain Prescription Drugs Offered for...

    Science.gov (United States)

    2012-07-24

    ..., functional diarrhea, drug- induced diarrhea, ulcerative colitis, urinary bladder spasm, and urethral spasm... HUMAN SERVICES Food and Drug Administration [Docket Nos. FDA-1975-N-0336 (Formerly 75N-0184), FDA-1975-N... Hydrocortisone Acetate and Pramoxine Hydrochloride] Drugs for Human Use; Drug Efficacy Study...

  2. Clinically relevant drug interactions with anti-Alzheimer's drugs.

    Science.gov (United States)

    Caraci, Filippo; Sultana, Janet; Drago, Filippo; Spina, Edoardo

    2017-03-03

    The aging world population had led to an increase in the prevalence of Alzheimer's disease (AD). The drugs used to slow down the onset of AD, galantamine, donepezil, rivastigmine and memantine, are generally well-tolerated. However, drug interactions between these drugs and other drugs are an important aspect of patient safety that should be borne in mind, particularly given the high burden of polypharmacy in the elderly. The aim of this review is to provide an updated review of clinically significant drug-drug interactions concerning drugs approved for AD. PubMed was searched for relevant keywords. No time limit was imposed but only articles in English published in peer-reviewed journals were selected. Relevant literature was also identified from the references of identified articles. Further information was obtained from drug summary of product characteristics. The major pharmacokinetic interactions identified concerned fluoxetine, paroxetine and ketoconazole when used with galantamine or donepezil. On the other hand, the major potential pharmacodynamic interactions concerned anti-dementia drugs and general anesthesia agents, anti-cholinergic drugs, conventional antipsychotics and bradycardia-inducing drugs. In clinical practice memantine shows a lower potential for pharmacodynamic drug-drug interactions (DDIs) compared to other drug classes. In conclusion, the concomitant use of anti-dementia drugs with other drugs can have variable clinical effects, making appropriate prescribing of these drugs very challenging. A simple and coherent way of presenting evidence on complex drug interaction information from heterogenous sources to clinicians is needed in order for the voluminous data available to have an impact on clinical practice.

  3. Drugs Used in COPD.

    Science.gov (United States)

    Plummer, Nancy; Michael, Nancy, Ed.

    This module on drugs used in chronic obstructive pulmonary disease (COPD) is intended for use in inservice or continuing education programs for persons who administer medications in long-term care facilities. Instructor information, including teaching suggestions, and a listing of recommended audiovisual materials and their sources appear first.…

  4. Prescription Drug Overdose

    Centers for Disease Control (CDC) Podcasts

    2013-07-02

    In this podcast, Dr. Tom Frieden, CDC Director, discusses the epidemic of prescription drug overdose, especially in women, and what can be done about it.  Created: 7/2/2013 by National Center for Injury Prevention and Control.   Date Released: 3/6/2014.

  5. Prevention and Drug Treatment

    Science.gov (United States)

    Testa, Mark F.; Smith, Brenda

    2009-01-01

    Evidence linking alcohol and other drug abuse with child maltreatment, particularly neglect, is strong. But does substance abuse cause maltreatment? According to Mark Testa and Brenda Smith, such co-occurring risk factors as parental depression, social isolation, homelessness, or domestic violence may be more directly responsible than substance…

  6. Prescription Drug Abuse

    Science.gov (United States)

    ... an opportunity to confront the person about the consequences of addiction and ask him or her to accept treatment. Think of an intervention as giving your loved one a clear opportunity to make changes before things get really bad. Prescription drug abuse may occur in people who ...

  7. ANTIMICROBIAL HERBAL DRUGS

    Directory of Open Access Journals (Sweden)

    K. Nishteswar

    2011-12-01

    Full Text Available An anti-microbial is a substance that kills or inhibits the growth of microorganisms such as bacteria, fungi, or protozoans. Antimicrobial drugs either kill microbes (microbiocidal or prevent the growth of microbes (microbiostatic. Sulphonamide drugs were the first antimicrobial drugs, and paved the way for the antibiotic revolution in medicine. The first sulfonamide, trade named Prontosil, was actually a prodrug. However, with the development of antimicrobials, microorganisms have adapted and become resistant to previous antimicrobial agents. In view of certain side effects caused due to usage of modern antimicrobial drugs and antibiotics scientists have made some attempts to screen some of the Ayurvedic herbs, which possess broader spectrum of safety. Some selected herbs which are used by tribal and rural people for curing various infective diseases caused due to bacteria, virus and fungi have been reported to possess anti-microbial properties. In the present paper and attempt is made to review about the indigenous medicinal plant which exhibited antimicrobial properties.

  8. Drugs in Sport

    Science.gov (United States)

    Mottram, David

    2012-01-01

    Drugs may be used by athletes for a number of reasons, including performance enhancement. The role of the World Anti-Doping Agency (WADA) is vital to ensure a winning performance has been achieved by fair means. Substances and methods that are included on the WADA Prohibited List are described. The procedures for testing banned substances are…

  9. Drugs and driving

    NARCIS (Netherlands)

    Walsh, J. Michael; De Gier, Johan J.; Christopherson, Asbjørg S.; Verstraete, Alain G.

    2004-01-01

    The authors present a global overview on the issue of drugs and driving covering four major areas: (1) Epidemiology and Prevalence-which reviews epidemiological research, summarizes available information, discusses the methodological shortcomings of extant studies, and makes recommendations for futu

  10. Drug development and manufacturing

    Energy Technology Data Exchange (ETDEWEB)

    Warner, Benjamin P.; McCleskey, T. Mark; Burrell, Anthony K.

    2015-10-13

    X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical, for estimating the binding selectivity of a chemical versus chemical analogs, for measuring post-translational modifications of proteins, and for drug manufacturing.

  11. Antiviral Drugs: Seasonal Flu

    Centers for Disease Control (CDC) Podcasts

    2010-09-29

    In this podcast, Dr. Joe Bresee explains the nature of antiviral drugs and how they are used for seasonal flu.  Created: 9/29/2010 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 9/29/2010.

  12. Drug approval and surveillance.

    Science.gov (United States)

    Potts, M

    1980-01-01

    This article argues that current regulations governing the licensing of drugs, particularly in the U.S., need to be changed and replaced by a system of provisional or conditional licensing and increased postmarketing surveillance of drug use. In terms of research and development of new forms of contraception, this proposal would have great impact. It is believed that the U.S./Food and Drug Administration (FDA) requirements--animal experiments and Phase 1 and 2 clinical trials--not only put an unacceptable financial burden on any institution attempting to develop new contraceptives, but do not demonstrably contribute to the reduction of risks. The author questions whether even if oral contraceptives introduced prior to new U.S./FDA regulations had been subject to these current regulations that convincing evidence would have been found to alert anyone to the now-known rare adverse effects, such as risk of thromboembolism. It is pointed out that these sorts of rare risks were uncovered by continuous screening processes which are not now a part of the FDA drug regulation requirements. The author also questions the politics of "conpulsory safety," such as might be legislated for regulated car safety belt use. Citing a partnership already established between government and private industry in high-risk/low cost ventures in the aerospace industry, the author sees no reason why such a relationship could not evolve in the pharmaceutical industry. In Britain, proposals have been made to establish a fund to compensate patients adversely affected by drugs which pharmaceutical companies would reimburse if proved negligent; such a fund may work in the U.S. under new regulations which stress postmarketing surveillance.

  13. Drug-induced lupus erythematosus

    Directory of Open Access Journals (Sweden)

    M. Carrabba

    2011-09-01

    Full Text Available Drug-induced lupus is a syndrome which share symptoms and laboratory characteristics with the idiopathic systemic lupus erythematosus (SLE. The list of medications implicated as etiologic agents in drug-induced lupus continues to grow. The terms used for this condition are lupus-like syndrome, drug-induced lupus erythematosus (DILE and drug related lupus. More than 80 drugs have been associated with DILE. The first case of DILE was reported in 1945 and associated with sulfadiazin. In 1953 it was reported that DILE was related to the use of hydralazine. Drugs responsible for the development of DILE can divided into three groups, but the list of these drugs is quite long because new drugs are included yearly in the list. The syndrome is characterised by arthralgia, myalgia, pleurisy, rash and fever in association with antinuclear antibodies in the serum. Recognition of DILE is important because it usually reverts within a few weeks after stopping the drug.

  14. Epigenetic Drugs for Multiple Sclerosis.

    Science.gov (United States)

    Peedicayil, Jacob

    2016-01-01

    There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.

  15. Drug Information in Space Medicine

    Science.gov (United States)

    Bayuse, Tina M.

    2009-01-01

    Published drug information is widely available for terrestrial conditions. However, information on dosing, administration, drug interactions, stability, and side effects is scant as it relates to use in Space Medicine. Multinational crews on board the International Space Station present additional challenges for drug information because medication nomenclature, information available for the drug as well as the intended use for the drug is not standard across countries. This presentation will look at unique needs for drug information and how the information is managed in Space Medicine. A review was conducted of the drug information requests submitted to the Johnson Space Center Pharmacy by Space Medicine practitioners, astronaut crewmembers and researchers. The information requested was defined and cataloged. A list of references used was maintained. The wide range of information was identified. Due to the information needs for the medications in the on-board medical kits, the Drug Monograph Project was created. A standard method for answering specific drug information questions was generated and maintained by the Johnson Space Center Pharmacy. The Drug Monograph Project will be presented. Topic-centered requests, including multinational drug information, drug-induced adverse reactions, and medication events due to the environment will be highlighted. Information management of the drug information will be explained. Future considerations for drug information needs will be outlined.

  16. Discrimination of approved drugs from experimental drugs by learning methods

    Directory of Open Access Journals (Sweden)

    Li Yixue

    2011-05-01

    Full Text Available Abstract Background To assess whether a compound is druglike or not as early as possible is always critical in drug discovery process. There have been many efforts made to create sets of 'rules' or 'filters' which, it is hoped, will help chemists to identify 'drug-like' molecules from 'non-drug' molecules. However, among the chemical space of the druglike molecules, the minority will be approved drugs. Classifying approved drugs from experimental drugs may be more helpful to obtain future approved drugs. Therefore, discrimination of approved drugs from experimental ones has been done in this paper by analyzing the compounds in terms of existing drugs features and machine learning methods. Results Four methodologies were compared by their performance to classify approved drugs from experimental ones. The best results were obtained by SVM, in which the accuracy is 0.7911, the sensitivity is 0.5929, and the specificity is 0.8743. Based on the results, consensus model was developed to effectively discriminate drugs, which further pushed the correct classification rate up to 0.8517, sensitivity up to 0.7242, specificity up to 0.9352. The applications on the Traditional Chinese Medicine Ingredients Database (TCM-ID tested the methods. Therefore this model has been proven to be a potent tool for identifying drug molecules. Conclusion The studies would have potential applications in the research of combinatorial library design and virtual high throughput screening for drug discovery.

  17. 76 FR 13880 - Investigational New Drug Applications and Abbreviated New Drug Applications; Technical Amendment

    Science.gov (United States)

    2011-03-15

    ... HUMAN SERVICES Food and Drug Administration 21 CFR Parts 312 and 314 Investigational New Drug Applications and Abbreviated New Drug Applications; Technical Amendment AGENCY: Food and Drug Administration... amending its investigational new drug application (IND) regulations and abbreviated new drug...

  18. 77 FR 71802 - Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs...

    Science.gov (United States)

    2012-12-04

    ... HUMAN SERVICES Food and Drug Administration Guidance on Investigational New Drug Applications for... ``Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs.'' The guidance is intended to assist manufacturers of PET drugs in submitting investigational new drug applications (INDs)....

  19. Drug: D06796 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 9], beta-Selinene [CPD:C09723], beta-Caryophyllene [CPD:C09629], alpha-Humulene [CPD:C09684], Nootkatol [CPD:C17915], 1,8-Cine...a oxyphylla fruit Major component: Cineole [CPD:C09844] Therapeutic category of drugs in Japan [BR:br08301] ...5 Crude drugs and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 51...00 Crude drugs D06796 Bitter cardamon (JP16) Traditional Chinese Medicine in Japan [BR:br08304] Crude Drugs

  20. Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery.

    Science.gov (United States)

    Chen, Haijun; Wu, Jianlei; Gao, Yu; Chen, Haiying; Zhou, Jia

    2016-01-01

    As commented by the Nobelist James Black that "The most fruitful basis of the discovery of a new drug is to start with an old drug", drug repurposing represents an attractive drug discovery strategy. Despite the success of several repurposed drugs on the market, the ultimate therapeutic potential of a large number of non-cancer drugs is hindered during their repositioning due to various issues including the limited efficacy and intellectual property. With the increasing knowledge about the pharmacological properties and newly identified targets, the scaffolds of the old drugs emerge as a great treasure-trove towards new cancer drug discovery. In this review, we summarize the recent advances in the development of novel small molecules for cancer therapy by scaffold repurposing with highlighted examples. The relevant strategies, advantages, challenges and future research directions associated with this approach are also discussed.

  1. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.

    Science.gov (United States)

    Islam, Md Mahmudul; Hameed, H M Adnan; Mugweru, Julius; Chhotaray, Chiranjibi; Wang, Changwei; Tan, Yaoju; Liu, Jianxiong; Li, Xinjie; Tan, Shouyong; Ojima, Iwao; Yew, Wing Wai; Nuermberger, Eric; Lamichhane, Gyanu; Zhang, Tianyu

    2017-01-20

    Drug-resistant tuberculosis (TB) poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insights into the resistant mechanisms of anti-TB drugs have been provided. Better understanding of drug resistance mechanisms helps in the development of new tools for the rapid diagnosis of drug-resistant TB. There is also a pressing need in the development of new drugs with novel targets to improve the current treatment of TB and to prevent the emergence of drug resistance in Mycobacterium tuberculosis. This review summarizes the anti-TB drug resistance mechanisms, furnishes some possible novel drug targets in the development of new agents for TB therapy and discusses the usefulness using known targets to develop new anti-TB drugs. Whole genome sequencing is currently an advanced technology to uncover drug resistance mechanisms in M. tuberculosis. However, further research is required to unravel the significance of some newly discovered gene mutations in their contribution to drug resistance.

  2. Drug safety and the impact of drug warnings

    DEFF Research Database (Denmark)

    Hostenkamp, G.; Fischer, K. E.; Borch-Johnsen, K.

    2016-01-01

    Objective To analyse the impact of drug safety warnings from the European Medicines Agency (EMA) on drug utilisation and their interaction with information released through national reimbursement bodies. Methods Insurance claims data on anti-diabetic drug prescriptions in primary care in Germany ...

  3. Drug-drug interactions with tyrosine-kinase inhibitors

    NARCIS (Netherlands)

    Croes, Sander; de Vries, Frank

    2014-01-01

    In their Review, Roelof van Leeuwen and colleagues1 recommend various dose adjustments during concomitant use of tyrosine-kinase inhibitors and drugs that inhibit or induce cytochrome P450 3A4 (CYP3A4).1 Most information is taken from the US Food and Drug Administration (FDA)'s drug label or the Eur

  4. Rhythmomimetic drug delivery

    CERN Document Server

    Calderer, M Carme; Siegel, Ronald A; Yao, Lingxing

    2015-01-01

    We present modeling, analysis and numerical simulation of a prototype glucose driven drug delivery device based on chemomechanical interactions and volume phase transitions in polyelectrolyte gels. The device consists of two fluid compartments, an external cell (I) mimicking the physiological environment, and a closed chamber (II), separated by a hydrogel membrane. Cell I, which is held at constant pH and ionic strength, provides a constant supply of glucose to cell II, and also serves as clearance station for reaction products. Cell II contains the drug to be delivered to the body, an enzyme that catalyzes conversion of glucose into hydrogen ions, and a piece of marble to remove excess hydrogen ions that would otherwise overwhelm the system. When the membrane is swollen, glucose flux into Cell II is high, leading to rapid production of hydrogen ions. However, the hydrogen ions are not immediately released to Cell I but react, instead, with the negatively charged carboxyl groups of the membrane, which collaps...

  5. [Visceral leishmaniasis: new drugs].

    Science.gov (United States)

    Minodier, P; Robert, S; Retornaz, K; Garnier, J M

    2003-12-01

    The standard treatment of visceral leishmaniasis is pentavalent antimony (meglumine antimoniate or sodium stibogluconate), but toxicity is frequent with this drug. Moreover, antimony unresponsiveness is increasing, both in immunocompetent and in immunosuppressed patients. Amphotericin B is a polyene macrolide antibiotic that binds to sterols in cell membranes. It is the most active antileishmanial agent in use. Its infusion-related and renal toxicity may be reduced by lipid-based delivery. Liposomal amphotericin B (Ambisome) seems to be less toxic than other amphotericin B lipid formulations (Amphocil, Amphotec). Optimal drug regimens of Ambisome vary from one geographical area to another. In the Mediterranean Basin, a total dose of 18 to 24 mg/kg is safe and effective. Shortening the duration of treatment without decreasing the total dose (i.e., 10 mg/kg/day for 2 days) seems promising to reduce the global cost of the therapy.

  6. [Drug therapy for cough].

    Science.gov (United States)

    Koskela, Heikki; Naaranlahti, Toivo

    2016-01-01

    An efficient therapy for cough usually requires identification and treatment of the underlying disease, like asthma. However an underlying disease in cough is not found in all cases and conventional treatment of the underlying disease is ineffective against cough. Drug therapy options are available also for these situations. Honey or menthol can be tried for cough associated with respitatory infections, antihistamines for cough associated with allergic rhinitis, blockers of the leukotriene receptor or muscarinic receptor for asthma-associated cough and morphine for cough associated with a malignant disease. Menthol, blockers of the muscarinic receptor, or dextrometorphan can be tried for prolonged idiopathic cough. Codeine is not necessary in the treatment of cough. Refraining from drug treatment should always be considered.

  7. Drug models of schizophrenia

    Science.gov (United States)

    Steeds, Hannah; Carhart-Harris, Robin L.

    2015-01-01

    Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients. Several drugs that act on neurotransmitter systems in the brain have been suggested to model aspects of schizophrenia in animals and in man. In this paper, we selectively review findings from dopaminergic, glutamatergic, serotonergic, cannabinoid, GABA, cholinergic and kappa opioid pharmacological drug models to evaluate their similarity to schizophrenia. Understanding the interactions between these different neurotransmitter systems and their relationship with symptoms will be an important step towards building a coherent hypothesis for the pathogenesis of schizophrenia. PMID:25653831

  8. Chronicles in drug discovery.

    Science.gov (United States)

    Davies, Shelley L; Moral, Maria Angels; Bozzo, Jordi

    2007-03-01

    Chronicles in Drug Discovery features special interest reports on advances in drug discovery. This month we highlight agents that target and deplete immunosuppressive regulatory T cells, which are produced by tumor cells to hinder innate immunity against, or chemotherapies targeting, tumor-associated antigens. Antiviral treatments for respiratory syncytial virus, a severe and prevalent infection in children, are limited due to their side effect profiles and cost. New strategies currently under clinical development include monoclonal antibodies, siRNAs, vaccines and oral small molecule inhibitors. Recent therapeutic lines for Huntington's disease include gene therapies that target the mutated human huntingtin gene or deliver neuroprotective growth factors and cellular transplantation in apoptotic regions of the brain. Finally, we highlight the antiinflammatory and antinociceptive properties of new compounds targeting the somatostatin receptor subtype sst4, which warrant further study for their potential application as clinical analgesics.

  9. [Drug control of appetite].

    Science.gov (United States)

    Makoundou, V; Golay, A

    2011-01-12

    The control of the appetite by drugs (sensation of hunger, satiation and satiety) is crucial in the management of obesity. Numerous drugs in this domain were forbidden these last years because of serious side effects. New researches allow the development of new substances presenting fewer side effects either by better specificity on receptors (locarserin), or by new mechanism of action (GLP-1, leptin, anti Ghrelin). The appetite is settled by a complex neurohormonal mechanism. To act on some systems at the same time, the development of products "polypill" combining naltroxone-bupropion, phentermine-topiramate or amylin-leptine give encouraging results. However the dominant mechanism of the appetite dysregulation needs to be better understood.

  10. Melatonergic drugs in development

    OpenAIRE

    Carocci A; Catalano A; Sinicropi MS

    2014-01-01

    Alessia Carocci,1 Alessia Catalano,1 Maria Stefania Sinicropi2 1Department of Pharmacy–Drug Sciences, University of Bari Aldo Moro, Bari, 2Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy Abstract: Melatonin (N-acetyl-5-methoxytryptamine) is widely known as "the darkness hormone". It is a major chronobiological regulator involved in circadian phasing and sleep-wake cycle in humans. Numerous other functions, including ...

  11. International Drug Control Policy

    Science.gov (United States)

    2009-08-24

    cannabis resin, coca leaf, cocaine, heroin, and opium. Psychotropic substances include ecstasy ,2 LSD,3 amphetamine, and methamphetamine. Examples of other...replaces CRS Report RL33582, International Drug Trade and U.S. Foreign Policy, by Raphael F. Perl. 2 Ecstasy is the street name for MDMA (3,4... mechanisms to monitor treaty adherence— through the International Narcotics Control Board (INCB)—and for the collection of data related to the illicit

  12. High throughput drug profiling

    OpenAIRE

    Entzeroth, Michael; Chapelain, Béatrice; Guilbert, Jacques; Hamon, Valérie

    2000-01-01

    High throughput screening has significantly contributed to advances in drug discovery. The great increase in the number of samples screened has been accompanied by increases in costs and in the data required for the investigated compounds. High throughput profiling addresses the issues of compound selectivity and specificity. It combines conventional screening with data mining technologies to give a full set of data, enabling development candidates to be more fully compared.

  13. New Antiplatelet Drugs

    Institute of Scientific and Technical Information of China (English)

    包承鑫

    2011-01-01

    @@ ADP- receptor antagonist Prasugrel is a thienopyridine of the third generation and needs conversion into an active drug metabolite (R138727).Preclinical and clinical studies showed a more rapid,potent and consistent inhibition of patelet function for prasugrel compared to clopidogrel.Prasugrel has been shown to be of particular benefit in patients with diabetes,especially those on insulin [30% relative risk reduction (RRR) in cardiovascular death, MI,or stroke (P <0.001 ) and 37% RRR,respectively] .

  14. Nanotopography applications in drug delivery

    Science.gov (United States)

    Walsh, Laura A; Allen, Jessica L; Desai, Tejal A

    2016-01-01

    Refinement of micro- and nanofabrication in the semiconductor field has led to innovations in biomedical technologies. Nanotopography, in particular, shows great potential in facilitating drug delivery. The flexibility of fabrication techniques has created a diverse array of topographies that have been developed for drug delivery applications. Nanowires and nanostraws deliver drug cytosolically for in vitro and ex vivo applications. In vivo drug delivery is limited by the barrier function of the epithelium. Nanowires on microspheres increase adhesion and residence time for oral drug delivery, while also increasing permeability of the epithelium. Low aspect ratio nanocolumns increase paracellular permeability, and in conjunction with microneedles increase transdermal drug delivery of biologics in vivo. In summary, nanotopography is a versatile tool for drug delivery. It can deliver directly to cells or be used for in vivo delivery across epithelial barriers. This editorial highlights the application of nanotopography in the field of drug delivery. PMID:26512871

  15. Drug: D06964 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Pancreatitis Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  16. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Testing Drugs and the Brain Genetics Global Health Hepatitis (Viral) HIV/AIDS Health Consequences of Drug Misuse ... be transmitted between users. Other infections-such as hepatitis C-can also be spread this way. Hepatitis ...

  17. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... depict the devastating consequences of compromised judgment and critical thinking that can result from drug use. Young ... HIV epidemic. As we learn more about the critical connection between drug abuse and HIV/AIDS and ...

  18. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... patients who do not abuse drugs. In animal studies, methamphetamine has been shown to increase the amount ... behaviors. NIDA researchers have studied and continue to study the links between drug abuse and HIV/AIDS. ...

  19. Drug: D08468 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION M05BX Other drugs affecting bone structure and mine...ralization M05BX03 Strontium ranelate D08468 Strontium ranelate CAS: 135459-87-9 Pu

  20. Drug: D08689 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tic Chemical (ATC) classification [BR:br08303] M MUSCULO-SKELETAL SYSTEM M05 DRUGS FOR TREATMENT OF BONE... DISEASES M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION M05BA Bisphosphonate

  1. Drug: D08599 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ic Chemical (ATC) classification [BR:br08303] M MUSCULO-SKELETAL SYSTEM M05 DRUGS FOR TREATMENT OF BONE DISE...ASES M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION M05BA Bisphosphonates

  2. Drug: D07281 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DRUGS FOR TREATMENT OF BONE DISEASES M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION M05BA Bisphospho...apeutic Chemical (ATC) classification [BR:br08303] M MUSCULO-SKELETAL SYSTEM M05

  3. Drug: D02373 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rapeutic Chemical (ATC) classification [BR:br08303] M MUSCULO-SKELETAL SYSTEM M05 DRUGS FOR TREATMENT OF BONE... DISEASES M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION M05BA Bisphosph

  4. Drug: D00152 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS A03AX Other drugs for functional gastrointestinal diso...rders A03AX12 Phloroglucinol D00152 Phloroglucinol (JAN)

  5. Drug: D06261 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06261 Drug Typhoid vaccine Immunizing agent [active] USP drug classification [BR:b...r08302] Immunological Agents Vaccines Typhoid Vaccine Live Oral D06261 Typhoid vaccine PubChem: 47207919 ...

  6. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... of Drug Misuse Mental Health Military Naloxone Pain Prevention Treatment Trends & Statistics Women and Drugs Publications Funding ... antiretroviral medications that can suppress the virus and prevent or decrease symptoms of illness. To learn about ...

  7. Treatment Approaches for Drug Addiction

    Science.gov (United States)

    ... and Over-the-Counter Medications Stimulant ADHD Medications: Methylphenidate and Amphetamines Synthetic Cannabinoids Synthetic Cathinones ("Bath Salts") Effects of Drug Abuse Comorbidity: Addiction and Other Mental Disorders Drug Use ...

  8. Understanding Drug Use and Addiction

    Science.gov (United States)

    ... and Over-the-Counter Medications Stimulant ADHD Medications: Methylphenidate and Amphetamines Synthetic Cannabinoids Synthetic Cathinones ("Bath Salts") Effects of Drug Abuse Comorbidity: Addiction and Other Mental Disorders Drug Use ...

  9. Drugs that may cause impotence

    Science.gov (United States)

    Impotence caused by medications; Drug-induced erectile dysfunction; Prescription medicines and impotence ... Many medicines and recreational drugs can affect a man's sexual arousal and sexual performance. What causes impotence in one ...

  10. Drug: D00289 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tagonists Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 24 Hormones...drug classification [BR:br08302] Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) A

  11. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Drugs and HIV Learn the Link - Drugs and HIV Email Facebook Twitter 2005 –Ongoing Behaviors associated with ... Send the Message . Get the Facts What are HIV and AIDS? HIV (human immunodeficiency virus) is the ...

  12. Drug: D10244 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available LISM A10 DRUGS USED IN DIABETES A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS...ode: A10BD03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] A ALIMENTARY TRACT AND METABO

  13. Drug: D08229 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTHE...R SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DC Leukotriene receptor antagonists R03DC03 Montelukast

  14. Drug: D08408 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTH...ER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DC Leukotriene receptor antagonists R03DC02 Pranlukast

  15. Drug: D08227 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIONS FOR TOPICAL USE R01AD Corticosteroids R01AD09 Mometasone D08227 Mometasone (INN) R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES... R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS

  16. Drug: D00411 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Therapeutic Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES... R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DC Leukotriene receptor antagonists

  17. Drug: D07491 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fication [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES... R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines R03DA08 Bamifylline D07491 Bam

  18. Drug: D03051 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTH...ER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines R03DA08 Bamifylline D03051 Bamifylline hyd

  19. Drug: D07062 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTHER... SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines R03DA09 Acefyllin

  20. Drug: D10297 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available SES R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES...R03DA54 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEA

  1. Drug: D02884 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available c Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ...R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines R03DA10

  2. Drug: D00227 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES...contraction Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS

  3. Drug: D06104 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03D OTHER SY...STEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines R03DA04 Theophylline

  4. Drug: D01570 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drochloride I 123 (USAN); Spectamine (TN) C12H18IN. HCl 335.0262 339.6434 D01570.gif Diagnostic aid; Radioactive...4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radioactive

  5. Drug: D04881 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04881 Mixture, Drug Aluminum chloride - cetylpyridinium chloride - Lidocaine mixt; Dental...Therapeutic category: 2790 Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 27 Dental

  6. Drug: D00937 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available oporosis drugs Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 32 Nutrie...nts, tonics 321 Calcium preparations 3219 Others D00937 Dibasic calcium phosphate h

  7. Drug: D01154 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 32 Nutrients, tonics 322 Miner... Potassium acetate (JAN/USP) USP drug classification [BR:br08302] Therapeutic Nutrient

  8. Drug: D07021 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available itis Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  9. Drug: D07045 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medici...nes 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  10. Drug: D07018 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine for...mulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  11. Drug: D06952 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available herapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  12. Drug: D06947 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  13. Drug: D06930 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available pharyngodynia Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  14. Drug: D06973 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gory of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulatio...ns 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06

  15. Drug: D06985 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tegory of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06985 Shosaikoto extract (J

  16. Drug: D06998 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tegory of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06998 Seishinrenshiin Tradi

  17. Drug: D06991 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicin...es 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06991 Shir

  18. Drug: D07005 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medi...cines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07005 D

  19. Drug: D06994 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  20. Drug: D07030 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available egory of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulati...ons 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D0

  1. Drug: D06934 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ategory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formula...tions 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines

  2. Drug: D07013 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available erapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  3. Drug: D06918 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06918 Inchingoreisan Traditional Chi

  4. Drug: D06993 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ugh Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  5. Drug: D06954 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulatio...ns 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  6. Drug: D07002 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available utic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine f...ormulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  7. Drug: D06923 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available egory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulati...ons 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  8. Drug: D07040 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicines... 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07040 Boiogito Traditional Chinese Me

  9. Drug: D07043 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available y of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07043

  10. Drug: D06937 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available : 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese med...icines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06937

  11. Drug: D07022 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medi...cines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07022 T

  12. Drug: D06924 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  13. Drug: D06962 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available : 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese med...icines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  14. Drug: D07056 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medi...cines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07056 R

  15. Drug: D07019 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese med...icines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07019

  16. Drug: D07044 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tegory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulat...ions 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  17. Drug: D07010 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D07010 Jizusoippo Traditional Chin

  18. Drug: D06977 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese med...icines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06977

  19. Drug: D06968 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ry: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations... 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  20. Drug: D06975 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available eutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  1. Drug: D06927 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06927 Kakkont

  2. Drug: D06966 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 79] Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  3. Drug: D07037 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available herapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  4. Drug: D06931 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicine...s 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06931 Kam

  5. Drug: D07034 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tion; Headache Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicin

  6. Drug: D06978 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available y: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations ...52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06978

  7. Drug: D07015 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available herapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine... formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicine

  8. Drug: D06960 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulation...s 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D069

  9. Drug: D09966 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09966 Drug Talimogene laherparepvec (USAN); Talminogene laherparepvec; Oncovex (TN) Antineoplastic gene the...rapy drug (oncolytic HSV1, GM-CSF [HSA:1437] [KO:K05427]) CAS: 1187560-31-1 PubChem: 124490634 ...

  10. Drug-induced lupus erythematosus

    Science.gov (United States)

    ... A chest x-ray may show signs of pleuritis or pericarditis (inflammation around the lining of the ... anti-inflammatory drugs (NSAIDs) to treat arthritis and pleurisy Corticosteroid creams to treat skin rashes Antimalarial drugs ( ...

  11. Nanosuspension Technology for Drug Delivery

    Directory of Open Access Journals (Sweden)

    Jiraporn CHINGUNPITUK

    2007-06-01

    Full Text Available The poor water solubility of drugs is major problem for drug formulation. To date, nanoscale systems for drug delivery have gained much interest as a way to improve the solubility problems. The reduction of drug particles into the sub-micron range leads to a significant increase in the dissolution rate and therefore enhances bioavailability. Nanosuspensions are promising candidates that can be used for enhancing the dissolution of poorly water soluble drugs. Nanosuspensions contain submicron colloidal dispersion of pharmaceutical active ingredient particles in a liquid phase stabilized by surfactants. Production of drugs as nanosuspensions has been developed for drug delivery systems as an oral formulation and non-oral administration. This review describes the methods of pharmaceutical nanosuspension production, formulations and pharmaceutical applications in drug delivery as well as the marketed products.

  12. Drug: D07000 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ory of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese me...nal Chinese Medicine in Japan [BR:br08304] Formulas Diaphoretic formulas Diaphoretic dformula

  13. Drug: D06928 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chine...n'i Traditional Chinese Medicine in Japan [BR:br08304] Formulas Diaphoretic formulas Diaphoretic dformula

  14. Drug Establishments Current Registration Site

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Drug Establishments Current Registration Site (DECRS) is a database of current information submitted by drug firms to register establishments (facilities) which...

  15. Drug: D07477 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available PLAIN A03BA Belladonna alkaloids, tertiary amines A03BA01 Atropine D07477 Atropine oxide (INN) USP drug clas...DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS A03B BELLADONNA AND DERIVATIVES,

  16. Medicare Prescription Drug Benefit Manual

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Part D Prescription Drug Benefit Manual (PDBM) is user guide to Part D Prescription Drug Program. It includes information on general provisions, benefits,...

  17. Drug: D09255 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09255 Crude, Drug Sophora japoinca flower (non-JP); Sophora japonica flower bud; Sophorae flos Ru...a family) Sophora japonica flower bud; Standards for non-pharmacopoeial crude drugs Crude dru

  18. Drug: D02402 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available SP); Thallous chloride Tl 201 (TN) Tl. Cl 235.9397 239.8363 D02402.gif Diagnostic aid [radiopaque medium]; Radio...8301] 4 Agents affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radio

  19. Drug: D04527 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cetate injection (JAN); Indium DTPA In 111 (TN) Diagnostic aid [radionuclide cisternography]; Radioactive ag...s affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radio

  20. Drug: D02259 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 259.gif Antineoplastic; Diagnostic aid [thyroid function determination]; Radioactive agent [DS:H00032] Thera... affecting cellular function 43 Radioactive drugs 430 Radioactive drugs 4300 Radio